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A biomarker is a measurable biological characteristic that can be evaluated as an indicator of 
normal (physiological) or abnormal (pathogenic) processes. In cancer research, there remains a 
need for the identification of new biomarkers that can be used to close the gaps in the current 
understanding of cancer development, progression and treatment.  
HLXB9 is a homeobox gene located at 7q36. It encodes a transcription factor important in 
embryonic development. Its accurate regulation is significant in the organogenesis of the 
endodermal germ layer particularly in the development of the pancreas. After development, its 
expression is downregulated in the majority of adult tissues. Recently, aberrant expression of 
HLXB9 has been found in certain cancers such as hepatocellular carcinoma, testicular cancer, 
pancreatic cancer and leukaemia.  
The location of genes and chromosomes in the nuclei of healthy human cells has been shown to 
be non-random, therefore understanding the mechanisms that regulate nuclear genome 
organisation is important in understanding of cancer biology in cases where genes are relocated. 
The nuclear localisation of genes as a biomarker of tumour development in cancer is a relatively 
new but promising field in cancer research. Previous research by our group found 
overexpression of HLXB9 corresponded to an altered positioning of this gene in the nucleus of 
paediatric leukaemia patients harbouring the translocation t(7;12)(q36;p13).  
In this project, HLXB9 was evaluated as a biomarker in cancer development. In the first study, a 
new dual colour probe for the detection of the t(7;12)(q36; p13) was validated by fluorescence in 
situ hybridisation (FISH) in leukaemia patient samples previously described as harbouring the 
translocation. 
The expression of HLXB9 was then analysed by RT-PCR in 48 patients diagnosed with various 
haematological disorders. 25% of patients analysed expressed HLXB9. Additionally, HLXB9 
expression in leukaemia was found in patients with normal copies of chromosome 7 suggesting 
HLXB9 expression can occur independently of chromosome 7 abnormalities. An attempt was 
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made to evaluate the link between HLXB9 expression and its nuclear localisation in these 
patients.  
Four online databases were interrogated to identify cancer types and subtypes that exhibit 
differential HLXB9 expression. HLXB9 expression was not altered in the majority of cancer cases 
investigated. However, aberrant HLXB9 expression was found in cancer types not previously 
reported as showing differential HLXB9 expression such as kidney cancer, lung cancer and 
endometrial cancer. The identification of aberrant expression of HLXB9 in these cancer types 
provides a new avenue for research into understanding cancer development and progression in 
these tumour types. 
Finally, the expression of HLXB9 was analysed in four breast cancer cell lines by quantitative RT-
PCR and immunofluorescence. Additionally, the prognostic significance of HLXB9 expression was 
evaluated in publicly available breast cancer survival databases (Kaplan Meier plotter and 
BreastMark).  
Altogether, the findings emerging from this thesis work show that, although the potential for 
HLXB9 to be used as biomarker is appealing, further work is required to confirm the value of this 














I would like to express a special gratitude to my Principal Supervisor, Dr Sabrina Tosi for her 
enduring support, encouragement and guidance. Your support was a constant source of 
motivation to me. I also owe a debt of gratitude to my Secondary Supervisor, Dr Amanda Harvey, 
your help and guidance was incredibly valuable.  
 
I would also like to thank Dr Chris Eskiw, Dr Helen Foster, Dr Joanna Bridger, and Dr Ines Castro. 
Special thanks to my fellow PhD students (past and present) especially Dr Abdulbasit Naiel and 
Chiara Papucci; no one else could really fully understand the process and thanks for the laughs.  
 
To my family and friends, it could not have happened without you. I dedicate this work to my 
father, Thompson, my mother Mojisola and my brothers-Doyin, Femi, Siji and Sanmi. Your 
constant support was invaluable, your advice made sure I persevered to the end, your 
companionship made the journey immensely enjoyable. You give me a tremendous amount of 












Table of contents 
Declaration ................................................................................................................................................................................ II 
Abstract ...................................................................................................................................................................................................... III-IV 
Acknowledgment .......................................................................................................................................................................................... V 
Table of contents ................................................................................................................................................................................. VI-VII 
List of Figures ...................................................................................................................................................................................... VIII-IX 
List of Tables ............................................................................................................................................................................................. X-XI 
Abbreviations .................................................................................................................................................................................... XII-XIII 
 
Chapter 1: Introduction .................................................................................................................................................................... 1-39 
1.1. Cancer Biomarkers ........................................................................................................................................................................................... 2 
1.2. The HLXB9 gene ................................................................................................................................................................................................. 2 
1.3. HLXB9 in foetal development ....................................................................................................................................................................... 4 
1.4. Currarino Syndrome (CS) .............................................................................................................................................................................. 5 
1.5. HLXB9 constitutional mutations and diabetes ...................................................................................................................................... 6 
1.6. HLXB9 constitutional mutations and cancer .......................................................................................................................................... 6 
1.7. HLXB9 in pancreatic cancer .......................................................................................................................................................................... 7 
1.8. HLXB9 in leukaemia ......................................................................................................................................................................................... 8 
1.9. HLXB9 in breast cancer ................................................................................................................................................................................. 24 
1.10. HLXB9 in other cancers ................................................................................................................................................................................ 33 
1.11. The localisation of HLXB9 in the interphase nucleus ........................................................................................................................ 34 
1.12. Aims and objectives ....................................................................................................................................................................................... 37 
 
Chapter 2: Materials and methods ...........................................................................................................................................40-55 
2.1.   Description of leukaemia patient’s samples ......................................................................................................................................... 41 
2.2.  Cell culture .......................................................................................................................................................................................................... 41 
2.3.  RNA extraction .................................................................................................................................................................................................. 42 
2.4.  cDNA synthesis .................................................................................................................................................................................................. 43 
2.5.  Reverse transcriptase-polymerase chain reaction (RT-PCR) ......................................................................................................... 44 
2.6. Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) .............................................................................. 45 
2.7.  Indirect Immunofluorescence (IF) ............................................................................................................................................................ 45 
2.8.  Cytogenetic cell harvesting........................................................................................................................................................................... 46 
2.9.  Slide preparation .............................................................................................................................................................................................. 47 
2.10.  G-banding of breast cancer cell lines ..................................................................................................................................................... 47 
2.11.  Preparation of PAC Probe RP5-1121A15 ............................................................................................................................................. 47 
2.12.  Nick translation .............................................................................................................................................................................................. 48 
2.13.  Probe purification.......................................................................................................................................................................................... 49 
2.14.  Fluorescence in situ hybridisation .......................................................................................................................................................... 49 
2.15.  Erosion analysis (nuclear localisation) ................................................................................................................................................. 51 
2.16. Determining the prognostic significance of HLXB9 expression in breast cancer patients ................................................ 52 
 
Chapter 3: Detection of t(7;12)(q36;p13) in paediatric leukaemia using dual colour FISH  ..............56-62 
3.1.   Introduction ...................................................................................................................................................................................................... 57 
3.2.   Aim ........................................................................................................................................................................................................................ 57 
VII 
 
3.3.   Materials and methods .................................................................................................................................................................................. 58 
3.4.   Results ................................................................................................................................................................................................................. 60 
3.5.   Discussion .......................................................................................................................................................................................................... 62 
 
Chapter 4: Investigating the expression and nuclear localisation of HLXB9 in leukaemia pts  ........63-95 
4.1.   Introduction ...................................................................................................................................................................................................... 64 
4.2.   Aims ...................................................................................................................................................................................................................... 65 
4.3.   Materials and methods .................................................................................................................................................................................. 65 
4.4.   Results ................................................................................................................................................................................................................. 65 
4.4.1: HLXB9 expression in patients diagnosed with various haematological malignancies ............................................... 65 
4.4.2: HLXB9 nuclear localisation in patients diagnosed with various haematological malignancies .............................. 77 
4.5.   Discussion .......................................................................................................................................................................................................... 88 
4.6.   Conclusion .......................................................................................................................................................................................................... 94 
 
Chapter 5: Investigating HLXB9 as a biomarker by datamining cancer online databases  ............... 96-121 
5.1.   Introduction ...................................................................................................................................................................................................... 97 
5.2.   Aims ...................................................................................................................................................................................................................... 97 
5.3.   Methods............................................................................................................................................................................................................... 98 
5.4.   Results .............................................................................................................................................................................................................. 100 
I: Overview on HLXB9 expression in cancer according to databases .......................................................................................... 100 
II: HLXB9 expression by cancer type ........................................................................................................................................................ 114 
5.5.   Discussion ....................................................................................................................................................................................................... 117 
5.6.   Conclusion ....................................................................................................................................................................................................... 121 
 
Chapter 6: Investigating HLXB9 as a biomarker in breast cancer .................................................................. 122-162 
6.1.   Introduction ................................................................................................................................................................................................... 123 
6.2.   Aim ..................................................................................................................................................................................................................... 123 
6.3.   Materials and methods ............................................................................................................................................................................... 124 
6.4.   Results .............................................................................................................................................................................................................. 124 
I-IV: HLXB9 expression in non-tumorigenic mammary cells and breast cancer cell lines  ................................................. 124 
V-VI: HLXB9 nuclear localisation in non-tumorigenic mammary cells and breast cancer cell lines  .............................. 135 
VII: The impact of differential HLXB9 expression on breast cancer patients’ survival  ....................................................... 143 
6.5.   Discussion ....................................................................................................................................................................................................... 155 
6.6.   Conclusion ....................................................................................................................................................................................................... 162 
 
Chapter 7: General discussion and future work ....................................................................................................... 163-170 
Chapter 8: Appendix ................................................................................................................................................................... 171-182 




List of figures 
Chapter 1 
 
Figure 1.1: Leukaemia types by proportion of cases diagnosed in the UK in 2013  9 
Figure 1.2: Schematic representation of haematopoiesis 10 
Chapter 3 
 
Figure 3.1: Ideograms of chromosome 7 and 12 showing the localisation of FISH probe 58 
Figure 3.2: Schematic representation of FISH signals expected in interphase nuclei using dual colour 
t(7;12) (q36;p13) probe 
59 
Figure 3.3: Ideograms and example of FISH hybridisation patterns observed in patients 1-3 60 
Figure 3.4: Ideograms and example of FISH hybridisation patterns observed in patient 4 61 
Chapter 4 
 
Figure 4.1: Agarose gel electrophoresis analysis of RT-PCR products in control samples 68 
Figure 4.2: Agarose gel electrophoresis analysis of RT-PCR products in leukaemia (K562, GFD-8, 
GDM1) and lymphoma (CRL 2632 and 2630) derived cell lines 
69 
Figure 4.3: Agarose gel electrophoresis analysis of RT-PCR products in patients diagnosed with 
various haematological disorders 
69 
Figure 4.4: The proportion of patients with haematological disorders that showed HLXB9 expression 71 
Figure 4.5: Proportion of patients with HLXB9 expression categorised by the type of haematological 
disorder diagnosed 
72 
Figure 4.6: HLXB9 had an intermediate nuclear localisation in bone marrow mononuclear cells 78 
Figure 4.7: Nuclear localisation of HLXB9 in control peripheral blood samples with or without 
stimulation with PHA 
79 
Figure 4.8: HLXB9 had an intermediate nuclear localisation in peripheral blood mononuclear cells 
before and after PHA stimulation 
80 
Figure 4.9: HLXB9 had a peripheral-intermediate nuclear localisation in peripheral blood cells 
stimulated with PHA and synchronised with thymidine 
82 
Figure 4.10: HLXB9 had an intermediate nuclear localisation lymphoblastoid cell lines analysed 83 
Figure 4.11: HLXB9 had an intermediate nuclear localisation in the two AML patients without 
chromosome 7 abnormalities expressing HLXB9 
85 
Figure 4.12: HLXB9 had a peripheral nuclear localisation in patient 1027, an ALL patient without 
chromosome 7 abnormalities 
86 





Figure 5.1: Boxplots showing differential expression of HLXB9 in cancer originating from various 
tissues 
103 
Figure 5.2: Boxplots showing differential expression of HLXB9 in cancer originating from various 
tissues 
103 
Figure 5.3: Boxplots showing differential expression of HLXB9 in cancer originating from various 
tissues (U133A microarray platform) 
105 
Figure 5.4: Boxplots showing differential expression of HLXB9 in cancer originating from various 
tissues (U133 Plus 2 microarray platform) 
107 
Figure 5.5: Boxplots showing differential expression of HLXB9 (MNX1) in normal and cancer samples 
(FIREBROWSE) 
110 
Figure 5.6: The frequency of significant differential expression of HLXB9 in cancer types 113 
Figure 5.7: HLXB9 expression in various cancer types 116 
Chapter 6 
 
Figure 6.1: Agarose gel electrophoresis analysis of RT-PCR products in control (non-cancer) samples 
and MCF 10A cancer derivatives 
127 
Figure 6.2: Agarose gel electrophoresis analysis of RT-PCR products in breast cancer cell lines 128 
Figure 6.3: HLXB9 transcript variants 1 and 2 at 98bp and an additional band above 800bp in breast 
cancer cell lines analysed 
129 
Figure 6.4: Histograms of HLXB9 expression in controls and breast cancer cell 132 
Figure 6.5: HLXB9 was downregulated in the breast cancer cell lines analysed 134 
Figure 6.6: Fluorescence in situ hybridisation patterns observed in the metaphases and nuclei of non- 135 
IX 
 
cancer HMEC 184D, HMEC 240L and MCF 10A cells 
Figure 6.7A: Fluorescence in situ hybridisation patterns observed in the T47D cell line 136 
Figure 6.7B: A representative image showing G banded T47D chromosome spread  136 
Figure 6.8: Fluorescence in situ hybridisation patterns observed in the metaphase and nuclei HLXB9 in 
green (FITC labelled), chromosome 7 in Red and nuclei counterstained with DAPI and representative 
G-banding chromosome spread of BT474 cell line 
137 
Figure 6.9: Fluorescence in situ hybridisation patterns observed in the metaphase and nuclei of MDA-
MB-231 cell line HLXB9 in green (FITC labelled), and Nuclei/Chromosome counterstained with DAPI 
138 
Figure 6.10: Nuclear localisation of HLXB9 gene in non-cancer breast cells/cell lines and Breast cancer 
cell lines studied 
142 


























List of tables 
Chapter 1 
 
Table 1.1: Incidence and 5-year survival rate of Myeloid Malignancies diagnosed in Europe between 
1995 and 2002  
12 
Table 1.2:The FAB classification of AML showing subtypes and the most common chromosomal 
abnormality (cytogenetic) finding for each subtype 
14 
Table 1.3: WHO classification of AML showing the four groups of AML subtypes and the criteria for 
classification into each group 
15 
Table 1.4: Risk classification of common chromosomal abnormality found in AML patients 16 
Table 1.5: TNM classification of breast tumours 27 
Table 1.6: American Joint Committee of Cancer Breast Cancer Staging (7th Edition) 28 
Chapter 2 
 
Table 2.1: Description of non-tumorigenic cells and breast cancer cell lines analysed 42 
Table 2.2: Description of RT-PCR primers used in study 44 
Table 2.3: Primer sequence used in qRT-PCR experiments 45 
Table 2.4: Entrez ID, Affymetrix ID of Oncotype DX genes 53 
Table 2.4: Entrez ID, Affymetrix ID of MammaPrint genes 54 
Chapter 3 
 
Table 3.1. Clinical and cytogenetic data of patients analysed in this study 62 
Chapter 4 
 
Table 4. 1: Four out of the five cell lines investigated expressed HLXB9 70 
Table 4.2: Clinical and cytogenetic data of patients positive for HLXB9 expression in our study 74 
Table 4.3: Table showing the clinical and cytogenetic data of patients negative for HLXB9 expression 75 
Table 4.4: Comparison of the nuclear localisation of HLXB9 in three peripheral blood samples before 
and after PHA stimulation 
81 
Table 4.5: Comparison of the nuclear localisation of HLXB9 in peripheral blood samples stimulated 
with PHA and thymidine (con 6 and con7) to three peripheral blood samples (pbmc, con 41 and con 
43) stimulated with PHA only 
82 
Table 4.6: Clinical and cytogenetic characteristics of patients analysed for nuclear localisation of 
HLXB9 
84 





Table 5.1: Eleven cancer types with aberrant expression of HLXB9, HLXB9 is unregulated in most 
cancers suggesting a pro oncogenic role for HLXB9 in most cancers (Oncomine) 
101 
Table 5.2: Number of samples in the GENT database across the U133A and U133 Plus 2 platforms  104 
Table 5.3a: Boxplots of HLXB9 expression in control and cancer samples from the U133A platform 
(GENT) 
106 
Table 5.3b: Comparison of HLXB9 expression box plots in normal samples to cancer samples using the 
U133A microarray platform in the GENT database 
106 
Table 5.4a: Boxplots of HLXB9 expression in control and cancer samples from the U133A platform 
(GENT) 
108 
Table 5.4b: Comparison of HLXB9 expression box plots in normal samples to Cancer samples using the 
U133Plus 2 microarray platform in the GENT database 
109 
Table 5.5: Comparison of HLXB9 expression box plots in normal samples to cancer samples 
(FIREBROWSE) 
111 
Table 5.6: Cancer types, frequency of overexpression or underexpression and the frequency of 
statistical significance differential expression of HLXB9 in cancer samples 
114 
Table 5.7: Overview on HLXB9 expression in various cancers by databases 115 
Chapter 6 
 
Table 6.1: Table showing the molecular subtypes, expression profile of the biomarkers currently used 
in categorising breast tumours on cell lines studied and results of HLXB9 expression experiments 
125 
Table 6.2: The nuclear localisation of HLXB9 in the T47D cell line compared to the two non-cancer 140 
XI 
 
HMEC cells and MCF 10A cell line analysed 
Table 6.3: The nuclear localisation of HLXB9 in the BT474 cell line compared to the two non-cancer 
HMEC cells and MCF 10A cell line analysed  
140 
Table 6.4: Comparison of the nuclear localisation of HLXB9 in MDA-MB-231 cell line to the two non-
cancer HMEC cells and MCF 10A cell line analysed  
141 
Table 6.5: High HLXB9 expression is a negative prognostic indicator in breast cancer 145 
Table 6.6: High expression of HLXB9 is a better prognostic indicator of relapse in breast cancer 
patients than a number of Oncotype DX genes. 
147 
Table 6.7: High expression of HLXB9 is a better prognostic indicator of relapse in breast cancer 
patients than a number of MammaPrint genes 
148 
Table 6.8: High expression of HLXB9 reduces the survival of breast cancer patients diagnosed with 
grade 2 tumours. 
151 
Table 6.9: High expression of HLXB9 reduced the relapse free survival of breast cancer patients with 
lymph node involvement. 
152 
Table 6.10: Overexpression of HLXB9 reduces the relapse free survival of patients diagnosed with 
























List of abbreviations 
-7 Monosomy of chromosome 7 
 




ALL Acute lymphoid leukaemia 
 
AML Acute myeloid leukaemia 
 
ANGPT1 Angiopoietin 1 
 
bp Base pair 
 
BRCA 1/2 Breast cancer susceptibility 
gene 1 or 2 
 
BSA Bovine Serum Albumin 
 
cDNA Complementary DNA 
 
CEBPA CCAAT enhancer binding 
protein alpha 
 
CLL Chronic lymphoid leukaemia 
 
CLP Common myeloid progenitor 
 
CML Chronic myeloid leukaemia 
 
CMML Chronic myelomonocytic 
leukaemia 
 
CMP Common lymphoid progenitor 
 
CO2 Carbon dioxide 
 
CS Currarino syndrome 
 
Ct Cycle threshold 
 


























ER Estrogen receptor 
 
ETV6 Ets Variant 6  
 
EZH2 Enhancer Of Zeste 2 Polycomb 
Repressive Complex 2 Subunit  
 
FAB French- American- British 
classification of AML 
 
FISH Fluorescent in situ 
hybridisation 
 
FITC Fluorescein isothiocyanate 
 
FLT3 Fms Related Tyrosine Kinase 3 
 
GATA GATA Binding Protein 
 
HER2 Human epidermal growth 
factor receptor  
 
HLXB9 Homeobox gene B9 also known 
as HB9 or MNX1 
 









Ki 67 Ki- 67 protein 
 
KIT Kit Oncogene 
 
 






LT-HSC Long term hematopoietic stem 
cell 
MDS Myelodysplatic syndrome 
 
MEN1 Menin 1 
 
MLL3 Myeloid/Lymphoid or Mixed-
Lineage Leukaemia 3 
 
MNX1 Motor Neuron And Pancreas 
Homeobox 1 
 
MPD Myeloproliferative neoplasms 
 
MPP Multipotent progenitor blood 
cells 
 
mRNA Messenger RNA 
 
NPM1 Nucleophosmin 1 
 
nsd No significant difference 
 
p-arm Short arm of chromosome 
 
PAC P1- derived artificial 
chromosome 
 








PR Progesterone receptor 
 





















q-arm Long arm of chromosome  
 
qRT-PCR Quantitative PCR 
 
RARA Retinoic Acid Receptor, Alpha 
 
RNA Ribonucleic acid 
 
RPM Revolutions per minute 
 
RT-PCR Reverse transcriptase- 
polymerase chain reaction 
 
RUNX1 Runt-related Transcription 
Factor1 
 
SDS Sodium Dodecyl Sulfate 
 
siRNA Small interfering RNA 
 
 
SSC Saline-Sodium Citrate 
 









TE  TRIS-EDTA 
 
TNM Tumour size, node involvement 
and metastasis system 
 


















Chapter 1: General Introduction 
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Introduction 
1.1. Cancer biomarkers  
A biomarker is a measurable biological characteristic that can be evaluated as an indicator of normal 
(physiological) or abnormal (pathogenic) processes (Strimbu and Tavel 2011; Henry and Hayes 2012). 
Therefore, biomarkers are used to objectively differentiate unaffected individuals from affected 
individuals (patients). Apart from the diagnosis of cancer, biomarkers can also be used to identify risk 
factors that predispose to cancer development, judge patients’ prognosis, monitor disease progression 
(relapse or metastasis) and evaluate response to therapy (Henry and Hayes 2012; Burke 2016). There are 
various types of biomarkers. They include cellular/anatomical markers such as histological changes and 
molecular markers such as nucleic acids, genes, proteins, antibodies and gene expression profiles (Henry 
and Hayes 2012; Burke 2016). 
In cancer, the common ways in which genetic biomarkers are routinely used in clinics include: the 
identification of germ line BRCA1/2 mutations as a risk factor in the development of breast and ovarian 
cancer; the BCR/ABL fusion gene to confirm diagnosis and monitor disease status in chronic myeloid 
leukaemia or acute lymphoblastic leukaemia; HER2 amplification to predict response to trastuzumab in 
the treatment of breast or gastric tumours; elevated PSA protein level after treatment for prostate cancer 
indicating disease relapse (Henry and Hayes 2012; Burke 2016). An important aim of cancer research is 
the identification of biomarkers, primarily the detection of biomarkers that can be targeted for therapy.  
 
1.2. The HLXB9 gene 
Homeobox gene HB9 (HLXB9) also known as MNX1 (Motor Neuron and Pancreas Homeobox gene 1) 
encodes a 401 amino acid (aa) protein and maps to the long arm of chromosome 7 at q36.3 (Harrison et 
al. 1994; Ross et al. 1998; Hagan et al. 2000). HLXB9 was first identified and subsequently cloned in 
human B lymphocytes by Harrison and colleagues in 1994 (Harrison et al. 1994). They also identified 
HLXB9 mRNA expression in a variety of adult tissues/organs including pancreas, small intestine, tonsils, 
colon and CD34 positive bone marrow cells (Harrison et al. 1994).  
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HLXB9 is encoded by three exons. Exon one encodes the translation start site, two glycine stretches 
(amino acid (aa) 42-29 and aa100-105 respectively) and a polyadenine repeat of variable length 
(Harrison et al. 1994; Hagan et al. 2000; Crétolle et al. 2008; Garcia-Barceló et al. 2009; Wildenhain et al. 
2012). Exons 1 and 2 together encode an interspecies conserved 82 amino acid sequence unique to 
HLXB9 (aa 161-242) while exon 2 and 3 encode the 60 aa homeodomain (aa 243-302) (Harrison et al. 
1994; Hagan et al. 2000; Crétolle et al. 2008; Garcia-Barceló et al. 2009; Wildenhain et al. 2012). The 
homeodomain in HLXB9 is folded into three alpha helices in a helix turn helix motif, which facilitates both 
its DNA and protein binding function. (Hagan et al. 2000; Nagel et al. 2005; Garcia-Fernàndez 2005; 
Wildenhain et al. 2012)  
HLXB9 belongs to the Antennapedia (ANTP) superclass of homeobox (hbx) genes. The identification of 
another MNX1 orthologue called MNR2 in chicken has led to a sub classification of HLXB9 into its own 
gene family (Holland et al. 2007; Wendick et al. 2004; Odden et al. 2002). The MNX gene family includes 
one gene in mammals: MNX1/HB9; two genes in chicken: MNX1/HB9 and MNX2/MNR2; and three genes 
in zebra fish: MNX1/HB9, MNX2a/MNR2a and MNX2a/MNR2b (Holland et al. 2007; Wendick et al. 2004; 
Odden et al. 2002). Orthologues of both HB9 and MNR2 genes have also been found in drosophila 
(Holland et al. 2007; Wendick et al. 2004; Odden et al. 2002). 
Homeobox genes mainly function as transcription factors and regulate gene expression by binding to DNA 
and/or other proteins to either promote or repress transcription (Holland and Takahashi 2005; Holland 
2013). They play an essential role in embryonic development by directing differentiation and the spatial 
positioning of cells of the germ layer into the mesoderm, endoderm and ectoderm (Garcia-Fernàndez 
2005; Holland et al. 2007; Holland 2013). After embryonic development, they continue to be expressed in 
a tissue specific manner and play a pivotal role in regulating cell division, cell maturation and apoptosis 
(Garcia-Fernàndez 2005; Holland et al. 2007; Holland 2013). Abnormal expression of homeobox genes 
have been implicated in the development of different types of cancers such as leukaemia, breast cancer, 
renal cancer (Chen and Sukumar 2003; Svigen and Tonissen 2003; Nagel et al. 2005; Dormoy et al. 2012). 
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1.3. HLXB9 in foetal development 
Most of the research carried out to elucidate the function of HLXB9 is primarily on its role in foetal 
development. HLXB9 is known to play an essential role in the development of endoderm tissue 
derivatives, which forms the digestive and respiratory tracts (Harrison et al. 1999; Fonseca et al. 2008; 
Sherwood et al. 2009).  
HLXB9 expression has been examined by in situ hybridisation in two studies on human embryo sections. 
The first study by Ross and colleagues found HLXB9 was expressed in the sacral region of the embryo 
(Ross et al.1998). The second study by the same group found HLXB9 expressed in the neural tube, the 
anterior horns (site of motor neuron development), the hindbrain, the pharynx, the oesophagus, the 
stomach, the pancreatic bud and the spinal cord at various stages of embryonic development (Hagan et al. 
2000). 
Other studies to elucidate the role of HLXB9 in foetal development have been carried out on mouse 
embryos. Through these studies, HLXB9 was found to be expressed in a dorsal-ventral gradient 
throughout the anterior-posterior axis of the endoderm (Li et al. 1999; Harrison et al. 1999; Sherwood et 
al. 2009). From these studies, HLXB9 expression has been found to be crucial for the development of the 
pancreas and motor neurons (Li et al. 1999; Arber et al. 1999; Thaler et al. 1999; Harrison et al. 1999; 
Sherwood et al. 2009). 
Two HLXB9 mouse models have been developed to understand HLXB9 role in foetal development (Li et al. 
1999; Arber et al. 1999; Harrison et al. 1999). Heterozygous HLXB9+/- mice show no abnormal phenotype, 
however, their resulting homozygous offspring died at or soon after birth (Li et al. 1999; Harrison et al. 
1999). The homozygous HLXB9 -/-offspring were also smaller and showed abnormal spinal cord curvature 
compared to their littermates suggesting a role for HLXB9 in spinal development (Li et al. 1999; Arber et 
al. 1999). Additionally, in homozygous HLXB9 -/- mice, there were perturbations to pancreatic and motor 
neuron development. In these mice, the dorsal lobe of the pancreas failed to develop, and the pancreatic 
islets (islets of Langerhans) were abnormal (Harrison et al.1999; Li et al.1999; Li et al. 2001; Hagan et al. 
2000). Additionally, defects in the migration, subtypes and projection of motor axons of the motor 
neurons are also a phenotype displayed in homozygous HLXB9 mice (Arber et al. 1999; Thaler et al.1999). 
- 5 - 
Finally, the pattern of expression of HLXB9 in mouse and human embryo has been investigated and 
compared (Hagan et al. 2000). In the study by Hagan and colleagues, they found similar to mouse HLXB9, 
human HLXB9 is expressed in motor neuron progenitors. However, they also found a variety of 
differences in the pattern of HLXB9 expression between the two species during the development of the 
hindgut and the pancreas. This difference in pattern of HLXB9 expression might explain why 
heterozygous mouse show no phenotype while humans with loss of function mutation of HLXB9 develop 
Currarino syndrome.  
 
1.4. Currarino syndrome (CS) 
In humans, loss of function mutation/(s) or micro deletions of HLXB9 can be autosomal dominantly 
inherited or sporadically occur causing Currarino syndrome (CS) (Belloni et al. 2000; Hagan et al. 2000; 
Garcia-Barceló et al. 2009; Zu et al. 2011). Therefore, haploinsufficient expression of HLXB9 can be 
described as the cause of most cases of CS. CS is a rare medical condition (Yoshida et al. 2010; Zu et al. 
2011). A medical diagnosis of CS is characterised by three main phenotypes namely partial sacrum 
agenesis, presacral mass and anorectal malformations (Belloni et al. 2000; Hagan et al. 2000; Garcia-
Barceló et al. 2009; Zu et al. 2011). However, not all CS cases present with all three phenotypes and not all 
individuals with mutations in HLXB9 are symptomatic of CS. This suggests the possibility of a 
mechanism/(s) by which haploinsufficient HLXB9 expression is compensated for by other genes during 
development. (Belloni et al. 2000; Hagan et al. 2000; Garcia-Barceló et al. 2009; Zu et al. 2011). However, 
the responsible compensatory mechanism/(s) is yet to be identified. Other phenotypes which may be 
associated with CS include neural tube defects, urological abnormalities such as duplication of the kidney 
and ureter, horseshoe kidney, neurogenic bladder and gynaecological abnormalities such as bicornuate 
uterus and bifid clitoris (Belloni et al. 2000; Zu et al. 2011). These findings suggest HLXB9 has a role in 
urological development particularly in the organogenesis of the kidney. 
There have been two large scale studies to identify HLXB9 mutations in CS patients(Hagan et al. 2000; 
Crétolle et al. 2008). In 2000, Hagan and colleagues investigated mutations of HLXB9 in 21 cases of 
familial CS and seven cases of sporadically occurring CS. They found 95% of familial CS patients and 29% 
of sporadically occurring CS patients had mutations in HLXB9 (Hagan et al. 2000). The second study by 
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Crétolle and colleagues screened 20 cases of familial CS and 30 cases of sporadically occurring CS. They 
found the same incidence of HLXB9 mutations in familial CS patients by Hagan and colleagues and a slight 
reduction in the incidence of HLXB9 mutation (23%) in sporadic occurring CS (Crétolle et al. 2008).  
Studies to characterise the type of HLXB9 mutations found in CS patients found a majority of mutations in 
HLXB9 occur in exon 1 or exon 2 (exon 2 contains the homeodomain) (Belloni et al. 2000; Hagan et al. 
2000; Crétolle et al. 2008; Garcia-Barceló et al. 2009; Cuturilo et al. 2016). Types of HLXB9 mutations 
observed in these patients include: nonsense, missense, frameshift (insertion or deletion), splice site, 
other point mutations (not yet defined) (Belloni et al. 2000; Hagan et al. 2000; Crétolle et al. 2008; Garcia-
Barceló et al. 2009; Cuturilo et al. 2016). These mutations result in the loss of a functional HLXB9 protein.  
Interestingly, deletions in the long arm of chromosome 7 (7q) is a cytogenetic abnormality found in some 
CS patients (Hagan et al. 2000; Crétolle et al. 2008; Cuturilo et al. 2016).  
 
1.5. HLXB9 constitutional mutations and diabetes 
After foetal development, b-cells in the islets of Langerhans are the only pancreatic cell type that retain 
expression of HLXB9 (Li et al. 1999; Harrison et al. 1999). Pancreatic b-cells are involved in the storage 
and release of insulin. Therefore, it is not surprising that loss of function mutations of HLXB9 have now 
been reported in cases of neonatal diabetes, a disease of insulin deficiency (Flanagan et al. 2014; Pan et al. 
2015). Additionally, HLXB9 has also been found to directly regulate genes that regulate cellular insulin 
such as VSNL1 and PLD1 (Shi et al. 2013).  
 
1.6. HLXB9 constitutional mutations and cancer 
One of the observed phenotypes in CS is the presence of a presacral mass such as anterior meningocele, 
Lipomeningocele, teratoma, dermoid cyst and lipoma (Belloni et al. 2000; Hagan et al. 2000; Crétolle et al. 
2008; Garcia-Barceló et al. 2009; Yoshida et al. 2010; Zu et al. 2011). Teratomas, a type of germ cell 
tumour accounts for 25-40% of presacral mass observed in CS (Dirix et al. 2015). In a study by Crétolle 
and colleagues, 88% of CS patients with intragenic HLXB9 mutations developed benign teratomas 
compared to 50% of CS patients without HLXB9 mutations (Crétolle et al. 2008). This indicates the 
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possibility of HLXB9 functioning as a tumour suppressor.  However, only a very small proportion of CS 
teratomas have been observed to undergo malignant transformation in clinic (nine cases) (Yoshida et al. 
2010). Additionally, only two cases of metastasis to other sites have been observed and both patients 
showed brain metastasis. This finding suggests a possible association for HLXB9 mutations as a single 
cause of cancer development. This also indicates that HLXB9 acts as a modulator of cancer development in 
conjunction with other genetic factors. 
 
1.7. HLXB9 in pancreatic cancer 
Given the role HLXB9 plays in pancreatic development, it is not surprising that aberrant expression has 
been found in pancreatic cancer. HLXB9 was found to downregulated in the squamous subtype of 
pancreatic ductal adenocarcinoma (Bailey et al. 2016). Downregulation of HLXB9 was associated with a 
loss of differentiation in this pancreatic tumour subtype.  
Conversely, upregulation of HLXB9 has been found in insulinomas, a cancer of pancreatic b-cells (Shi et al. 
2013; Desai et al. 2014; Desai et al. 2015). In insulinomas, HLXB9 has been found to be crucial in the 
regulation of apoptosis of b-cells (Shi et al. 2013). In the study by Shi and colleagues, they found that 
HLXB9 was able to regulate apoptosis by binding to Menin (MEN1). However, when MEN1 was deficient 
either due to loss of function mutations or experimental knockdown, HLXB9 becomes upregulated and 
becomes unable to induce apoptosis. 
In a subsequent study by the same group to understand the mechanism by which HLXB9 becomes 
deregulated in insulinomas, they found that serine/threonine kinase glycogen synthase kinase 3 (GSK-3B) 
phosphorylates overexpressed HLXB9 (Desai et al. 2014). The phosphorylation of HLXB9 was shown to 
result in a loss of its pro apoptotic function. They also showed that loss of MEN1 results in an increase of 
phosphorylated HLXB9.  
A final study was carried out by the group to identify the targets and binding partners of phospho-HLXB9 
in insulinomas (Desai et al. 2015). They found that phosphorylated HLXB9 was able to bind to the 
promoter of Casitas B-lineage lymphoma b (Cblb), an E3 ubiquitin ligase to repress its expression (Desai 
et al. 2015). They also found the downregulation of CBIB results in an upregulation of CMET, a tyrosine 
kinase because CBIB is unavailable to target CMET for degradation. Additionally, they found knocking 
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down HLXB9 expression directly decreased the expression of CMET. They proposed that CMET 
overexpression because of HLXB9 overexpression could be a mechanism by which HLXB9 contributes to 
oncogenesis in insulinomas. This series of studies was the first comprehensive investigation into the 
function of HLXB9 in cancer development and demonstrated that accurate regulation of HLXB9 is crucial 
in the pancreas. 
 
1.8. HLXB9 in leukaemia 
Leukaemia is a progressive disorder of haematological cells characterised by uncontrolled proliferation 
and a block in differentiation (Chang and Weiss 2007; Bomken and Josef Vormoor 2009). This disorder 
results in the accumulation of immature ‘blast’ cells in the bone marrow and circulation of these ‘blast’ 
cells in the peripheral blood. There are two main types of leukaemia: acute leukaemia and chronic 
leukaemia. In acute leukaemia, a majority of stem or progenitor blood cells are unable to give rise to 
mature functional blood cells whereas in chronic leukaemia, a smaller proportion of stem or progenitor 
blood cells are unable to give rise to mature blood cells. Because of the difference in proportion of stem 
cell affected, chronic leukaemia has a better prognosis than acute leukaemia. 
In the UK, leukaemia is the 11th most commonly diagnosed cancer and the 9th most common cause of 
cancer deaths (Cancer Research, UK). Acute leukaemia is classified by the lineage of the blood cells 
affected into acute myeloid leukaemia (AML) and acute lymphoid/lymphoblastic leukaemia (ALL). 
Chronic leukaemia is also classified by the linage of the affected blood cells into chronic myeloid 
leukaemia (CML) and chronic lymphoid/lymphoblastic leukaemia (CLL). According to Cancer Research 
UK, these four main types of leukaemia account for 85% of leukaemia cases diagnosed in the UK in 2013 
(as shown in figure 1.1). 
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Figure 1.1: Leukaemia types by proportion of cases diagnosed in the UK in 2013 (Cancer Research, UK). AML, 
acute myeloid leukaemia, ALL: acute lymphoid leukaemia, CML, chronic myeloid leukaemia, CLL, chronic lymphoid 
leukaemia, other types of leukaemia diagnosed in the UK in 2013 include chronic myelomonocytic leukaemia (CMML) 
and hairy cell leukaemia. 
 
 
1.8.1. Normal blood cell development 
Mature blood cells have a limited life span so need to be produced throughout life (Chang and Weiss 
2007; Mazo et al. 2011). The process by which blood cells are produced is called haematopoiesis (Chang 
and Weiss 2007; Mazo et al. 2011). In the early weeks of foetal development, haematopoiesis occurs in 
the embryo’s yolk sac, however, by the third month of foetal development, the liver becomes the main site 
of haematopoiesis (Chang and Weiss 2007; Mazo et al. 2011; Jagannathan-Bogdan and Zon 2013). By the 
fourth month of embryonic development, the bone marrow is the primary site of haematopoiesis (Chang 
and Weiss 2007; Mazo et al. 2011; Jagannathan-Bogdan and Zon 2013). 
The process of blood cell development involves the division and differentiation of pluripotent 
hematopoietic stem cells (HSCs) in the bone marrow (Kondo 2010; Kosan and Godmann 2016). Upon 
activation, long term quiescent HSCs (LT-HSC) with unlimited self-renewal potential give rise to short 
term HSCs (ST-HSCs) with limited self-renewal potential (Chang and Weiss 2007; Kondo 2010; Bruin et 
al. 2014; Kosan and Godmann 2016). These ST-HSCs give rise to multipotent progenitors blood cells 
(MPPs), which give rise to either common lymphoid or myeloid progenitor cells (CMP or CLP). CMP or 
CLP undergo subsequent cell division and differentiation to give rise to the mature blood cells of myeloid 
and lymphoid linages found in the peripheral blood (as shown in figure 1.2) (Chang and Weiss 2007; 
Kondo 2010; Bruin et al. 2014; Kosan and Godmann 2016).  
For this process to occur, HSCs and subsequent progenitor cells respond preferentially to molecules such 
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that control differentiation and proliferation to give rise to mature blood cells of myeloid and lymphoid 
cell linages found in the peripheral blood (Chang and Weiss 2007; Mazo et al. 2011).  
 
Figure 1.2: Schematic representation of haematopoiesis. A long term hematopoietic stem cell (LT-HSC) gives rise 
to short term hematopoietic stem cells (ST-HSCs), which undergo subsequent division and differentiation to give rise 
to lymphoid, and myeloid progenitor cells, which divides and differentiates into mature blood cells. Adapted from 
Bruin et al. 2014.  
 
1.8.2. Commonly mutated genes in haematopoiesis 
Mutation in crucial genes involved in haematopoiesis such as FMS-related tyrosine kinase 3 (FLT-3), 
CCAAT enhancer binding protein alpha (CEBPA) and KIT tyrosine receptor kinase are some of the 
commonly mutated genes found in leukaemia patients (Gregory et al. 2009; Gulley et al. 2010; Betz and 
Hess 2010; Ohgami and Arber 2015; Yohe 2015).  
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Both mutations in genes that confer a proliferative advantage such as FLT, KIT, KRAS, NRAS and mutations 
in genes that block differentiation such as CEBPA, NPM1 have been observed in leukaemia patients 
(Gregory et al. 2009; Gulley et al. 2010; Betz and Hess 2010; de Rooij et al. 2015; Yohe 2015). The 
presence of mutations in these genes are used as biomarkers of patient prognosis (Gregory et al. 2009; 
Gulley et al. 2010; Yohe 2015).  
 
1.8.3. Leukaemia development 
The aetiology of leukaemia is unknown; however, risk factors associated with the development of 
leukaemia include: pre-existing genetic disorders such as Down’s syndrome, Fanconi anaemia; exposure 
to environmental factors such as ionising radiation, chemical or cytotoxic agents; and genetic instability 
such as abnormal DNA repair or gene mutations (Greaves 1999; Langmuir et al. 2001; Bomken and Josef 
Vormoor 2009; Eden 2010). A hypothesis for leukaemia development is that it is a ‘two hit hypothesis’, 
where the first genetic mutation occurs in stem cell in utero termed the ‘first hit ‘and a subsequent 
genetic mutation occurs after birth due to exposure to one of the aforementioned risk factors termed the 
‘the second hit’ (Langmuir et al. 2001; Estey and Döhner 2006; Bomken and Josef Vormoor 2009; Eden 
2010). The two hit model has been validated in literature for most cases of Infant Acute Lymphoid 
Leukaemia (ALL) and in some cases of AML (Bomken and Josef Vormoor 2009; Eden 2010).  
The two hit hypothesis is thought to contribute to cancer development via two mechanisms: the ‘cancer 
stem cell model’ or the ‘stochastic model’ (Nguyen et al. 2012). The cancer stem cell model (also termed 
the hierarchal model of cancer development) proposes the existence of an abnormal hematopoietic stem 
cell termed the ‘cancer stem cell’. Cancer stem cells are able to undergo subsequent cell division to 
produce additional cancer stem cells thereby initiating and supporting cancer development (Nguyen et al. 
2012; Terwijn et al. 2014). In fact the existence of cancer stem cells were first observed in AML; the 
CD34+/CD 38 low/- cells isolated from AML patients were found to be tumour initiating in 
immunocompromised mice (Nguyen et al. 2012; Terwijn et al. 2014). This model of cancer development 
is also thought to explain the frequency of relapse observed in AML patients because if any of the cancer 
stem cell remains after treatment they are able to support tumour growth causing relapse (Terwijn et al. 
2014). 
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The stochastic (random) model of cancer development proposes that any of the cells in the population 
can acquire a mutation or epigenetic change to initiate tumour development (Nguyen et al. 2012). In ALL, 
cancer initiating cells have been observed at different differentiation stages suggesting that ALL is 
developed in a stochastic manner (Purizaca et al. 2012; Mcclellan and Majeti 2013). Although there have 
been numerous attempts to identify cancer stem cells in ALL, there remains no agreement on the 
existence of ALL cancer stem cells(Mcclellan and Majeti 2013). 
 
1.8.4. Myeloid Malignancies 
Myeloid malignancies are disorders that affect myeloid hematopoietic stem or progenitor blood cells. 
Myeloid malignancies can be chronic or acute. Types of chronic myeloid malignancy include 
myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and chronic myeloid leukaemia 
(CML). Acute myeloid malignancies are classified as acute myeloid leukaemia. The incidence and five-year 
relative survival rate of myeloid malignancies diagnosed in Europe between 1995 and 2002 are described 
in table 1.1. From the table, it is evident that patients diagnosed with AML, MPN and MDS have very poor 
prognosis, therefore finding biomarkers that can be targeted in these malignancy types is crucial. 




survival rate in 
Europe (%) 
Acute Myeloid Leukaemia (AML) and related 
precursor neoplasms 
3.7 19% 
Acute Promyelocytic Leukaemia (AML with t(15;17) 0.1 66 
AML, other and not otherwise defined (NOS)  3.4 17 
Myeloproliferative Neoplasms (MPN) 3.1 62% 
Myelodysplastic syndrome (MDS) 1.5 29% 
MDS and MPD 1.8 27% 
Chronic Myeloid Leukaemia (CML) 1.2 44% 
Table 1.1: Incidence and 5-year survival rate of Myeloid Malignancies diagnosed in Europe between 1995 and 
2002 (Visser et al. 2012). 
 
Myeloid malignancies occur as a result of genetic and epigenetic changes that affect either or both the 
proliferation and differentiation of myeloid blood cells. In MDS, the differentiation of myeloid stem or 
progenitor cells into matured cells becomes impaired whilst in MPD, there is an abnormal increase in 
proliferation of myeloid stem or progenitor cells (Foucar 2009; Cazzola et al. 2011). A proportion of MDS/ 
MPD patients have been observed to undergo further malignant transformation and progress to AML 
(Foucar 2009; de Rooij et al. 2015).  
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In AML, both the differentiation and proliferation of myeloid stem/ progenitor blood cells are impaired 
(de Jonge et al. 2011). Myeloid disorders are characterised by the presence of chromosomal 
abnormalities, which have prognostic significance. Common chromosomal abnormality found in MDS or 
AML include del(5q), del(7q), monosomy 7, trisomy 8, 11q23 (Nimer 2008, Visser et al. 2012, Murati et al. 
2012; Van Etten and Shannon 2004). 
 
1.8.5. Acute Myeloid Leukaemia (AML) 
AML is a heterogeneous disease of myeloid progenitor cells in the bone marrow. A diagnosis of AML has a 
poor prognosis with a 5 year survival rate of 30-40% (Langmuir et al. 2001; Estey and Döhner 2006). It is 
the most commonly diagnosed myeloid malignancy in western countries with an annual incidence of 2 
cases per 100,000 (Estey and Döhner 2006; Chang and Weiss 2007). It is more commonly diagnosed in 
adults than children with a peak incidence age of 65 years; when diagnosed in children it usually occurs 
before the age of 2 (Zwaan and Kaspers 2004; Estey and Döhner 2006; Chang and Weiss 2007; Vardiman 
et al. 2009). Children diagnosed with AML have a higher incidence of chromosomal abnormalities than 
adults diagnosed with AML (Mrozek et al. 2004).  
o Classification of AML 
The most commonly used systems for categorising AML diagnosis are the French-American-British (FAB) 
classification and the World Health Organisation (WHO) classification (Chang and Weiss 2007). The 
classification of AML into subtypes with the same biological characteristics has been significant for 
understanding of the mechanism of oncogenesis and informing patients prognosis (Segeren and Veer 
1996; Chang and Weiss 2007; Vardiman et al. 2009; Gulley et al. 2010). 
 The French-American-British (FAB) Classification of AML 
In the 1970s, the FAB classification of AML based on the morphology and cytochemistry of leukaemia 
cells was developed (Bennett et al. 1976; Segeren and Veer 1996). AML was classified into eight subtypes 
by the different degrees of differentiation and cell linage affected (table 1.2).  
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FAB 
subtype 
Description (name) Commonly associated cytogenetic 
finding 
M0 Myeloblastic leukaemia with minimal differentiation Trisomy 11(Alseraye et al. 2011)  
M1 Myeloblastic leukaemia with little differentiation Trisomy 11 (Alseraye et al. 2011) 




Acute promyelocytic leukaemia (APL)- two variants 
M3h APL, hypergranular or 
M3v APL, microgranular  
t(15; 17)(Allford et al. 1999) 
M4/M4 eo Acute myelomonocytic leukaemia  (AMML) or M4 eo- AMML 
with dysplastic marrow eosinophils 
t(16;16), inv(16), del(16q)(Delaunay et 
al. 2003) 
M5 Acute monoblastic leukaemia (AMoL)- two types M5A poorly 
differentiated and M5 B- differentiated  
t(9;11) (Kuipers et al. 2011), del(11q), 
t(11;19)(Tallman et al. 2004) 
M6 Erythroleukaemia- 2 variants 
M6a AML with erythroid dysplasia 
M6b Erythroleukaemia 
t(3;5) (Kwong 1998) 
M7 Acute megakaryoblastic leukaemia (AMkL) t(1;22)(Mercher et al. 2002) 
Table 1.2: The FAB classification of AML showing subtypes and the most common chromosomal abnormality 
(cytogenetic) finding for each subtype (Rubin and Hansen 2012). 
 
 World Health Organisation (WHO) classification of AML  
In 2001, the WHO integrated the morphology and cytogenetic characteristics of blast cells (already used 
in the FAB classification) with additional information on the molecular genetics and immunological 
characteristics of blast cells (Tallman et al. 2004; Chang and Weiss 2007; Vardiman et al. 2009). This 
review of the classification of AML was carried out to improve treatment and prognostic decisions. The 
list was updated in 2008 and categorised into four groups, which are shown in table 1.3 (Vardiman et al. 
2009). 
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AML with recurrent cytogenetic 
abnormalities: This group of AML patients 
have a de novo cytogenetic abnormality. The 
most common are translocations, which 
results in a fusion protein that contributes to 
leukaemogenesis.(Falini et al. 2010). There 
are eight categories under this classification: 
I. t(8;21)(q22;q22)  




IV. t(9;11)(p22;q23)  
V. t(6;9)(p23;q34)  
VI. inv(3)(q21q26.2) or 
t(3;3)(q21;q26.2) 
t(1;22)(p13;q13)  
VII. Provisional entity: AML with 
mutated Nucleophosmin-1 
NPM1  
VIII. Provisional entity: AML with 
mutated CEBPA 
Category I-III are classified as AML 
regardless of blast counts and the other 
categories are classified as AML if the blast 
count is greater than 20%.  
AML with Myelodysplasia 
(MD) related changes: This 
group of AML patients fit into 
one or more of the following 
criteria below.  
I. A history of MD/MD 
neoplasm 
II. MD related 
cytogenetic 
abnormalities e.g-




dysplasia in bone 
marrow or 
peripheral blood 
smears in 50% of 













alkylating agents and 
topoisomerase 
inhibitors, most 
patients in this group 
have a worse 
prognosis than 
patients with de novo 
chromosomal 
abnormalities. 
AML, not otherwise 
specified: This 
group of patients are 
categorised has 




techniques but do 
not fall into the 
other 3 groups.  
 
Table 1.3: WHO classification of AML showing the four groups of AML subtypes and the criteria for 
classification into each group. (Tallman et al. 2004; Vardiman et al. 2009) 
 
Although older than the WHO classification, the FAB classification is still very useful in diagnosis, 
treatment and prognosis as it takes less time to carry out thereby facilitating quick decision making by 
clinical staff (Tallman et al. 2004; Chang and Weiss 2007; Vardiman et al. 2009).  
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1.8.6. Prognostic indicators in leukaemia 
The single most important prognostic indicator used in leukaemia diagnosis and treatment is the 
presence of specific chromosomal abnormalities. 
o Chromosomal abnormalities in leukaemia 
Chromosomal abnormalities, which are changes to the normal chromosomal composition, are a recurrent 
finding in leukaemia. (Greaves 1999; Langmuir et al. 2001; Bomken and Josef Vormoor 2009; Eden 2010; 
Ebert 2011; Wiemels 2012). They are used as biomarkers to classify patient response to therapy into 
favourable, intermediate or adverse categories (Bertz and Hess 2010; Ferrarra and Schiffer 2013; Heng et 
al. 2006). For instance t(15;17) which fuses PML-RARA is successfully treated with trans-retinoic acid 
whilst t(11;17) which fuses ZBTB16/RARA does not respond well to trans-retinoic acid treatment 
(Mrózek et al. 2004; Hasle et al. 2007; Betz and Hess 2010; Ferrara and Schiffer 2013; Estey et al. 2014; 
Ohgami and Arber 2015).  
Although the majority of AML patients have no chromosomal abnormality (55%), there remains a 
significant proportion of AML patients that have recurrent abnormal chromosome rearrangements (45%) 
(Betz and Hess 2010). The most common chromosomal abnormality found in AML patients and their 
impact on patient’s outcome are summarised in table 1.4. 
Table 1.4: Risk classification of common chromosomal abnormality found in AML patients. Patients outcome 
are determined based on patient response to therapy, remission and survival rate. (*Conflicting reports – some 
studies have sometimes classified as being associated with medium risk). (Mrózek et al. 2004; Hasle et al. 2007; 
Manola 2009; Betz and Hess 2010; Grimwade et al. 2013; Ferrara and Schiffer 2013; Estey et al. 2014; Ohgami and 
Arber 2015) 
 
Risk Patient outcome Chromosomal abnormality 




Medium Intermediate Normal Karyotype  
Trisomy 8 
t(9;11) 
Other chromosomal abnormality 









Complex karyotype (>3 chromosomal abnormalities) 
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1.8.7. Chromosomal abnormalities and leukaemia development 
Most normal human cells have a diploid karyotype (2n) comprised of 46 chromosomes, however, due to 
genome instability arising as a result of several essential cellular processes such as DNA damage repair 
and mitosis, chromosomal abnormalities may arise (Agarwal et al. 2006; Thompson et al. 2010; Bakhoum 
and Compton 2012). Chromosomal abnormalities can either be changes in the number of chromosomes 
(numerical abnormalities) or changes in the structure of chromosomes (structural abnormalities). In 
cancer, chromosomal abnormalities are referred to as ‘acquired’ because they are confined to the cancer 
cells. Chromosomal abnormalities may contribute to cancer development by a number of mechanisms 
including: disruption of normal gene expression due to the juxtaposition of genes with regulatory or 
enhancer elements; the deletion or inactivation of tumour suppressor genes; the activation of oncogenes; 
increase in copy number (amplification) or the formation of fusion genes that have oncogenic potential 
(Stephens et al. 2011).  
Once an initial progenitor cell develops a chromosomal abnormality that confers an oncogenic advantage, 
that cell and its progeny are able to divide more rapidly and may gain additional chromosomal 
abnormalities that aid cancer development and progression (Stephens et al. 2011; Greaves and Maley 
2012; Potapova et al. 2013). 
Chromosomal abnormalities are detected by cytogenetic methods such as chromosome banding, 
fluorescent in situ hybridisation (FISH) or molecular methods such as polymerase chain reaction (PCR), 
Microarray, next generation sequencing (NGS) (Bain 2001; Mrózek et al. 2004; Talkowski et al. 2011; Choi 
et al. 2011; Shaffer et al. 2012; Braoudaki and Tzortzatou-Stathopoulou 2012). 
o Structural chromosomal abnormalities and leukaemia development  
Chromosomal abnormalities that result in the rearrangement of the structure of the chromosome are 
termed structural abnormalities. Structural chromosomal abnormalities are referred to as balanced if 
there is no loss or addition of genetic material or as unbalanced if there is a loss or additional of genetic 
material. Structural abnormality occur due to incorrect DNA damage repair or abnormal mitosis 
(Charames and Bapat 2003; Lieber et al. 2003; Stephens et al. 2011; Ganem and Pellman 2012; Shaffer et 
al. 2012). Some of the most common types of structural abnormalities observed in AML and the 
mechanism by which they contribute to cancer development are discussed in detail below. 
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 Chromosomal deletions and leukaemia development 
This structural rearrangement results in the loss of genetic material, which can be the loss of whole 
arms of chromosomes or segments of chromosomes. Deletions of genetic material might lead to 
cancer development due to haploinsufficiency or loss of heterozygosity of tumour suppressor genes 
(Ebert 2011). Chromosomal deletions are more common in myelodysplastic syndrome (MDS) than in 
AML; common deletions in both disorders include del(5q) and del(7q) (Zhang and Rowley 2006; 
Ebert 2011; Braoudaki and Tzortzatou-Stathopoulou 2012; Ferrara and Schiffer 2013). 
 Chromosomal translocations and leukaemia development 
This structural rearrangement occurs when two chromosome exchange segments of genetic material 
(Nambiar and Raghavan 2011; Shaffer et al. 2012; Braoudaki and Tzortzatou-Stathopoulou 2012). 
Translocations are the most commonly occurring structural chromosomal abnormality in leukaemia. 
Additionally, most translocations observed in cancer are reciprocal. The resulting translocations are 
referred to as ‘balanced’ if no loss or gain of genetic material occurs or ‘unbalanced’ indicating loss or 
gain of genetic material (Shaffer et al. 2012).  
Translocations initiate leukaemogenesis by two main mechanisms. The first mechanism is due to the 
disruption of normal gene expression by incorrect juxtaposition with regulatory or enhancer elements 
of other genes. For example, in CML patients, t(8;14) the proto-oncogene c-MYC on chromosome 8 is 
overexpressed due to juxtaposition with the IgH gene locus on chromosome 14 (Agarwal et al. 2006; 
Nambiar and Raghavan 2011). The second mechanism is by the formation of an oncogenic fusion 
protein. For example in AML patients, the formation of PML-RARA fusion protein due to t(15;17); PML-
RARA represses the expression of genes involved in differentiation and apoptosis thereby promoting 
oncogenesis (Rabbitts 1994; Martens and Stunnenberg 2010; Nambiar and Raghavan 2011).  
Apart from these mechanisms, other hypothesis for translocation related cancer development include a 
position effect mechanism of aberrant gene expression or inactivation of tumour suppressor genes 
(Ballabio et al. 2009; Harewood et al. 2010; Nambiar and Raghavan 2011). 
 Chromosomal inversions (inv) and leukaemia development 
This chromosomal rearrangement ensues when two breaks occurring within a chromosome are 
incorrectly repaired. The repair results in a wrong orientation of the chromosomal segment thereby 
changing the order of genes ( Strachan and Read 2011). They are two types of inversions: paracentric 
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inversions where the chromosomal breakpoints are on either side of the centromere and pericentric 
inversions where the breakpoints occur within one of the chromosome arms. Inversions of 
chromosomal material are thought to aid leukaemogenesis in a similar manner to translocations. 
Common inversion in leukaemia include inv(16) in AML, inv (12p) in ALL (Welborn et al. 2004; 
Braoudaki and Tzortzatou-Stathopoulou 2012).  
o Numerical chromosomal abnormality and leukaemia development 
Numerical chromosomal abnormalities are a common occurrence in leukaemia. Aneuploidy is a type of 
numerical chromosomal abnormality where there is loss or gain of one or more chromosomes resulting 
in a loss of the normal diploid karyotype. It is the most common type of chromosomal abnormality and it 
occurs as a result of chromosome missegregation during mitosis resulting in an abnormal distribution of 
chromosomes into daughter cells (Gordon et al. 2012; Braoudaki and Tzortzatou-Stathopoulou 2012; 
Potapova et al. 2013). Types of aneuploidy include trisomy (three copies of a particular chromosome) and 
monosomy (one copy of chromosome). Examples of commonly found aneuploid karyotypes in leukaemia 
include monosomy 7(-7), monosomy 5(-5), trisomy 8 (+8) (Estey and Döhner 2006; Hasle et al. 2007; 
Manola 2009; Braoudaki and Tzortzatou-Stathopoulou 2012).  
Depending on the number of chromosomes lost or gained by cells, the karyotype can be described as 
being near-haploid, hypodiploid or hyperdiploid. Near-haploid cells have lost almost half of the 
chromosomes, hypodiploid cells have fewer chromosomes than a diploid karyotype (<46) and 
hyperdiploid cells have more chromosomes than a diploid karyotype (>46). Hyperdiploidy is associated 
with a more favourable outcome than hypodiploidy or near haploid karyotype, and the prognosis of an 
hypodiploid or near haploid karyotype is linked in severity with the number of chromosomes lost 
(Braoudaki and Tzortzatou-Stathopoulou 2012).  
Another type of numerical abnormality is polyploidy; as most human cells are diploid (2n), polyploidy 
involves gains of whole sets of chromosomes e.g. triploidy (3n) and tetraploidy (4n). Polyploidy can occur 
in leukaemia and although this is very rare, it is associated with very poor prognosis (Kim et al. 2012; 
Braoudaki and Tzortzatou-Stathopoulou 2012; Li et al. 2012). The mechanisms by which numerical 
chromosomal abnormalities contribute to leukaemogenesis remains unknown due to large amount of 
genetic material lost or gained (whole chromosomes) (Gordon et al. 2012).  
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1.8.8. Chromosome 7 abnormalities in leukaemia 
Monosomy 7 (-7) and deletions in the long arm of chromosome 7, del(7q) are commonly observed in 
myeloid malignancy (Tosi et al. 1996; Johnson and Cotter 1997; van der Straaten et al. 2005; Hasle et al. 
2007). Del(7q) is particularly associated with secondary myelodysplastic syndrome (MDS) or AML, which 
arises as a result of chemotherapy treatment with alkylating agents and topoisomerase (Döhner et al. 
2010; Hasle et al. 2007; Tosi et al. 1996). Monosomy 7 and Del(7q) are also found in De novo cases of 
MDS and AML although with significantly reduced incidence when compared to secondary AML/MDS 
(Hasle et al. 2007; Tosi et al. 1999; Döhner et al. 2010).  
Monosomy 7 and deletion in 7q in myeloid disorders are more commonly found in elderly patients 
compared to younger patients (Hasle et al. 2007; Honda et al. 2015). Yet, these chromosomal 
abnormalities are also found in significant proportion of paediatric and adolescent patients. In a study of 
124 paediatric and adolescent cases of AML, monosomy 7 was found in 10% of cases while del(7q) was 
found in 4 % of cases (Manola et al. 2013). 
Reported cases of AML with chromosome 7 abnormalities include cases with del(7q) as the only 
abnormality, cases of del(7q) associated with complex karyotype, deletions of 7q due to unbalanced 
translocation, deletion in 7p due to unbalanced translocation and translocation of chromosome 7 without 
deletions in 7q/7p (Březinová et al. 2007).  
Monosomy 7 and del(7q) are not associated with a particular FAB subtype implying that all myeloid 
linages are equally affected (Hasle et al. 2007; Manola et al. 2013). Clinically, 7/del (7q) is used as a 
prognostic biomarker as patients with -7/del(7q) respond poorly to therapy and have a low survival rate 
(three year event free survival of 34%) (Tosi et al. 1996; van der Straaten et al. 2005; von Bergh et al. 
2006; Březinová et al. 2007). 
Due to the poor prognosis of -7/del(7q) in AML, research was carried out to identify the commonly 
deleted regions on 7q. The common breakpoints on 7q are at q22, q31-q35, q36. Therefore, it was 
hypothesised that these regions might contain tumour suppressor gene(s), which when deleted or 
disrupted lead to leukaemogenesis (De Weer et al. 2010; Tosi et al. 2003; Tosi et al. 1999; Tosi et al. 1996; 
Park et al. 2009). 
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Genes identified in the commonly deleted region of chromosome 7 that are thought to contribute to 
leukaemogenesis include CUX1, EZH2, MLL3 and LUCL7 (Hosono et al. 2014; Honda et al. 2015). Using 
transcriptome sequencing and SNP array analysis, McNerney and colleagues identified a commonly 
deleted region at 7q 22.1 in monsomy 7/del 7q patients (McNerney et al. 2013). They subsequently 
identified the deleted region contained the CUX1 tumour suppressor gene. They found patients with 
del(7q) showed haploinsufficient expression of CUX1, a transcription factor crucial in the regulation of the 
cell cycle, cell migration and cell differentiation. They also found transplanted CUX1 haploinsufficient 
hematopoietic stem cells were better able to engraft immunocompromised mouse by 40% (McNerney et 
al. 2013). CUX1 as a tumour suppressor has also been implicated in other cancers (McNerney et al. 2013; 
Hosono et al. 2014; Honda et al. 2015).  
Another gene in the commonly deleted region at 7q36 is EZH2 (De Weer et al. 2010). Ernst and colleagues 
found EZH2 was commonly mutated in MDS/MPN patients. They found these patients had loss of function 
mutations of EZH2 suggesting EZH2 functions as a tumour suppressor in myeloid cells (Ernst et al. 2010; 
De Weer et al. 2010; Hosono et al. 2014; Honda et al. 2015). 
The method of identifying and investigating the function of genes in the commonly deleted region in -
7/7q patients is promising and has started to help in the understanding of leukaemogenesis in these 
patients. However, considering the loss of whole chromosome observed in patients harbouring 
monosomy 7 and that the deleted region in 7q (7q22-7q36) is heterogeneous, several genes that are lost 
or deregulated might play a role in contributing to leukaemogenesis in these patients (Ernst et al. 2010; 
De Weer et al. 2010; Boultwood 2013; Hosono et al. 2014; Honda et al. 2015). 
 
1.8.9. Chromosomal abnormalities and HLXB9 expression in leukaemia 
Studies carried out on AML infant patients harbouring a translocation of chromosome 7 and 12 t(7;12) 
(q36;p13) show an overexpression of the HLXB9 gene in all of the cases investigated (von Bergh et al. 
2006; Ballabio et al. 2009; Park et al. 2009). The breakpoint in these cases were variable but have been 
observed not to disrupt the HLXB9 gene (Tosi et al. 2000; Simmons et al. 2002; Tosi et al. 2003; Naiel et al. 
2013). Patients with this translocation have a very poor prognosis, a three-year event free survival of 0% 
(von Bergh et al. 2006). 
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In t(7;12) patients, the translocation involves the HLXB9 and ETV6 genes. ETV6 (TEL) belongs to a group 
of ETS transcription factor family; it is a ubiquitously expressed and is encoded at 12p13 (Tosi et al. 
2000). ETV6 plays a very important in haematopoiesis (Kralik et al. 2011). The chromosome band 12p13 
has been shown to be involved in translocation with various partners in many haematological 
malignancies including AML (Bohlander 2005; Kralik et al. 2011; Tosi et al. 1999). The adverse prognosis 
of patients diagnosed with AML harbouring t(7;12) has naturally led to research to identify the molecular 
mechanism of leukaemogenesis in these patients. 
As one of the mechanisms by which translocations contribute to leukaemogenesis is the production of a 
oncogenic fusion protein, a number of studies have been employed to identify a fusion transcript in 
t(7;12) patients. Reverse transcriptase-polymerase chain reaction (RT-PCR) used to identify the fusion 
transcript in t(7;12) patients showed a fusion of exon 1 of the HLXB9 gene to either exons 2 or 3 of the 
ETV6 gene (von Bergh et al. 2006; Taketani et al. 2008; Ballabio et al. 2009; Park et al. 2009). Two 
different HLXB9-ETV6 fusion transcripts have been described, an out of frame longer variant (exon 1 of 
HLXB9 to exon 2 of ETV6) and an in-frame shorter variant (exon 1 of HLXB9 to exon 3 of ETV6). However, 
both fusion transcripts contains the regulatory (promoter) sequence, the first exon of the HLXB9 gene, the 
ETS domain (DNA and protein binding domain) and the pointed N terminal domain (PNT) (protein-
protein binding domain) of the ETV6 gene (von Bergh et al. 2006; Taketani et al. 2008; Ballabio et al. 
2009; Park et al. 2009). Although a fusion transcript has been observed for this translocation, it is only 
present in 50% of cases suggesting that the formation of an oncogenic fusion protein may not be the 
mechanism for oncogenesis in these patients (von Bergh et al. 2006; Taketani et al. 2008; Ballabio et al. 
2009; Park et al. 2009). 
A commonality in all AML patients harbouring t(7;12) is the overexpression of the HLXB9 gene suggesting 
that the overexpression of HLXB9 might be the driver of leukaemogenesis in these patients. 
Overexpression of HLXB9 in t(7;12) patients was identified by von Bergh and colleagues when they 
quantified the expression of genes at 7q36 in these patients by Real Time Quantitative PCR (von Bergh et 
al. 2006). They found the expression of other genes localised on 7q36-NOM1, LMBR1 and RNF32 in t(7;12) 
AML patients was not altered compared to normal bone marrow. They also found the expression of the 
ETV6 gene (HLXB9 translocation partner) was also unchanged compared to normal bone marrow. The 
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aberrant expression of HLXB9 in t(7;12) AML patients has subsequently been observed in studies by 
other groups (Ballabio et al. 2009; Wildenhain et al. 2012).  
Although all t(7;12) AML patients overexpress HLXB9, only 50% of patients show the HLXB9-ETV6 fusion 
transcript. This raised a question on how ectopic expression of HLXB9 occurs in these patients. A study by 
Ballabio et al. 2009 suggested that a change in the nuclear localisation of the translocated 7 from the 
nuclear periphery to the nuclear interior might result in the overexpression of HLXB9 observed due to a 
position change effect. Another hypothesis for the potential driver of aberrant HLXB9 expression 
observed is that the wild type chromosome 7 is responsible although this is yet to be confirmed 
experimentally.  
Although these studies identified the aberrant overexpression of HLXB9 in t(7;12) AML patients, the 
question of whether HLXB9 is expressed by healthy blood cells (bone marrow or peripheral blood) is 
debated. A study by Deguchi and Kehrl in 1991 found low expression of HLXB9 in whole population of 
bone marrow cells and increased expression in bone marrow fractions enriched for CD34+ cells (Deguchi 
and Kehrl 1991). However, subsequent studies have been unable to detect HLXB9 expression in healthy 
CD34+ bone marrow cells and peripheral blood (Nagel et al. 2005; von Bergh et al. 2006; Wildenhain et al. 
2012). Notwithstanding the question of whether HLXB9 is expressed in healthy blood cells, it can be 
concluded from studies comparing HLXB9 expression in t(7;12) AML patients to healthy progenitor blood 
cells and other AML patients without t(7;12) that the overexpression of HLXB9 observed in t(7;12) AML 
patients is abnormal (von Bergh et al. 2006; Balgobind et al. 2011; Wildenhain et al. 2012). 
o Gene expression changes in t(7;12) AML patients 
The functional significance of the overexpression of HLXB9 observed in t(7;12) AML patients is an 
important research question because of the extremely poor prognosis of these patients.  
Wildenhain and colleagues compared the gene expression profile of t(7;12) AML patients to mixed linage 
leukaemia (MLL) rearranged AML patients, another group of patients with a poor prognosis (Wildenhain 
et al. 2010). They found compared to MLL rearranged AML patients, t(7;12) patients shown 
downregulation of HOX genes and up regulation of cell to cell interacting genes EDIL3, CNTNAP5, ANGPT1, 
DSG2, ITGA9, ITGAV, KDR, SIGLEC6. This finding suggests the mechanism of leukaemogenesis in MLL AML 
patients is different from t(7;12) AML patients. Out of the genes upregulated in t(7;12) patients, two 
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genes: angiopoietin-1 (ANGPT1) and KDR are  involved in maintaining normal quiescent haematopoietic 
stem cells (HSC) in healthy bone marrow niche. Their findings suggest dysregulation of these crucial of 
these genes could contribute to leukaemogenesis.  
Another gene expression profiling study by Balgobind and colleagues also identified a unique gene 
expression signature in t(7;12) AML patients (Balgobind et al. 2011). They identified 16 genes that are 
differential expressed in t(7;12) AML patients compared to healthy bone marrow cells and other non 
t(7;12) AML patients. This finding implies that the presence of the translocation t(7;12) or HLXB9 
overexpression results in a unique gene expression profile that may contributes to leukaemogenesis in 
these patients (Balgobind et al. 2011).  
Wildenhain and colleagues also used ChIP on ChIP and gene expression profiling to identify HLXB9 target 
genes in t(7;12) AML patients by transfecting an AML derived cell line (HL-60) with a pMC vector 
containing HLXB9 (Wildenhain et al. 2012). They found that HLXB9 was able to bind to prostaglandin E 
receptor 2 (PGTER2) to downregulate the expression of PGTER2, thereby reducing intracellular cAMP 
level. They suggested the downregulation of PGTER2 might contribute to the disruption of bone marrow 
homeostasis, as PGE2 the ligand for PGTER2 has a crucial function in maintaining bone marrow 
homeostasis. They also found HLXB9 expression in HL60 cell line had a repressive effect on other genes, 
particularly downregulating the expression of genes involved in cell adhesion and cell to cell interaction 
such as ZYX, ETS1 (Wildenhain et al. 2012).  
In summary, these studies indicate the dysregulation of genes involved in cell to cell interaction occurs in 
t(7;12) patients. Therefore, HLXB9 overexpression in these patients may disrupt the homeostasis of the 
bone marrow niche contributing to leukaemogenesis. 
 
1.9. HLXB9 in breast cancer 
Breast cancer is the most commonly diagnosed cancer in the UK (Cancer Research UK). It is more 
commonly diagnosed in females than in males. In 2013, approximately 53,700 women were diagnosed 
with breast cancer compared to 340 men in the UK. Breast cancer is also the second leading cause of 
cancer deaths in women (Cancer Research UK). Breast cancer is a heterogeneous disease encompassing a 
variety of histological and biological subtypes.  
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Histologically, there are more than 20 distinct types of breast cancer (Weigelt et al. 2010). The most 
common type of breast tumours originates in the milk ducts. It is classified into ductal carcinoma in situ, 
DCIS (benign tumour) or invasive ductal carcinoma (malignant tumour). Approximately 50-80% of all 
breast tumours diagnosed are of the invasive ductal carcinomas (no specific subtypes) (Weigelt et al. 
2010; Caldarella et al. 2013).  
The second most commonly diagnosed type of breast tumours diagnosed originates from the breast 
lobules. They are classified into lobular carcinomas in situ (LCIS) and invasive lobular carcinomas. 
Approximately 5%-15% of breast tumours are invasive lobular carcinoma (Weigelt et al. 2010; Caldarella 
et al. 2013). There are other rare forms of breast carcinomas that originate from breast tissues such as 
the fatty tissue, connective tissue and nipples (Weigelt et al. 2010). 
Risk factors 
Factors that affect the risk of developing breast cancer in women are divided into factors that increase 
risk and those that reduce risk. Factors that increase the risk of developing breast cancer include age, 
lifestyle factors, exogenous hormones, reproductive factors and genetic factors (García-Closas et al. 2006; 
Murray and Davies 2013). The risk of a woman developing breast cancer increases with age; 
approximately half of all breast cancer cases are diagnosed in women aged 65 and over (Cancer Research, 
UK). The use of exogenous hormones such as oral contraceptives and hormone replacement therapy 
(HRT) has also been showed to increase the risk of breast cancer. Lifestyle factors such as obesity, alcohol 
and lack of exercise have also been linked to breast cancer development. Other factors that have been 
shown to increase breast cancer risk include reproductive factors such as early age at menarche, late age 
at first birth, late menopause, null parity, high breast density and mutations in tumour suppressor genes.  
Germline mutations in tumour suppressor genes that predispose inheritants to developing breast cancer 
can be classified into high penetrant, moderate penetrant and low penetrant mutations (Buchholz and 
Wazer 2002; Mavaddat et al. 2010). High penetrant mutations in tumour suppressor genes such as breast 
cancer gene 1 and 2 (BRCA1/2), TP53 (Li Fraumeni syndrome), ATM (ataxia telangiectasia) and PTEN 
(cowden’s factor) are rare in the population but are responsible for a majority of familial breast cancer 
development (Buchholz and Wazer 2002; Liebens et al. 2007; Murray and Davies 2013). For instance, 
germline mutations of BRCA1/2 account for about 20-25% of familial case of breast cancer but only 5% of 
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all cases of breast cancers (Buchholz and Wazer 2002; García-Closas et al. 2006; Liebens et al. 2007; 
Mavaddat et al. 2010; Davies 2012; Murray and Davies 2013). Women who carry germline mutations of 
high penetrant tumour suppressor genes have a significantly increased risk of breast cancer 
development. For example BRCA1/2 mutations confers a 60-85% risk of breast cancer development in 
inheritants (Liebens et al. 2007; Mavaddat et al. 2010; Davies 2012).  
Moderate penetrant tumour suppressor mutations account for less than 3% of breast cancer cases 
(Mavaddat et al. 2010). They include mutation in tumour suppressor genes such as CHEK2, PALB, BRIP1; 
genes important in DNA repair (Mavaddat et al. 2010; Apostolou and Fostira 2013). Low penetrant 
tumour suppressor mutations in genes such as FGFR2, MAP3K1 have very weak associations with breast 
cancer development (Mavaddat et al. 2010; Apostolou and Fostira 2013). The mechanism by which low 
penetrant mutations confer familial risk is thought to be through interactions with other genetic, 
environmental or lifestyle factors.  
Factors that reduce risk of developing breast cancer includes young age at first birth, high parity and an 
increased period of breast-feeding (García-Closas et al. 2006; Davies 2012). 
 
Prognostic indicators in breast cancer 
Prognostic indicators in breast cancer include tumour size, lymph node involvement, distant metastasis, 
tumour grade and tumour intrinsic molecular markers (Arnone et al. 2010; Davies 2012). These 
characteristics are used to judge a patient’s treatment options and prognosis in clinic (Arnone et al. 2010; 
Davies 2012; Tang et al. 2016). 
o TNM prognostic staging of breast cancer 
The traditional way of assessing patients’ prognosis is an assessment of tumour size, node involvement 
and metastasis (TNM system) described in table 1.5. Tumour size (T) is an indicator of cancer 
progression. Smaller tumours are usually associated with a better prognosis than larger tumours as it 
usually means the tumour was detected early and is unlikely to have metastasised (Narod 2012). Lymph 
node involvement (N) is also an indicator of cancer progression as the presence of local metastasis in the 
lymph node indicates the cancer has spread from the breast (metastasis) (Galea et al. 1992). Metastasis 
(M) is also an indicator of cancer progression; the presence of distant metastasis significantly reduces a 
- 27 - 
patient’s survival and is the leading cause of breast cancer related death (Arnone et al. 2010; Davies 
2012). Common sites of metastasis in breast cancer include lungs, bone, liver and brain (Davies 2012). 
Tumour Size 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1  T1mi: Tumour ≤ 1 mm  
T1a Tumour: > 1 mm but ≤ 5 mm  
T1b Tumour: > 5 mm but ≤ 10 mm  
T1c Tumour: > 10 mm but ≤ 20 mm  
T2  > 20 mm but ≤ 50 mm 
T3 > 50 mm 





N0 No regional lymph node metastases Negative of isolated tumour clusters (ITC)*.  
N1 Metastasis to mobile regional nodes 1–3 micro or macro metastasis  
N2 Metastasis to Fixed regional or internal mammary 
nodes  
4–9 nodes 
N3 Metastasis to supraclavicular lymph node >10 nodes, axillary and internal mammary 
or supraclavicular nodes 
Distant Metastasis 
M0 No clinical or radiographic evidence of distant metastases 
cM0(i+) No clinical or radiographic evidence of distant metastases, but deposits of molecularly or 
microscopically detected tumour cells in circulating blood, bone marrow, or other nonregional 
nodal tissue that are no larger than 0.2 mm in a patient without symptoms or signs of metastases 
M1  Distant detectable metastases as determined by classic clinical and radiographic means and/or 
histologically proven larger than 0.2 mm 
Table 1.5: TNM classification of breast tumours. 7th Edition of American Joint Committee of Cancer (AJCC) breast 
cancer staging. *Isolated tumour cell clusters (ITC) are defined as small clusters of cells not greater than 0.2 mm, 
single tumour cells, or a cluster of fewer than 200 cells in a single histologic cross-section (Davies 2012; Ozsaran and 
Alanyah 2013). 
The TNM classification of breast tumours is used to assign the stage of breast cancer progression in 
patients (as shown in table 1.6). There are four main stages of breast cancer. Breast cancer stages are 
associated with patient’s prognosis; the earlier in the staging classification the tumour falls into, the 
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Stage TNM Five year Survival Rate* 
Stage 0 Tis, M0, NO N/A 
Stage I Stage IA: T1 N0 M0  
Stage IB: T0-T1 N1M0 
99% 
Stage II Stage IIA: T0 N1 M0  
T1 N1M0 
                   T2 N0 M0  
Stage IIB: T2 N1 M0 
                   T3 N0 M0 
90% 
Stage III Stage IIIA: T0 N2 M0  
  T1 N2 M0  
  T2 N2 M0  
  T3 N1 M0  
  T3 N2 M0  
Stage IIIB: T4 N0 M0  
  T4 N1 M0  
 T4 N2 M0  
Stage IIIC Any T N3 M0 
60% 
Stage IV Any T, Any N, M1 15% 
Table 1.6: American Joint Committee of Cancer Breast Cancer Staging (7th Edition) (Davies 2012; Ozsaran and 
Alanyah 2013). The five-year survival rates were obtained from the Cancer Research UK and are based on survival 
rates of breast cancer patients diagnosed between 2002 and 2006. 
 
o Tumour grade 
Histological tumour grade is an indicator of tumour aggressiveness. Tumour grade is used in conjunction 
with the TNM stage to determine the patient’s prognosis (Rakha et al. 2010; Weigelt et al. 2010). It is 
incorporated into various prognostic indices, algorithms and treatment guidelines such as the 
Nottingham Prognostic Index, Adjuvant! Online and St. Gallen guidelines (Rakha et al. 2010; Weigelt et al. 
2010). Tumour grade is a measure of the tumour cell differentiation and proliferation (Rakha et al. 2010; 
Weigelt et al. 2010). Tumour cell differentiation is a judgement of the tumour’s cell ability to form 
functional glands and nuclear appearance. Progression in cancer development is characterised by a block 
in the ability to form functional glands and abnormal nuclear appearance termed ‘nuclear pleomorphism’, 
which is change to nuclear shape and size in tumour cells. Tumour proliferation or mitotic index is a 
measure of cellular growth pattern.  
In the UK, tumour grade is measured using the Nottingham Grading System (NGS) (Rakha et al. 2010; 
Weigelt et al. 2010). The NGS classifies breast tumours into three grades (Grade 1 to 3). Grade 1 tumours 
are described as well differentiated tumour cells that are slowly growing. Grade 2 tumours have 
moderately differentiated cells that are starting to proliferate uncontrollably. Grade 3 tumours have 
poorly differentiated cells with a marked increase in proliferation. Similar to breast cancer stages, higher 
tumour grades are associated with significant reduction in patient’s survival (Rakha et al. 2010; Weigelt 
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et al. 2010). Higher-grade tumours are also associated with increased metastatic potential and is usually 
an indication that metastasis had already occurred or is likely to occur (Harvey et al. 2009). 
o Genetic biomarkers in breast cancer  
The heterogeneity of breast tumours is also observed in its gene expression profile. Microarray gene 
expression profiling of breast tumours resulted in the classification of breast cancer into four main 
‘intrinsic’ molecular subtypes (Perou et al. 2000; Sorlie et al. 2003; Parker et al. 2009; Curigliano 2012; 
Tang et al. 2016). These ‘intrinsic’ molecular subtypes include luminal A, luminal B, HER2-overexpressing 
and basal like tumours. These molecular subtypes are also used to inform patient’s treatment decisions 
and can be used to predict patients’ outcome as they have prognostic significance.  
This classification is based on differential expression of genes associated with breast cancer proliferation 
such as oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER 
2) and cell proliferation measured by Ki 67 expression. Increased expression of oestrogen receptor (ER) 
and progesterone receptor (PR) were identified in breast tumours early on in breast cancer research as 
reviewed in Sommer and Fuqua 2001 and Murphy and Watson 2002. Activation of these receptors results 
in cellular signalling processes that induce uncontrolled cell proliferation (Murphy and Watson 2002; 
Sommer and Fuqua 2001). 
ER positive tumours are termed luminal tumours because their gene expression profiles are similar to 
non-cancer breast luminal epithelium cells. ER positive tumours are classified into luminal A and luminal 
B tumours (Perou et al. 2000; Sorlie et al. 2003; Parker et al. 2009; Weigelt et al. 2010). 
Luminal A subtype breast tumours are the most commonly diagnosed type of breast tumours, 
representing 40-60% of all breast cancer cases (Eroles et al. 2012; Tang et al. 2016). These tumours are 
characterised by high expression of ER related genes; low expression of HER2 related genes; low levels of 
proliferation as detected by Ki-67, and are usually low grade tumours (Perou et al. 2000; Sorlie et al. 
2003; Parker et al. 2009; Weigelt et al. 2010; Eroles et al. 2012). These tumours are associated with a 
favourable prognosis as they can be treated successfully with hormonal therapies that target ER 
signalling such as tamoxifen or aromatase inhibitors (Curigliano 2012; Davies 2012; Tang et al. 2016).  
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Luminal B subtypes account for 10-20% of all breast cancers (Eroles et al. 2012; Tang et al. 2016). These 
tumours are characterised by a lower expression of ER related genes than luminal A tumours, usually 
show overexpression of HER2; have high levels of proliferation as detected by Ki-67; lymph node 
involvement; and are usually high grade tumours (Perou et al. 2000; Sorlie et al. 2003; Parker et al. 2009; 
Weigelt et al. 2010; Eroles et al. 2012; Inic et al. 2014). As this tumour molecular subtype is associated 
with poorer prognostic characteristics markers, it is usually associated with poor prognosis. These 
tumours can also be treated with ER targeted therapy, however, they are less responsive to ER targeted 
therapy than luminal A tumours and may respond better to treatment with chemotherapy agents 
(Curigliano 2012; Eroles et al. 2012; Tang et al. 2016).  
ER negative molecular subtype tumours include HER2 overexpressing tumours and basal and normal like 
tumours. HER2 overexpressing breast tumour accounts for 10-20% of diagnosis (Eroles et al. 2012; Tang 
et al. 2016). These tumours are characterised by their overexpression of HER2. They usually lack the 
expression of ER and PR, are poorly differentiated, highly proliferative, show lymph node involvement 
and a high risk of metastasis (Perou et al. 2000; Sorlie et al. 2003; Parker et al. 2009; Weigelt et al. 2010; 
Eroles et al. 2012; Tang et al. 2016). Therefore, this tumour molecular subtype is associated with poor 
prognosis. HER2 belongs to the human epidermal growth factor receptor (HER) family of receptors 
(Davoli et al. 2010). Upon activation, these receptors are involved in signalling pathways that control cell 
growth, differentiation and survival (Davoli et al. 2010). Targeted antibody therapy to the HER2 receptor 
such as trastuzumab (Herceptin) and pertuzumab (Perjeta), has considerably improved the prognosis of 
patients diagnosed with this molecular subtype (Parker et al. 2009; Davoli et al. 2010; Eroles et al. 2012; 
Tang et al. 2016). 
Basal tumours, also called triple negative tumours are so termed because they do not express either ER, 
PR or HER2 receptors (Perou et al. 2000; Sorlie et al. 2003; Parker et al. 2009; Weigelt et al. 2010; 
Bertucci et al. 2012; Eroles et al. 2012). They are characterised by high proliferation and are associated 
with a poor prognosis because of the lack of molecular targets for therapy (Perou et al. 2000; Sorlie et al. 
2003; Parker et al. 2009; Weigelt et al. 2010; Bertucci et al. 2012; Eroles et al. 2012). Basal tumours 
account for 10-20% of breast cancer cases (Bertucci et al. 2012; Eroles et al. 2012; Tang et al. 2016). Their 
gene expression profiles are similar to basal epithelial cells (Bertucci et al. 2012; Eroles et al. 2012). This 
tumour molecular subtype is characterised by large tumour size, high levels of proliferation, poor 
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differentiation, high tumour grade, lymph node involvement, high metastatic potential, high relapse rate, 
TP53 mutations, and are thereby associated with a very poor prognosis (Bertucci et al. 2012; Eroles et al. 
2012). Basal tumours also make up most breast cancer associated with BRCA1 mutations (Bertucci et al. 
2012; Eroles et al. 2012; Murray and Davies 2013). Currently, there are no options for targeted gene 
therapy in the treatment of triple negative tumours. Therefore, patients are treated with standard options 
such as surgery, radiotherapy and chemotherapy. However, patients with triple negative tumours are 
known to respond poorly or acquire resistance to chemotherapy. Consequently, there are on-going 
attempts to identify gene targets for therapy for this intrinsic subtype (Curigliano 2012; Bertucci et al. 
2012; Tang et al. 2016). 
Although the use of these prognostic factors to inform treatment decisions has considerably improved 
patients’ outcome, several gaps remain in the understanding of the class of diseases termed ‘breast 
cancer’. Some of these gaps include: the heterogeneity of tumours (both intra and inter tumour), 
identification of markers for early diagnosis, stratification of in situ breast tumours to prevent 
overtreatment of patients, understanding disease progression (relapse and metastasis), side effects of 
current treatments and therapy resistance. Therefore, the identification and validation of new genetic 
biomarkers, which can be used to answer some of these questions, will be very useful in improving 
patients’ outcome.  
o Breast cancer tumour sequencing based classifications 
There have been a number of studies to identify other genes that can be targeted for therapy in breast 
cancer. The studies have arisen due to the development of new techniques such as DNA and RNA 
sequencing methods (Desmedt et al. 2013). A landmark study on 2,000 breast tumours by Curtis et al in 
2012 (METABRIC) identified ten ‘types’ of breast cancer as well as a number of frequently deleted genes 
such as PPP2R2A, MTAP, and MAP2K4.  A follow up study by the same group on 2,433 breast tumours 
samples identified 173 frequently mutated genes from which they were able to identify 40 potential 
cancer driver genes including PIK3CA, AKT1, KMT2C (Pereira et al. 2016). These studies are starting to 
provide potential targets for therapy. They have also started to advance our understanding of breast 
cancer, for instance, they have shown that although there are numerous gene mutations in breast cancer, 
these mutations are not frequently occurring but usually involve mutation in genes involved in similar 
signalling pathways or biological processes (Desmedt et al. 2013; Pereira et al. 2016). A frequent process 
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deregulated in breast cancer is apoptosis; therefore aberrant HLXB9 expression, which is known to be 
anti-apoptotic in insulinomas, was examined in breast cancer.  
HLXB9 expression in Breast Cancer 
Aberrant expression of HLXB9 has been found in breast cancer (Neufing et al. 2003; Tommasi et al. 2009; 
Lian et al. 2012; Siletz et al. 2013b; Siletz et al. 2013a). The earliest study on HLXB9 expression in breast 
cancer was carried out by in 2003 (Neufing et al. 2003). In their study, they compared HLXB9 expression 
in matched normal and cancer samples in breast cancer patients. They found HLXB9 was expressed in 
both normal and cancer breast sections. Additionally, they found, although a greater proportion of cancer 
epithelial cells in breast cancer patients showed HLXB9 expression, there was a significant reduction in 
the intensity of HLXB9 staining in these cancer sections compared to normal sections. They also found a 
decrease in the staining intensity of HLXB9 associated with increased tumour grade in patients. These 
findings imply a loss of HLXB9 expression in breast cancer associated with cancer progression suggesting 
that HLXB9 has a tumour suppressive role in breast cells. 
Other studies have subsequently supported these findings by identifying a downregulation of HLXB9 in 
breast cancer (Tommasi et al. 2009; Lian et al. 2012; Siletz et al. 2013b; Siletz et al. 2013a). These include 
two studies that found hypermethylation of HLXB9 in breast cancer samples compared to control samples 
(Tommasi et al. 2009; Lian et al. 2012). In the first study by Tomassi and colleagues, they found early 
occurring breast cancer specific hypermethylation of HLXB9 in breast cancer patients diagnosed with 
ductal carcinoma in situ tumours. The second study by Lian and colleagues also found hypermethylation 
of HLXB9 in early stage invasive breast cancer samples compared to normal breast samples (Lian et al. 
2012). In conjunction, results from both studies showed hypermethylation of HLXB9 was an early 
occurrence in breast cancer development and downregulation of HLXB9 may have potential as an early 
biomarker of breast cancer development.  
Two other studies on transcription factor activity in breast cancer by Siletz and colleagues have also 
reported downregulation of HLXB9 was associated with cancer progression (Siletz et al. 2013b; Siletz et 
al. 2013a). In their first study investigating the epithelial-mesenchymal transition (EMT) process in 
cancer, they identified down regulation of HLXB9 in all models of EMT that they investigated (Siletz et al. 
2013b). EMT is a process that facilitates cancer progression as epithelial cells take on mesenchymal 
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characteristics such as loss of polarity, loss of cell-to-cell adhesion that enables cells migration and 
invasion, and are critical processes for cancer progression. They also found downregulation of HLXB9 in 
breast carcinoma associated fibroblasts (CAF) in their other study (Siletz et al. 2013a). CAFs are tumour 
activated stromal cells and are associated with cancer progression as they promote proliferation, 
invasion, angiogenesis and other cellular process that aid cancer progression. 
Although downregulation of HLXB9 has been found in breast cancer, the function of HLXB9 in healthy 
breast is unknown. Consequently, its function in breast cancer is also unknown. However, as HLXB9 role 
in foetal development is in the differentiation of cells, it can be assumed that that HLXB9 may be 
implicated in the differentiation of breast cells. This hypothesis has also been proposed by other studies 
(Siletz et al. 2013b; Siletz et al. 2013a). Therefore, downregulation of HLXB9 in breast cancer is not 
surprising as a block in differentiation is a hallmark of cancer development (Xu et al. 2010). 
Finally, another study that implicated HLXB9 deregulation to breast cancer development is the finding 
that patients with germline mutations of MENIN (MEN1) show susceptibility to developing breast cancer 
(Shi et al. 2013; Dreijerink et al. 2014). These patients are also susceptible to developing other tumours 
associated with deregulation in HLXB9 expression such as pancreatic cancers. In the study by Shi and 
colleagues, HLXB9 was shown to interact with MEN1 to regulate cellular proliferation by promoting 
apoptosis in mouse pancreatic b-cells. MEN1 is a known co-activator of oestrogen receptor in breast 
cancer (Imachi et al. 2010). Menin has also been observed to directly activate the oestrogen receptor 
(Dreijerink et al. 2006; Dreijerink et al. 2014). Therefore, these studies indicate the possibility of HLXB9 
interacting with MEN1 in ER related breast cancer to aid development and/or progression.  
1.10. HLXB9 in other cancers 
Aberrant HLXB9 expression has also been observed in other cancers such as testicular cancer, 
hepatocellular carcinoma, colorectal and lymphomas. In testicular cancer, overexpression of HLXB9 has 
been found in patients diagnosed with pre-invasive testicular carcinoma in situ and malignant seminoma 
(a malignant type of testicular cancer) (Almstrup et al. 2005; Almstrup et al. 2007; Novotny et al. 2007). 
These studies suggest HLXB9 has a pro oncogenic role in testicular cancer. 
Hepatocellular carcinoma (HCC), the most commonly diagnosed type of liver cancer, is also a cancer type 
associated with overexpression of HLXB9 (Wilkens et al. 2011). In the study by Wilkens and colleagues, 
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HLXB9 overexpression was found in HCC cell lines by microarray analysis. Additionally, they found HLXB9 
was upregulated in patients diagnosed with high-grade HCC tumours. HLXB9 overexpression in these 
patients was associated with abnormal development of glands indicating a dedifferentiation of the 
tumour cells. In HCC patients overexpressing HLXB9, they also found the upregulation of genes involved 
in cell-cell contacts, which are genes previous reported to be upregulated in leukaemia patients with 
HLXB9 overexpression.  
Aberrant overexpression of HLXB9 has been found in lymphoma cell lines (Nagel et al. 2005; Nagel et al. 
2014; Nagel et al. 2015). In lymphoma, HLXB9 overexpression has been implicated with increased 
immune response (a characteristic of lymphoma) by binding to interleukin 6 (IL6) promoter to increase 
its expression (Nagel et al. 2005). Further studies into the role of homeobox genes in lymphoma identified 
the aberrant overexpression of OTX2 and MSX2, which are homeobox genes involved in early b cell 
differentiation (Nagel et al. 2014; Nagel et al. 2015). Results from both studies also showed that 
overexpression of the homeobox genes (OTX2 and MSX2) directly contributes to the overexpression of 
HLXB9 observed in lymphoma 
Finally, HLXB9 has been found to be downregulated in colorectal cancer (Hollington et al. 2004). In the 
study by Hollington and colleagues, HLXB9 was found to be downregulated in moderately differentiated 
colorectal patient samples (Hollington et al. 2004). 
These studies indicate the aberrant HLXB9 expression may have potential as a biomarker in cancer as its 
abnormal expression was observed in a number of cancer types. 
 
1.11. The localisation of HLXB9 in the interphase nucleus 
After mitosis, decondensed chromosomes are organised in the nucleus into distinct regions termed 
‘chromosome territories’ (Meaburn and Misteli 2007). Gene rich chromosomes were observed to be 
localised in the nuclear interior whilst gene poor chromosomes were localised in the nuclear periphery 
(Boyle et al. 2001; Cremer and Cremer 2001; Cremer and Cremer 2010). Consequently, this nuclear 
organisation has been linked to gene expression as the nuclear periphery is characterised by the presence 
of closed chromatin ‘heterochromatin’ whilst the nuclear interior is characterised by open chromatin 
‘euchromatin’, which is more readily accessible for transcription. This pattern of nuclear organisation has 
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also been observed for individual chromosomes. For instance, in the nuclear organisation of chromosome 
7 in the nucleus of lymphocytes, gene poor chromosomal regions were localised in the nuclear periphery 
whilst gene rich chromosomal regions were localised in the nuclear interior (Federico et al. 2008). In 
their study, Federico and colleagues found that 7q36, a poor gene region containing the HLXB9 gene, was 
localised in the nuclear periphery.   
Apart from chromatin structure, regions or organelles in the nucleus have also been associated with 
transcription activation or repression. For instance, in yeast nuclear periphery, regions associated with 
gene silencing have been observed, in addition to regions associated with transcription such as the 
nuclear pore complex (Taddei et al. 2006). In yeast, tethering of genes to the nuclear pore complex has 
been observed to directly result in their expression. In mammalian cells, although there have been cases 
of genes associating with the nuclear pore complex and subsequent gene expression, there remains a lack 
of consensus on whether the association is the direct cause of the observed expression (Dieppois and 
Stutz 2010).  
In support of the presence of transcriptionally active regions in the mammalian nuclear periphery are 
genes, which have been observed to transcribe in the nuclear periphery such as β-globin during murine b-
cell differentiation  (Ragoczy et al. 2006). However, the link between localisation in the nuclear periphery 
and gene repression in the mammalian nucleus is better understood.  For instance, genes localised within 
heterochromatin blocks on the periphery have been found associated with the nuclear lamina in ‘lamina 
associated domains’ (LADs) which are characterised by the presence of gene repressive markers such as 
histone3 lysine 9 dimethylation (Pombo and Dillion 2015). Although the nuclear interior is associated 
with active transcription, factors such as the distribution of transcription factories and splicing factors, 
polycomb repressive complex (PCG) and epigenetic regulation can have a repressive effect on expression 
of gene localised in the region (Geyer et al. 2011). 
A change in nuclear localisation of gene associated with subsequent expression has been observed in a 
number of studies. For example, during ex-vivo adipocyte differentiation, genes involved in 
differentiation were observed to move from the periphery to the interior to facilitate gene expression 
(Szczerbal et al. 2009). Additionally, during murine b-cell differentiation, the β-globin locus is observed to 
move progressively away from the nuclear periphery as b-cell maturation progresses (Ragoczy et al. 
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2006). Other examples of genes where a change in their nuclear localisation away from the nuclear 
periphery or heterochromatin to the nuclear interior results in increased gene expression include 
differentiation genes such as GATA, IgH and IgB (Skok et al. 2001; Zink et al. 2004; Szczerbal et al. 2009). 
This mechanism of gene regulation has also been observed in genes localised at 7q31, a region of 
chromosome 7 with the same gene density as 7q36 where HLXB9 is located (Zink et al. 2004; Federico et 
al. 2008).  
Further studies linking gene localisation to gene expression include a study into the monoallelic 
regulation of GFAP expression during neuronal differentiation (Takizawa et al. 2008). They found the 
active ‘expressing’ GFAP allele had a more interior nuclear position compared to the inactive ‘non-
expressing’ GFAP allele. Additionally, a change in the nuclear localisation from the nuclear interior to the 
nuclear periphery associated with gene repression has also been observed for a number of genes. For 
example, the SOX9 gene is downregulated during adipocyte differentiation, which is associated with a 
move of gene to the nuclear periphery (Szczerbal et al. 2009). Furthermore, deliberate repositioning of 
chromosomal regions to the nuclear periphery or to heterochromatin blocks has been linked to their 
subsequent downregulation (Finlan et al. 2008). 
Similarly, gene activation due to change in the nuclear localisation such as looping away chromosome 
territories have also been observed for a number of genes. For example, HOXB genes looping out of their 
chromosome territories is associated with their gene expression during b-cell differentiation 
(Chambeyron and Bickmore 2004).  These studies suggest a position effect mechanism as a means of 
regulating gene expression.  A number of the studies described above have utilised P1 or bacterial 
artifical chromosome (PAC/BAC) as probes to localise the genes of interest (Szczerbal et al. 2009, 
Takizawa et al. 2008; Ragoczy et al. 2006). For instance, In the Takizawa study, BAC probes of 188kb and 
183kb were used to localise β-actin and IGF-2 in murine neuronal cells. 
 
Cancer specific nuclear reorganisation of genes, which can be used to accurately differentiate cancer cells 
from normal cells, has also been observed in breast cancer and prostate cancer (Meaburn and Misteli 
2008; Meaburn et al. 2009; Leshner et al. 2015; Meaburn et al. 2016). Additionally, the formation of 
chromosomal translocations (an hallmark of cancer genome instability) by incorrect repairs of double 
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strand breaks between chromosomes have been found to be related to the proximal localisation of genes 
in the 3D nucleus (Agarwal et al. 2006). 3D chromosomal capture experiments have shown chromosomal 
translocations occur more frequently between genes occupying close spatial proximity in the interphase 
nucleus (Meaburn et al. 2007; Engreitz et al. 2012; Corces and Corces 2016).  
Apart from the nuclear reorganisation of genes itself being a biomarker of cancer, changes in the nuclear 
localisation of genes resulting in aberrant gene expression have also been observed in cancer (Wiech et al. 
2009; Ballabio et al. 2009). For instance, a change in the nuclear localisation of the BCL2 gene to the 
nuclear periphery in cervical cancer has been associated with its aberrant increased expression. Similarly, 
a change in the nuclear localisation of HLXB9 associated with subsequent overexpression of HLXB9 has 
been previously described in leukaemia patients (Ballabio et al.2009). In the study by our group, there 
was a change in the nuclear localisation of HLXB9 from the nuclear periphery to the nuclear interior in 
leukaemia patients harbouring the translocation t(7;12)(q36;p13). In these patients, the translocated 
HLXB9 gene occupies a more interior nuclear position to the normal non-translocated HLXB9 gene. 
Another study has also described a relationship between HLXB9 expression and its nuclear localisation in 
neuronal differentiation (Leotta et al. 2014). In their study, Leotta and colleagues showed a change in the 
nuclear localisation of HLXB9 from the nuclear periphery to the nuclear interior was associated with its 
increased expression during neuronal differentiation.  




1.12. Aim and objectives 
The primary aim of this project was to investigate HLXB9 as a potential biomarker in cancer. The project 
covers the following areas and addresses the following questions: 
1. The detection of the t(7;12)(q36;p13) translocation in leukaemia patients.  
Question: Can a dual colour FISH assay be used to accurately detect this translocation in 
leukaemia patients? 
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2. The investigation of HLXB9 expression and its nuclear localisation in patients diagnosed with 
various haematological disorders.  
Questions:  
o Is HLXB9 expression limited to patients harbouring chromosome 7 abnormalities?  
o Is the disruption of 7q due to a deletion event sufficient to activate aberrant HLXB9 
expression by a position effect mechanism? 
o Do interstitial deletions of 7q result in an altered nuclear localisation of HLXB9?  
o Is there a link between the deletion in 7q, HLXB9 nuclear localisation and its expression? 
 
3. The investigation of HLXB9 expression in various cancers by datamining online transcriptomics 
database.  
Questions: 
o What is the incidence of differential expression of HLXB9 in cancer?  
o What cancer types and subtypes are associated with differential expression of HLXB9? 
o Is there a link between HLXB9 expression and aggressive cancer types?  
 
4. The investigation of HLXB9 expression and nuclear localisation as a biomarker in breast cancer.  
Questions:  
o Does differential expression of HLXB9 have prognostic significance in breast cancer?  
o Is HLXB9 upregulated or downregulated in breast cancer? 
o Is the nuclear localisation of HLXB9 altered in breast cancer?  
o Is there a link between HLXB9 expression and its nuclear localisation in breast cancer? 
 
The following objectives were pursued in order to answer to these questions: 
1. The testing of a new dual colour probe produced by MetaSystems GmbH to detect t(7;12) 
(q36;p13) in leukemia patients. 
2. The analysis of the expression of HLXB9 in leukaemia patients with or without deletion in 7q by 
RT-PCR. The nuclear localisation of HLXB9 will be examined by fluorescence in situ hybridisation 
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(FISH) and erosion analysis. The results will then be evaluated to determine if there is a link 
between HLXB9 gene expression and nuclear localisation.  
3. The investigation of online transcriptomics databases to identify cancer and cancer subtypes 
exhibiting differential expression of HLXB9. 
4. The analysis of breast cancer survival databases to determine the prognostic significance of 
HLXB9 expression. Moreover, the expression of HLXB9 in breast cancer cell line will be analysed 
by RT-PCR, qRT-PCR and immunofluorescence. The nuclear localisation of HLXB9 will be 
analysed by FISH and erosion analysis. The results will then be evaluated to determine if there is 
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2.1. Description of leukaemia patient’s samples  
 
Archival bone marrow cell suspensions in 3:1 methanol: glacial acetic acid from patients diagnosed with 
haematological disorders was used in this study. Fixed chromosome and nuclei suspensions used in this 
project were leftover from previous studies (Tosi et al., 1996; Tosi et al., 1999; Tosi et al., 2000; Tosi et al., 
2003; Ballabio 2009; Naiel et al., 2013).  The samples used were obtained from the following cytogenetic 
laboratories in the UK and Europe: Oncocytogenetic laboratory, Children’s Hospital, University of Giessen, 
Germany; Children’s Cancer Research Institute, St. Anna Children’s Hospital, Vienna, Austria; Department 
of Medical Genetics, Churchill Hospital, Oxford, UK; Wessex Regional Genetics Laboratory, Salisbury, UK; 
Clinica Pediatrica dell’Universitá di Milano, Ospedale S. Gerardo, Monza, Italy; King’s College School of 
Medicine and Dentistry, London, UK; Paterson Institute of Cancer Research, Christie Hospital, 
Manchester; Institute of Pathology, Odense University Hospital, Odense, Denmark; Institute of Human 
Genetics, University of Marburg, Germany and St Bartholomew Hospital Medical College, London, UK. 
2.2. Cell culture 
Leukaemia study- Chapter 4 
Lymphoblastoid cell lines; GM00893 and GM17208b donated by Dr Predrag Slijepcevic were grown in 
RPMI-1640 containing 10% foetal calf serum (v/v), 2mM L-glutamine and 100 Uml-1/µgml-1 
Penicillin/Streptomycin at 37⁰C at 5% CO2. Cells were subcultured twice a week. 
Breast cancer study –Chapter 6 
Three non-cancer cell lines HMEC 184D, HMEC 240L and MCF 10A were analysed in this study. HMEC 
184D and HMEC 240L were donated by Dr Yassei, MCF10A was obtained from Dr Harvey and cultured in 
1:1 HamsF12: DMEM supplemented with 10% foetal bovine serum, 1% PSQ and 1 μg/ml hydrocortisone, 
5 ng/ml EGF and 5 μg/ml insulin.  
Six breast cancer cell lines were analysed in this study. MCF 10A-T1K and MCF 10A-CA1a cell lines were 
donated by Dr Paola Vagnarelli. T47D, BT474 and MDA-MB-231 breast cancer cell lines were obtained 
from Dr Amanda Harvey and maintained in a RPMI-1640 medium supplemented with 10% foetal calf 
serum and 1% PSQ (Penicillin-Streptomycin-Glutamine) in T25 cell culture flasks. These cells were grown 
at 37°C with 5% CO2 in a humidified incubator. 
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Cells/Cell 
Line 
Description and Reference 
HMEC 184D Non-cancer cells derived from a reduction mammoplasty from patient aged 21 (Garbe et al. 2009, Garbe 
et al. 2014). 
HMEC 240L Non-cancer cells derived from a reduction mammoplasty from patient aged 19 (Garbe et al. 2009,Garbe 
et al. 2014). 




A pre-malignant cell line obtained by transforming the MCF 10A cell line by HRAS (Kadota et al. 2010, 
Wendt and Schiemann 2009). 
MCF 10A-
CA1a 
A well differentiated metastatic tumour cell line derived from MCF-10A-T1K (Kadota et al. 2010, Wendt 
and Schiemann 2009). 
T47D  Cell line was derived from a patient with invasive ductal breast carcinoma and has been classified to be 
a Luminal A molecular breast cancer cell line as it was positive for estrogen and progesterone receptor 
(ATCC, Perou et al. 2000; Sorlie et al. 2003). 
BT474  Cell line was derived from an invasive ductal carcinoma and has been classified to be a Luminal B 
subtype as it is positive for estrogen, progesterone and human epidermal growth factor receptors 2 
(ATCC, Perou et al. 2000; Sorlie et al. 2003). 
MDA-MB-
231 
Cell line was derived from an invasive ductal carcinoma and has been classified as a basal molecular 
subtype as it negative for estrogen, progesterone and human epidermal growth factor receptors (ATCC, 
Perou et al. 2000; Sorlie et al. 2003). 
Table 2.1: Description of control and cancer cells/cell lines used in breast cancer study 
2.3. RNA extraction 
 
Breast cancer cell lines: medium from cells in T25 tissue culture flask was removed and cells were 
washed in 2mls of PBS. 2mls of TrypLE express, a dissociation reagent (Life Technologies, Paisley, UK) 
was added to cells flask. The flasks were incubated at 37°C for two minutes. 1 ml of fresh medium was 
added to neutralise TrypLE express. The content of the flask was transferred into 15ml tube and cells 
were counted using a haemocytometer. An aliquot of cell suspension containing 5X106 cells was 
transferred to a sterile 2ml tube. The tube was centrifuged at 1200rpm for five minutes to collect cells 
and the supernatant completely removed.  
Lymphoblastoid, Leukaemia and lymphoma cell lines: cells were grown in T25 tissue culture flask. 
The content of the flask was transferred into 15ml tube; cells were counted using a haemocytometer. An 
aliquot of cell suspension containing 5X106 cells was transferred to a sterile 2ml tube. The tube was 
centrifuged at 1200rpm for five minutes to collect cells and the supernatant completely removed.  
Archival patient samples: archival bone marrow samples fixed in 3:1 methanol: acetic acid were spun at 
12,000g for 5 mins at room temperature. The supernatant was completely removed and 1ml of absolute 
ethanol or 96% ethanol was added without mixing or dislodging the cell pellet. The samples were spun at 
12,000g for 3 mins at room temperature and supernatant completely removed. 
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RNA was extracted using Qiagen RNeasy mini Kit (Qiagen, Manchester, UK) by adding 350l RLT buffer 
containing 1:10 ratio β-mercaptoethanol to lyse the cells. Cells in RLT buffer were homogenised by 
vortexing for 1 minute. 350l of 70% ethanol was added to the homogenised lysate and mixed by 
pipetting. The mixture was transferred to the RNeasy spin column and centrifuged at 8000g for 15 
seconds. 700l of RW1 buffer was added to the RNeasy spin column and centrifuged at 8000g at 15 
seconds to wash the spin column. 500l of RPE buffer was then added to RNeasy spin column and 
centrifuged at 8000g for 15 seconds to wash the column. 500l of RPE buffer was added to the spin 
column and centrifuged at 8000g for 2 minutes to dry the spin column membrane and to eliminate any 
residual ethanol. The spin column was transferred to a 1.5 ml collection tube and 29l of RNase-free 
water was added directly to the spin column membrane, the sample was then centrifuged at 8000g for 
one minute to elute the RNA.RNA from the samples was immediately placed on ice and 1l of 20U/µl 
Superase In © (Life technologies, Paisley, UK), a RNASE inhibitor was added then the sample was mixed 
by gentle pipetting. 
The concentration of the sample was measured in ng/l using a spectrophotometer (Nanodrop 2000; 
Thermoscientific, UK). Reading the A260/280 value assessed the quality of the sample. RNA samples with 
A260/280 ratios 1.8 were used immediately in experiments or stored at -80C for future use. 
2.4. cDNA synthesis by superscript III reverse transcriptase 
cDNA was synthesised using Superscript III reverse transcriptase kit (Life technologies, Paisley, UK). 
Dependant on the RNA yield, approximately 1µg of RNA was used in a 20l final reaction volume. 1μl of 
10mM dNTP MIX (Roche, Burgess Hill, UK), 1μl of 100ng/l Random Hexamers (Life technologies, 
Paisley, UK), 1μg of RNA and PCR grade water was added to a sterile 0.2ml PCR tube, mixed gently by 
pipetting and quickly centrifuged. The mixture was incubated at 65°C for 5 minutes and collected on ice 
to cool; the tubes were then quickly centrifuged to collect any condensation formed. 4μl of First Strand 
Buffer (250 mM Tris-HCl, pH 8.3, 375 mM KCl; 15 mM MgCl2), 2μl of 0.1M DTT, 1μl of 20U/µl Superase In 
© (Life technologies, Paisley, UK), was added to the tube and the contents of the tube was gently mixed by 
pipetting. The sample was then incubated at 25°C for 2 minutes, 1 l of Superscript III reverse 
transcriptase was added and mixed gently by pipetting, the tubes were spun quickly to collect sample and 
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the tube was incubated at 25°C for 10 minutes followed by 42°C for 50 minutes. The cDNA synthesis 
reaction was stopped by heating at 70°C for 15 minutes then holding the samples at 4°C.  
2.5. Reverse transcriptase- polymerase chain reaction (RT-PCR) 
PCR experiments were carried out in 50µl volume reaction using Clonetech Advantage GC 2 PCR Kit 
(Takara bio Europe/ Clontech, Saint-Germain-en-Laye, France). The 50l reaction contained: 1 X master 
mix using 2µl (10pmol/µl) of each primer, 10l of 5X Advantage GC 2 Buffer, 5µl of GC-Melt, 1l of 50X 
dNTP mix, 1l of 50X Advantage GC2 Polymerase mix and PCR grade water to make up the final volume. 
The amplification conditions were 1 cycle of denaturation at 94C for 3 minutes, followed by 35 cycles of 
annealing at 60°C (β-actin) or 68C (HLXB9) for 30 seconds, then extension at 68C for 1 minute, final 
extension at 68C for 3 minutes and holding the sample at 4C.  
HB9-WTI and HB9-WT1R primers were used for the first HLXB9 PCR reaction and HB9-1994-F and HB9-
WT-2R primers were used for the nested HLXB9 PCR reaction HLXB9 primer sequence: HB9-WT1 
forward: 5’-CTTCCAGCTGGACCAGTGGCTG-3’ and HB9-WT1 reverse: 5’-CGTCCTCGTCCTCGTCCTCC-3’, 
HB9-1994 forward: 5’-TCCACCGCGGGCATGATCCTG-3’ and HB9-WT2 reverse: 5’-
GGCCCCAGCAGCTCCTCGGCTC-3’. β-actin gene expression was used as a loading control for HLXB9 
expression. β-actin primer sequences:β-actin forward: 5-’TGACGGGGTCACCCACACTGTGCCCATCTA-3’and 
β-actin reverse: 5’-CTAGAAGCATTGCGGTGGACGATGGAGGG-3’. 
Primer Position  Exon 
HB9-WTI 808-830 Exon 1 
HB9-WT1R 1278-1258 Exon 3 
HB9-1994-F 836-857 Exon 1 
HB9-WT-2R 1195-1173 Exon 3 
β-actin forward 541-570 Exon 4 
β-actin reverse 1201-1172 Exon 6 
Table 2.2: Description of RT-PCR primers used in study. 
 
PCR products were detected in 1.2% agarose gel containing 0.5μg/ml ethidium bromide. 5l of PCR 
product was added to 1µl of loading dye then loaded in agarose gel. The gel was run in 1X TBE buffer 
(0.089 M Tris, 0.089 boric acid and 2Mm EDTA) at 80v for 45 minutes, then product size were 
determined by comparing to peqGOLD DNA-Sizer XI (Peqlab, Erlangen, Germany). 
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2.6. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) 
 
Professor Saccone, Catania, Italy, provided results for the qRT-PCR experiments. The experiments were 
carried out using the method previously described in Leotta et al. 2014. Sybr green Real Time PCR 
experiments using primers for HLXB9 and control gene Tubulin were carried out in non-cancer breast 
cells and breast cancer cell lines.  
Primer Sequence 
HLXB9 forward AACCTCCTGGGGAAGTGC 
HLXB9 reverse GGTGAGCATGAGCGAGG 
Tubulin forward GCCAAGAGTGAAGAACAG 
Tubulin reverse GAAGTCCAAGAACTTAGCTG 
Table 2.3: Primer sequence used in qRT-PCR experiments 
The Ct value of HLXB9 was normalised using the Ct value of the endogenous control tubulin to obtain the 
ΔCt value. The ΔCt of the samples were then normalised to the calibrator to obtain the ΔΔCt . Finally, the 
relative concentration of HLXB9 in the samples of interest was obtained using the 2-ΔΔCt formula. 
2.7. Indirect immunofluorescence (IF) 
 
Breast cancer cells at 70% confluency were split 1:4 and 250l aliquot of cell suspension was added to 
each well of an 8-well Nunc™ Lab-Tek™ II Chamber™ System (Thermo-scientific, Loughborough, UK). 
Cells in chamber slides were grown at 37°C with 5% CO2 in a humidified incubator a day before IF 
experiments. On the day of experiment, the medium was removed from each well and cells were washed 
twice in 500l PBS. The cells were then fixed with 4% paraformaldehyde for 20 minutes at room 
temperature. After fixation, cells were washed in 500l PBS then permeabilised by incubating in 500l 
PBS containing 0.5% Triton X-100 for 15 minutes. Before antibody was added, aspecific binding sites in 
cells were blocked in 0.1% BSA in PBS for 1 hour to prevent non-specific binding/staining at 37C in a 
humid chamber. Primary antibody: 500l of anti HB9 antibody or anti tubulin antibody in blocking 
solution (Sigma-Aldrich, Dorset, UK; 1:100 dilution in blocking solution) was added to each chamber and 
the slides were incubated at 37c for 1 hour. After incubation in primary antibody, the cells were washed 
three times in PBS for five minutes each. Secondary antibody: 500l of antirabbit FITC for HLXB9, anti-
mouse FITC for tubulin (Sigma-Aldrich, Dorset, UK; 1:100 dilution in blocking solution) and/or Alexa 
Fluor® 568 phalloidin in blocking solution (Invitrogen, Paisley, UK 1:200 dilution in blocking solution) 
for F-actin staining was added to the slide chamber and the slides were washed in PBS three times for five 
minutes each. The chamber box was removed; the slides were then mounted in Vectashield (Vector 
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Laboratories Ltd., Peterborough, UK) containing 4,6-Diamidine-2-phenylindole dihydrochloride (DAPI) 
and a coverslip was added to slide and sealed with bicycle glue.  
Images for analysis were initially captured using HF14 Leica DM4000 SOP v2 and Leica AF6000 software 
(data not show). Professor Saccone captured the images from the slide with a confocal microscope (Zeiss 
LSM 700 microscope) so that the cellular localisation of HLXB9 could be determined.  
2.8. Cytogenetic cell harvesting  
 
Cell lines were harvested after reaching approximately 80% confluence by adding 0.01g/ml Colcemid in 
Hank's Balanced Salt Solution (HBSS) (Gibco © KaryoMAX, Life Technologies, Paisley, UK) to tissue 
culture flask and incubating at 37ºC for 2.5 hours. The medium was then transferred into a sterile 15ml 
tube to prevent cell loss. The cells in the tissue culture flask were then washed in 2mls of PBS and the 
supernatant transferred into the same tube. 2 mls of TrypLE express a dissociation reagent (Life 
Technologies, Paisley, UK) was added to tissue flask to lift cells from flask then incubated at 37°C for 2 
minutes, 1 ml of fresh medium was added to neutralise the TrypLE express action. The cell suspension 
was pipetted up and down to aid complete dissociation of cells from flask, the content of the flask was 
transferred into same 15ml tube as before. The cells were then centrifuged at 1500rpm for 5 minutes.  
The supernatant was partially removed and the cells were resuspended in approximately 1ml of 
supernatant by vortexing. Pre-warmed hypotonic solution (0.075M KCl, Sigma-Aldrich, Dorset, UK) was 
added drop-wise whilst agitating the tube until 10mls of hypotonic solution was added; the cells were 
then incubated at 37ºC for 10 minutes. Ten drops of fixative solution (3:1 methanol: glacial acetic acid, 
Fisher Scientific, Paisley, UK) were added to the cells before the cells were spun at 1000rpm for 5 
minutes. The supernatant was removed and pellet was resuspended in 1ml of fixative solution drop by 
drop. Whilst vortexing, the solution was topped up to 10mls by adding 9mls of fixative slowly, and then 
incubated for 15 minutes at room temperature before being spun at 1000rpm for 5 minutes. The 
supernatant was removed and 10mls of fixative was added in the manner described previously, then spun 
at 1000rpm for 5 minutes. This was repeated until the cell suspension was clear. The cell pellet was 
resuspended in about 1ml of fixative depending on size of pellet. The cell suspension was used 
immediately in slide preparation or was stored at -20°C until use. 
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2.9. Slide preparation 
 
The fixed cell suspension was spun at 1000rpm for 5 minutes. The supernatant was removed then 
approximately 1ml of fresh 3:1 methanol: glacial acetic fixative was added depending on the size of the 
pellet. 8µl of cell suspension was added to SuperFrost glass slide (Thermo-scientific, Loughborough, UK). 
The slides were air-dried and the quality of metaphase and interphase cells on the slides was checked 
using a phase contrast microscope. The slides were stored in a box overnight at room temperature to age 
before being used for FISH or stored at -20°C. 
2.10. G-banding of breast cancer cell lines 
 
Fresh slides were prepared as previously described on the day there were to be banded. The slides were 
then aged for 1 hour 30 minutes in the oven at 70°C. The slides were allowed to cool, then placed in a 
coplin jar containing 2.5% trypsin (GIBCO, Life Technologies, Paisley, UK) in 0.9% NaCl (Sigma-Aldrich, 
Dorset, UK) mixture for 3-5 seconds then rinsed by twice transferring into a coplin jar containing 0.9% 
NaCl. The slide was then placed in the Gurrs Giemsa stain (GIBCO, Life Technologies, Paisley, UK) for 5 
minutes for staining. After five minutes, the slide was rinsed twice in fresh coplin jars containing Gurrs 
buffer pH 6.8 (Gibco, Life Technologies, Paisley, UK). The slide was then allowed to air dry, and a coverslip 
containing cytoseal 60 mounting medium (Thermo scientific, Loughborough, UK) was added to the slide. 
The slide was allowed to air-dry then images were captured using Zeiss Axioskop 2 microscope and 
MetaSystems Isis software.  
2.11. Preparation of PAC probe RP5-1121A15 
 
P1 artificial chromosome (PAC) clone H_DJ1121A15 (RP5-1121A15) in E.coli was purchased from 
https://bacpac.chori.org. The pac clone DJ1121A15 contains the chromosome region 7q36 region 
encompassing the HLXB9 gene (Tosi et al. 2003). The exact coordinates of the PAC Probe were unknown. 
However, the probe was selected as it has been used in other studies to detect the HLXB9 gene (Simmons 
et al. 2002; Tosi et al. 2003; von Bergh et al. 2006; Baglobind et al. 2011; Leotta et al. 2014). Additionally, 
a map showing the approximate localisation of the probe on 7q is presented as figure A5 in the Appendix. 
The PAC clone was grown in streaks on a Luria-Bertani (LB) agar plate with 12.5 μg/ml Kanamycin 
(Sigma-Aldrich, Dorset, UK) and incubated at 37°C for 24 hours. One colony was selected from the plate 
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and grown in 10mls of LB medium and 12.5μg/ml of kanamycin overnight. Spinning at 3500rpm for 15 
minutes pelleted the bacterial cells. To extract the PAC DNA, the pellet was completely resuspended in 
450μl of P1 solution (15mM Tris pH 8.0, 10mM EDTA, 100μg/ml Rnase A), then 450μl of P2 (0.2M NaOH, 
1% SDS) was added and mixture was inverted. Finally 450μl of P3 (3M Potassium acetate) was added and 
inverting mixed the sample. The sample was placed on ice for 5 minutes, then spun at 10000rpm for 20 
minutes at 4°C. 800μl of ice-cold isopropanol was added to a 2ml microcentrifuge tube and the 
supernatant from the sample was transferred into the ice-cold isopropanol. The sample was mixed by 
inversion and incubated at -20°C overnight. The next day, the probe was spun at 10000rpm for 30 
minutes at 4°C to pellet out the DNA. The supernatant was completely removed and 500μl of ice cold 70% 
ethanol was added to the pellet, the tube was inverted to wash the pellet and tube was spun at 10000rpm 
for 5 minutes at 4°C. The supernatant was completely removed, and then the pellet was air dried before 
being resuspended in 40μl of TE buffer (10mM Tris and 1mM EDTA, pH 8.0). The quantity and size of the 
probe was checked using 1% agarose gel containing 0.5μg/ml ethidium bromide.  
5 l of probe was added to 1µl of loading dye then loaded in agarose gel. The gel was run in 1X TBE buffer 
(0.089 M Tris, 0.089 boric acid and 2Mm EDTA) at 80v for 1 hour, then product size and quantity were 
determined by comparing to Peqlab DNA Sizer III marker (Peqlab, Erlangen, Germany). 
2.12. Nick Translation 
 
1μg of DNA PAC probe DJ1121A15 was labelled using either 1μM digoxigenin (DIG) -11-dUTP (Roche, 
Hertfordshire, UK) or 20μM fluorescein (FITC) -12-dUTP (Roche, Hertfordshire, UK) by nick translation. 
Abbott Molecular nick translation kit (Abbott Molecular, Berkshire, UK) was used to label the probe. A 
0.2ml microcentrifuge tube was placed on ice and allowed to cool, then the following components were 
added in the following order:  1μg of DNA PAC probe DJ1121A15, 2.5l of either digoxigenin (DIG) -11-
dUTP or 20μM fluorescein (FITC) -12-dUTP, 5l of 0.1mM dTTP, 10l of dNTP mix, 5l of 10X nick 
translation buffer and 10l of nick translation enzyme. Lastly nuclease free water was added to make a 
final reaction volume of 50l. The mixture was quickly centrifuged, then vortexed.  
The sample was incubated for 16 hours at 15C and placed in ice to stop the reaction. The probe size was 
checked in 2% agarose gel containing 0.5μg/ml ethidium bromide. 5l of nick translation sample was 
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added to 1l of loading dye, and the mixture was then loaded into the agarose gel. The gel was run in 1X 
TBE buffer (0.089 M Tris, 0.089 boric acid and 2Mm EDTA) at 80v for 1 hour. The probe size and quantity 
were analysed by comparing to Peqlab DNA size XIII Marker (Peqlab, Erlangen, Germany).  
2.13. Probe purification 
 
The labelled probe from the nick translation reaction was added to Illustra microspin G-50 columns (GE 
Healthcare, Amersham, UK) to remove the unincorporated nucleotides. The spin column was then 
centrifuged at 6000rpm for 1 minute to collect the purified probe. 10l of 1mg/ml of Human Cot-1 DNA, 
10l of 3M sodium acetate and 2.25V of 100% ice-cold ethanol was added to the purified probes. The 
DNA probe was allowed to precipitate overnight by incubating at -20C. The sample was centrifuged at 
13000rpm for 30 minutes at 4c and the supernatant was discarded. 200l of ice-cold ethanol was added 
to wash the DNA pellet; the sample was then centrifuged at 13000rpm for 15 minutes at 4C. The 
supernatant was discarded and the DNA pellet was allowed to air dry. The purified probe DNA was 
resuspended in 5l TE buffer (10 mM Tris-Cl, pH 7.5, 1 mM EDTA) and 45l hybridisation buffer (50% 
(v/v) formamide, 10% (w/v) dextran sulphate, 1% (v/v) Tween 20 in 2 XSSC, pH7.0) and stored at -20C 
until use. 
2.14. Fluorescence in situ hybridisation 
 
FISH was performed using commercially available whole chromosome 7 (XCP Orange XCyting Chromosome 
Paint, MetaSystems GmbH, Altlussheim, Germany) and PAC probe RP5-1121A15 labelled with either 
digoxigenin (DIG) or fluorescein (FITC). 
Pre-treatment of Cells (breast cancer cells only) 
In order to remove excess cytoplasm around metaphase and interphase cells on aged slides and to 
improve the efficiency of the FISH experiment, a pepsin pre-treatment of slide was carried out as 
described by Padilla-Nash et al, 2006. Cells on slides were equilibrated in 2X SSC without shaking for 5 
minutes at room temperature, 120µl of 0.1mg/ml-1 of Rnase A in 2X SSC was added to the slides at room 
temperature, covered with parafilm and incubated at 37°C for 45minutes. The parafilm was removed and 
the slides were washed three times in 2X SSC for 5 minutes whilst shaking at room temperature. 10l of 
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pepsin 100mg/ml-1 was added to an empty clean 100ml glass beaker followed by 100mls of pre-warmed 
0.01M HCl and the solution was mixed thoroughly. The pH of the pepsin-HCl solution was adjusted to 2.0, 
and slides were incubated in the solution at 37°C for 10 seconds. The slides were transferred into petri 
dish containing 1X PBS and checked under the microscope to confirm there was no longer any cytoplasm 
surrounding the nucleus and metaphases and that the nuclei integrity was maintained. If there was still 
cytoplasm visible around the cells, incubation in Pepsin-HCl was repeated. The slides were washed twice 
for 5 minutes in fresh 1X PBS whilst shaking then transferred into a coupling jar containing 1X 
PBS/0.05M MgCl2 for 5 minutes. The slides were then fixed in 1% (v/v) formaldehyde/1X PBS/MgCl2 
solution for 10 minutes at room temperature without shaking. After fixation was complete, the slides 
were washed for 5 minutes in 1X PBS at room temperature whilst shaking.  
Probe Denaturation 
Labelled 1121a15 probe was added to Hybridisation buffer in a 1:4 ratio. 10l of either labelled 1121a15 
(20ng/l) or whole chromosome 7 paint was denatured 85°C for 8 minutes then at 37°C for 30 minutes to 
allow preannealing of repetitive sequences. 
Sample Denaturation 
The cells on slides were dehydrated through a series of 70%, 90% and 100% ethanol for 3 minutes each 
and allowed to air dry. The cells on slides were denatured in 70% formamide in 2X SSC, pH 7.0 at 72°C for 
5 minutes. After denaturation, the slides were immediately transferred into ice-cold 2X SSC on a shaker 
for 5 minutes at room temperature before being dehydrated using a series of 70%, 90% and 100% 
ethanol then allowed to air dry.  
Hybridisation 
Denatured probe was added on slides, covered with a 22X22 glass coverslip and sealed with rubber 
cement. The rubber cement was allowed to air dry, and the slides were transferred into a humid chamber 
at 37°C for hybridisation overnight. 
Post Hybridisation washes and detection of probe  
Following overnight hybridisation, the rubber cement was carefully removed and slides were washed in 
2X SSC for 5 minutes on the shaker in the dark to remove coverslip. The slides were transferred into 0.4X 
SSC at 72°Cf or 5 minutes then washed in 2X SSC for 5 minutes in the dark whilst shaking. 
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1121A15 probe labelled with FITC: these slides were washed three times in 2X SSC/0.05%Tween20 on 
the shaker for 5 minutes in the dark. A final wash was done in 1X PBS for 5 minutes on shaker in the dark; 
the slides were then mounted in Vectashield (Vector Laboratories Ltd., Peterborough, UK) containing 
DAPI.  
1121A15 probe labelled with DIG: 80μl of blocking solution (0.45g BSA in 15ml of 4 X 
SSC/0.05%Tween20) was added to these slides, which were then covered in parafilm and incubated in a 
humid chamber at 37°Cfor at least 1 hour.  Mouse anti-dig (Sigma-Aldrich, Dorset, UK) in blocking 
solution was added to slides (final dilution of 1:666). The slides were then covered with parafilm and 
incubated in humid chamber at 37°C for 30 minutes. After incubation, the slides were washed three times 
in 4X SSC/0.05%Tween20 for 5 minutes on the shaker. After the washes, rabbit anti-mouse-FITC (Sigma-
Aldrich, Dorset, UK) in blocking solution (final dilution of 1:1000) was added to the slides, then the slides 
were covered in parafilm and incubated in a humid chamber at 37°C for 30 minutes. The slides were then 
washed three times in 4X SSC/0.05%Tween20 for 5 minutes on the shaker in the dark. Anti-rabbit-FITC 
(Sigma-Aldrich, Dorset, UK) in blocking solution was added to the slides (final dilution 1:100), and then 
the slides were covered in parafilm and incubated in a humid chamber at 37°C for 30 minutes. After 
incubation, the slides were washed three times in 4X SSC/0.05%Tween20 for 5 minutes on the shaker in 
the dark. A final wash using 1X PBS for 5 minutes on the shaker in the dark was carried out before the 
slides were mounted in Vectashield (Vector Laboratories Ltd., Peterborough, UK) containing DAPI, and 
covered with a coverslip and sealed with rubber cement. 
Image capture 
200-300 hybridised nuclei were captured using an Olympus BX41 fluorescence microscope, 100X oil 
immersion lens with Smart Capture Software v3 (Digital Scientific, Cambridge, UK). 
2.15. Erosion analysis (Nuclear Localisation) 
Images were processed using Adobe Photoshop to remove non-specific background signals. The 
processed images were run through an erosion script donated by Dr Boyle and Dr Bickmore; used with 
permission from Dr Bridger in IPLab spectrum software. The script outlines the nucleus by detecting the 
DAPI staining, and it divides the nucleus into five concentric shells of equal volume with the outermost 
(first) shell denoting the nuclear periphery and the innermost (fifth) shell denoting the nuclear interior. 
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The script measures the pixel intensity of the DAPI and FITC labelled probe in each shell. The probe signal 
is normalised by dividing the percentage probe intensity by the percentage DAPI intensity in each shell. In 
order to simplify the data for analysis, data from shell 1 and 2 have been pooled together to represent the 
nuclear periphery, data from shell 3 represents an intermediate position in the nucleus, and data from 
shell 4 and 5 have been pooled together to represent the nuclear interior.  
Histograms were plotted from the average signal in each shell with error bars representing the standard 
error of the mean (average±sem). Statistical analyses were performed using either graphpad prism online 
tool (http://www.graphpad.com/quickcalcs/ttest1.cfm) or IBM SPSS statistics v18. 
2.16. Determining the prognostic signifiance of HLXB9 overexpression in Breast 
Cancer Patients. 
 
The prognostic significance of aberrant HLXB9 expression was evaluated in breast cancer patients using 
online databases: KM plotter and BreastMark (Gyorffy et al. 2013; Madden et al. 2013). In both databases, 
patient’s cohorts were divided into two groups by median gene expression. Patients with lower gene 
expression than the median were classified as showing low gene expression whilst patients with greater 
gene expression than the median were classified as showing high gene expression. A survival curve 
showing the patients’ outcome over time by level of gene expression was generated by the databases (as 
shown in figure 6.11). The difference in patients’ survival between the two groups was assigned a 
prognostic value (hazard ratio with 95% confidence intervals). Hazard ratios of less than 1 indicated a 
positive impact on prognosis whilst hazard ratios greater than 1 indicated a negative impact on 
prognosis. The P value of the hazard ratio was also calculated. P values equal or less than 0.05 indicated 
the hazard ratio observed was statistically significant.  
Patients’ outcome were categorised into:  
 overall survival (OS), which is the time from either diagnosis or treatment that patients are alive; 
 relapse free survival (RFS) or disease free survival (DFS), which is the time after primary 
treatment that the patient survives without any sign and symptom of cancer returning in the 
original tumour site;  
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 disease free metastatic survival (DFMS) or distant disease free survival (DDFS), which is the time 
after treatment or diagnosis that patients are alive without metastasis to secondary tumour 
site(s) and  
 post progression survival (PPS) which is the time after relapse or metastasis that patients are 
alive.  
Two multi-gene expression tests are now used clinically to determine the possibility of disease 
reoccurrence in patients in low-grade tumours without lymph node involvement. (Madden et al. 2013; 
Marrone et al. 2015). These tests are Oncotype DX, a 21-gene panel test (5 control genes and 16 
oncogenes) and MammaPrint, a 70-gene panel test.  The 16 oncogenes in the oncotype DX panel is 
composed of five proliferation genes (KI67, STK15, Survivin, CCNB1 and MYBL2), two invasion genes 
(MMP11 and CTSL2), two HER2 associated genes (GRB7 and HER2), ER defining genes (ER, PGR, BCL2 and 
SCUBE2) and three other genes (GSTM1, CD68, BAG1). The expression of these genes are normalised to 
the control genes and then scored with the proliferation genes having the highest impact on the overall 
score. In MammaPrint, 16 genes are associated with good prognosis whilst 45 genes are associated with 
poor prognosis (However, results could only be obtained on 43 out of 45 genes usng their Entrez ID in 
BreastMark).  
The prognostic impact of gene expression was investigated by entering the Entrez ID in BreastMark. In 
KM plotter, Affymetrix ID’s for the U133A and U133Plus2 microarray platform were generated from 
https://biodbnet-abcc.ncifcrf.gov/db/db2db.php. In cases were there were mutiple Affymetrix probes for 
a particular gene, an average of probe intensity was calculated. HLXB9’s Entrez ID is 3110 whilst its 
Affymetrix probe is 214614_at. 
The Entrez ID and the Affymetrix ID/(s) for genes in the Oncotype DX and MammaPrint tests are 
presented in tables below.  
Entrez ID Gene Symbol Affymetrix ID 
4288 KI67 212020_s_at; 212021_s_at; 212022_s_at; 212023_s_at  
6790 AURKA 204092_s_at; 208080_at; 208079_s_at  
332 BICR5 202095_s_at; 210334_x_at; 202094_at  
891 CCNB1 214710_s_at; 228729_at  
4605 MYBL2 201710_at  
4320 MMP11 203878_s_at; 203876_s_at  
1515 CTSL2 210074_at  
2886 GRB7 210761_s_at  
2064 ERBB2 216836_s_at; 210930_s_at  
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2099 ESR1 
211233_x_at; 205225_at; 215552_s_at; 211234_x_at; 217163_at; 211235_s_at; 
217190_x_at; 215551_at; 211627_x_at  
5241 PGR 208305_at; 228554_at  
596 BCL2 207004_at; 207005_s_at; 203684_s_at; 203685_at  
57758 SCUBE1  219197_s_at  
2944 GSTM1  204550_x_at; 215333_x_at  
968 CD68 203507_at  
573 BAG1  211475_s_at; 202387_at; 229720_at  
Table 2.4: Entrez ID, Gene Symbol and Affymetrix ID of Oncotype DX genes. 
Entrez ID Gene Symbol Affy ID 
Gene that indicate good prognosis 
8659 ALDH4 203722_at; 211552_s_at; 201612_at  
8817 FGF18 206986_at; 214284_s_at; 206987_x_at; 231382_at; 211029_x_at; 211485_s_at 
27113 BBC3 211692_s_at  
57593 EBF4 233850_s_at  
57758 SCUBE2 219197_s_at  
146923 RUNDC1  235040_at; 226298_at  
8840 WISP1 211312_s_at; 229802_at; 235821_at 206796_at  
2947 GSTM3 202554_s_at; 235867_at  
151126 ZNF385B 229019_at 1555801_s_at; 1555800_at  
146760 RTN4RL1 230700_at  
10455 PECI 218025_s_at; 221780_s_at; 215693_x_at; 219108_x_at 
7043 TGFB3   209747_at  
55351 HSA250839  219686_at  
58475 MS4A7  224358_s_at; 223343_at; 223344_s_at  
163 AP2B1  200615_s_at; 200612_s_at 
79132 LGP2 219364_at  
Genes that indicate good prognosis 
55321 C20ORF46 219958_at  
11082 ESM1 208394_x_at  
9134 CCNE2 211814_s_at; 205034_at  
54583 EGLN1 224314_s_at; 221497_x_at; 223046_at; 223045_at  
1058 CENPA  210821_x_at; 204962_s_at  
9055 PRC1 218009_s_at  
445815 AKAP2  202759_s_at; 202760_s_at  
10874 NMU 206023_at  
3488 IGFBP5  203424_s_at; 203425_s_at; 203426_s_at; 211958_at; 211959_at; 1555997_s_at  
10531 MP1 205273_s_at; 229644_at; 204117_at; 37950_at; 217971_at 
57110 HRASLS 219983_at; 219984_s_at  
8577 TMEFF1 205122_at; 205123_s_at  
4175 MCM6 201930_at; 238977_at  
643008 SMIM5  229740_at 
83879 CDCA7 224428_s_at  
5984 RFC4 204023_at  
23594 ORC6L  219105_x_at  
6515 SLC2A3 202497_x_at; 202498_s_at; 216236_s_at; 202499_s_at; 222088_s_at  
57211 GPR126 213094_at  
79791 FBXO31  224162_s_at; 219784_at; 219785_s_at; 218875_s_at 
1633 DCK 203302_at  
51514 L2DTL  218585_s_at; 222680_s_at  
1284 COL4A2 211964_at; 211966_at  
9833 KIAA0175  204825_at  
92140 MTDH 1559822_s_at; 212248_at; 212250_at; 212251_at; 227277_at  
51377 UCH37 219960_s_at; 220083_x_at; 229248_at  
51560 RAB6B 225259_at; 210127_at; 221792_at  
160897 GPR180 231871_at; 1556019_at; 1556021_at; 1566257_at  
79888 FLJ12443  201818_at  
8293 SERF1A  219982_s_at  
8476 PK428 213595_s_at; 214464_at; 215296_at; 203794_at  
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10403 HEC 204162_at  
8833 GMPS 214431_at  
1894 ECT2 234992_x_at; 219787_s_at  
4318 MMP9 203936_s_at  
5019 OXCT 202780_at  
2781 GNAZ 204993_at  
2321 FLT1  226497_s_at; 210287_s_at; 226498_at; 222033_s_at; 204406_at  
2131 EXT1 201995_at; 214985_at; 220393_at; 218502_s_at 
56942 DC13 218447_at  
81624 DIAPH3 232596_at; 220997_s_at; 229097_at 
169714 QSOX2  235239_at; 227146_at  
286052 LOC286052  241370_at  
51203 LOC51203        218039_at; 219978_s_at  
85453 TSPYL5 213122_at  
Table 2.5: Entrez ID, Gene Symbol and Affymetrix ID of MammaPrint genes. 
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3.1. Introduction 
Chromosomal translocations are a recurrent finding in cancer. In leukaemia, the detection of particular 
translocations at diagnosis is used as a biomarker to inform treatment decisions and judge patients 
prognosis (Betz and Hess 2010; Braoudaki and Tzortzatou-Stathopoulou 2012). The t(7;12)(q36;p13) 
translocation is found in approximately 30% of paediatric acute myeloid leukaemia (AML) patients and its 
presence is associated with an unfavourable outcome (Tosi et al. 2003; von Bergh et al. 2006). The 
chromosomal breakpoint of this translocation on chromosome 7 is heterogeneous, while the breakpoint 
on chromosome 12 involves the ETV6 gene at p13 (Tosi et al. 2000; Simmons et al. 2002; Tosi et al. 2003; 
Naiel et al. 2013). 
The use of conventional methods for detecting chromosomal translocation such as G-banding or RT-PCR is 
not ideal for the detection of t(7;12) (q36;p13) because of the characteristics of the translocation. For 
instance, the translocation involves subtelomeric regions on 7q36 and 12p13. Subtelomeric regions are 
difficult to distinguish microscopically because of a lack of distinct characteristics. Therefore there is a 
possibility of misidentifying this translocation as deletions of 7q (Tosi et al. 2015). Another method 
commonly used to detect translocations is the amplification of the fusion transcript by RT-PCR. However, 
this method is not suitable for the detection of t(7;12) (q36;p13) as the fusion transcript is only present in 
50% of cases (von Bergh et al. 2006).  
Therefore, fluorescent in situ hybridisation (FISH) remains the most suitable method for detecting this 
abnormality (Tosi et al. 2015). Initially, our research group working in collaboration with MetaSystems 
GmbH, Germany developed a three-colour FISH probe to identify this translocation (Naiel et al. 2013). 
However this approach is not ideal as it requires the use of microscopes equipped with at least four 
fluorescence filter sets in order to distinguish the probe signals from the nuclei rather than the more 
commonly available three fluorescence filter set in laboratories. 
3.2. Aim 
 
The aim of this chapter is to validate the detection of t(7;12)(q36;p13) using a novel dual-colour FISH 
assay. This aim will be met by carrying out FISH experiments on archival patient samples with confirmed 
t(7;12)(q36;p13) translocations using a combination of two FISH probes directly labelled with different 
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fluorochromes. The FISH images will be analysed to determine the sensitivity and accuracy of this 
diagnostic assay. 
3.3. Materials and Methods 
 
Description of patient’s samples 
Four archival bone marrow cell suspensions in 3:1 methanol:glacial acetic acid from patients diagnosed 
with haematological disorders previously described as harbouring a t(7;12)(q36;p13) were used for the 
study (see table 3.1 for patients clinical and cytogenetic characteristics). 
Description of dual colour Probe 
The dual-colour FISH probe for the detection of t(7;12)(q36;p13) was produced by MetaSystems GmbH, 
Germany. This is a break-apart probe designed to flank HLXB9 on 7q36 and ETV6 on 12p13 (figure 3.1). 
Figure 3.2 shows typical hybridisation patterns expected in the interphase nucleus from using the probe 
in FISH experiments (Method described in Chapter 2). 
 
Figure 3.1: Ideograms of chromosome 7 and 12 showing the localisation of FISH probe. The probes were designed 
to flank the HLXB9 gene (Red) and the ETV6 gene (Green). The genomic positions of probe and probe size in kilobase 
(kb) are located to the left of the ideograms, whilst the localisation of probe at 7q36 and 12p13 are shown to the right 





















Figure 3.2: Schematic representation of FISH signals expected in Interphase Nuclei using dual colour t(7;12) 
(q36;p13) probe. 
(A) Control nucleus without t(7;12): there are two different green gene signals (2G) representing two copies of HLXB9 
and two different red gene signals (2R) representing two copies of ETV6. As the probes are designed to break apart 
flanking the genes, these signals are observed as doublet signals. 
(B) Typical nucleus harbouring t(7;12): there are two fused red and green signal (2RG) representing t(7;12), one 
green signal (1G) and one red signal (1R). 
  
  
                A                                  B 
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3.4. Results 
All patients analysed were confirmed to have t(7;12) (q36;p13). Two different hybridisation patterns 
were observed in the nuclei and metaphases of patients’ bone marrow cells. The expected pattern of 
hybridisation described in figure 3.2 was observed in three out of the four analysed patients (Pt. 1,2 and 
3). In these patients, there were two fused red and green signals representing t(7;12), one red signal 
representing the non-translocated chromosome 7 and one green signal representing the non-translocated 
chromosome 12 (see figure 3.3).  
 
Figure 3.3: Ideograms and example of FISH hybridisation patterns observed in patients 1-3. 
 (A) Ideograms showing a schematic representation for t(7;12) (q36;p13) observed in patients 1,2 and 3, probe 
flanking HLXB9 in red and probe flanking ETV6 in green. (B & C) Dual colour FISH using a break-apart probe flanking 
HLXB9 on chromosome 7 (spectrum orange: Red) and ETV6 on chromosome 12 (FITC: green) on metaphase 
chromosome and interphase nucleus (counterstained in DAPI).  
The non-translocated chromosome 7 and 12 are observed as doublet signals and are shown by blue arrows. The 
translocation was observed as two co-localised (fused) red and green signals. Purple arrows on ideogram and 
metaphase cell show the translocated derivative 7 but not in the interphase cell as the origin of the translocation 
could not be determined in the interphase cell. Orange arrows on ideogram and metaphase cells show the 
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However, a different pattern of hybridisation was observed in patient 4. This included: one fused red and 
green signal representing one copy of translocated t(7;12),one red signal representing the non-
translocated chromosome 7 and two green signals representing one copy of the normal chromosome 12 
and the second green signal representing the second copy of the translocation on chromosome 7. This was 
assumed as the translocated chromosome 7, although no red signal was observed indicating a deletion on 
chromosome 7. The deleted 7q could be identified in the interphase chromosome due to a reduction in 
size of signal and the loss of the doublet signal on chromosome 7 (see figure 3.4C). 
 
Figure 3.4: Ideograms and example of FISH hybridisation patterns observed in patient 4.  
(A) ideograms showing a schematic representation for t(7;12) (q36;p13) observed in patient 4, probe flanking HLXB9 in red 
and probe flanking ETV6 in green. (B &C) Dual colour FISH using a break-apart probe flanking HLXB9 on chromosome 7 
(spectrum orange: Red) and ETV6 (FITC: green) on chromosome 12 on metaphase chromosome and interphase nucleus 
(counterstained in DAPI). The non-translocated chromosome 7 and 12 were observed as doublet signals and are shown by 
blue arrows. There was one copy of the translocation observed as one co-localised (fused) red and green signals; this was 
confirmed as the derivative 12 by analysing the metaphase cell and is shown by an orange arrow. The other green signal was 
identified as a derivative 7 with del (7q) by analysing the metaphase cell and is shown on the ideogram and metaphase 
spread by a purple arrow. This distinction could not be made in the interphase cell therefore the copies of chromosome 7 are 
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Using the dual colour break-apart probe, identifying the chromosomal origin of the translocated 





















82 Confirmed, patient previously 
analysed by FISH as pt. 4 in Tosi 
et al., 2000 
2 5 months/ 
male 
AML-M4 48,XY,+8,+19 78 Confirmed, patient previously 
analysed by FISH as pt 6 in Tosi 
et al., 2000 and pt 4 in Tosi et 
al., 2003 
3 3 months/ 
male 
AML-M0 47,XY,t(7;12)(q36,p13),+der(19) 73 Confirmed, patient previously 
analysed by FISH as pt 5 in Tosi 
et al., 2000 and pt 3 in Tosi et 
al., 2003 





155 Confirmed, patient previously 
analysed by FISH as pt 1 in Tosi 
et al., 2000; 2003 and Naiel et 
al., 2013. 
Table 3.1. Clinical and cytogenetic data of patients analysed in this study. AML, acute myeloid leukaemia (AML);M4 and 
M0 are AML FAB classification subtypes, MDS, myelodysplastic syndrome; T-ALL, T-acute lymphoblastic, leukaemia; pt, 
patient 
 
3.5. Discussion  
 
The dual colour probe enabled the detection of t(7;12)(q36, p13) translocation in all four patients 
previously described as harbouring the t(7;12) translocation (Tosi et al. 2000; Tosi et al. 2003; Naiel et al. 
2013).  The probe also allowed the detection of the translocation in a case where a deletion of 7q had 
occurred; being able to detect this translocation in cases of t(7;12) with an accompanied deletion of 7q 
will help reduce the misidentification of this translocation as a del 7q. However, a limitation of this dual 
colour probe was the inability to identify the chromosomal origin of derivatives chromosomes in 
interphase cells. 
In conclusion, this study proved that this dual colour FISH assay can be used to accurately identify the 
t(7;12)(q36;p13) using a microscope with three single band pass filters to distinguish the single probe 
signals and the dual colour signals in both metaphase chromosomes and interphase nuclei signal. This 
validation has proved that this probe set can be used in diagnostic laboratories that use fluorescence 
microscopes equipped with the conventional filter sets.  
  












Chapter 4: Investigating the expression 
and the nuclear localisation of HLXB9 in 









Some of the content of this chapter was submitted for publication as a research article to Chromosome 
Research: 
 
Owoka T, Leotta C, Foster H, Federico C, Bridger J, Saccone S, Tosi S. Repositioning of the HLXB9 gene in 
the nucleus of leukaemia cells depends on chromosome 7 rearrangements. 
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4.1. Introduction 
 
Chromosomal abnormalities of chromosome 7, particularly deletions in the long arm of chromosome 7, 
(del 7q) are commonly observed in myeloid haematological malignancies (Tosi et al. 1996; van der 
Straaten et al. 2005; Hasle et al. 2007; Březinová et al. 2007; Döhner et al. 2010; Honda et al. 2015). 
Clinically, del 7q are associated with a poor prognosis in both MDS and AML with the only option for 
curative treatment being allogeneic haematological stem cell transplantation (alloSCT) (van der Straaten 
et al. 2005). However, a significant proportion of del 7q patients treated with alloSCT are prone to 
relapse, making further research into characterising the genes in this region crucial in the understanding 
of oncogenesis in these patients (van der Straaten et al. 2005; Březinová et al. 2007; Honda et al. 2015). 
 
Studies carried out on AML infant patients with t(7;12) (q36;p13) have shown an overexpression of 
HLXB9 in all cases (von Bergh et al. 2006; Ballabio et al. 2009; Park et al. 2009). The breakpoints in these 
patients are variable but do not disrupt the HLXB9 gene, which might explain the observed 
overexpression of HLXB9 (Simmons et al. 2002; Tosi et al. 2003; Naiel et al. 2013). In these patients, a 
fusion transcript was only observed in approximately 50% of cases (Almstrup et al. 2007; Ballabio et al. 
2009). This suggests the formation of a fusion protein cannot be the mechanism for oncogenesis in these 
patients. 
 
However, the fusion of ETV6 with HLXB9 has been shown to lead to an altered nuclear localisation of 
HLXB9 from the nuclear periphery to the nuclear interior (Ballabio et al. 2009). This change in the nuclear 
localisation has been suggested to lead to the overexpression of HLXB9 observed in t(7;12) AML patients 
(Ballabio et al. 2009). HLXB9 overexpression has also been reported in the GDM-1 cell line, a cell line 
derived from an AML patient harbouring a translocation t(6;7) (q23;q36) (Nagel et al. 2005). 
 
The observation that the disruption of 7q36 due to a translocation results in HLXB9 overexpression poses 
the questions: whether an interstitial deletion in 7q might lead to the expression of HLXB9 in a similar 
way and if an altered nuclear localisation of HLXB9 accompanies its expression as seen in the 
translocations. 
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4.2. Aims 
 
The aim of this chapter is to investigate the expression of HLXB9 in patients diagnosed with various 
haematological malignancies. The nuclear localisation of HLXB9 in patients positive for HLXB9 expression 
or patients harbouring deletions in 7q will also be examined to determine if a change in the nuclear 
localisation of HLXB9 is affected by its expression or an alteration in the structure of chromosome 7.  
In order to meet these aims, the following objectives will be pursued: 
 HLXB9 expression will be investigated in patients diagnosed with various haematological 
malignancies with or without chromosome 7 abnormalities by RT-PCR, 
 Nuclear localisation of HLXB9 in patients diagnosed with haematological disorders either 
expressing HLXB9 or harbouring interstitial deletions of 7q will be analysed by erosion analysis 
of FISH images, 
 Finally, the results from the expression and nuclear localisation experiments will be analysed to 
determine if there is a link between HLXB9 nuclear localisation, its expression or the presence of 
chromosome 7 abnormalities. 
 
4.3. Methods and materials 
 
The methods and materials used in this study are described in Chapter 2. 
 
4.4. Results  
 
4 4.1. Investigating HLXB9 expression in haematological malignancies using RT-PCR 
 
HLXB9 expression was examined in control (peripheral blood cells, bone marrow cells, lymphoblastoid 
cell lines) and cancer patients samples and cell lines by RT-PCR. RNA was extracted from samples fixed in 
methanol:acetic acid and converted into cDNA. RT-PCR experiments were carried out using the cDNA 
template and -actin primers to check the quality and quanity of the cDNA template. When the cDNA 
template was determined to be of good quality, RT-PCR using primers for HLXB9 were carried out. 
Amplified products from the RT-PCR experiments were electrophoresed in a 1.2% Agarose gel and 
analysed. Results from these experiments are presented and discussed below. 
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 HLXB9 expression in non-cancer blood cells I.
a) HLXB9 was expressed in a number of control peripheral blood cells 
RT-PCR was carried out on peripheral blood cells from nine control (non-cancer) peripheral blood 
samples. Peripheral blood cells are mature cells therefore undergo very limited cell division. In order 
to culture them, phytohaemagglutinin (PHA), a plant mitogen that selectively stimulates lymphocyte 
proliferation is normally used (O’Donovan et al. 1995; Branco et al. 2008; Ioannou et al. 2015). 
However, stimulating cells with PHA alters the nuclear volume and the gene expression of 
lymphocytes (Branco et al. 2008; Ioannou et al. 2015). Therefore, the expression of HLXB9 was 
analysed before and after PHA stimulation (when possible) in these experiments. Another reagent 
used in culturing peripheral blood cells is thymidine. Because obtaining metaphase cells is crucial for 
the evaluation of patients cytogenetic information; lymphocytes grown in culture are blocked in the 
DNA synthesis stage of the cell cycle (synchronisation) through the addition of thymidine which is 
then washed away to increase the proportion of cells harvested in mitosis (Bangs and Donlon 2005). 
The expression of HLXB9 was also investigated in peripheral blood samples after thymidine addition 
to examine any alteration to HLXB9 expression.  
The peripheral blood samples used as controls were divided into two groups:  
o Non-stimulated and stimulated normal peripheral blood (unmatched samples): The 
expression of HLXB9 was also analysed in six control peripheral blood (described below) samples 
with or without PHA and/or thymidine.  
 two of the samples were peripheral blood samples (figure 4.1A:lanes 1 and 2) and these 
samples showed no expression of HLXB9 
 two were peripheral blood cells stimulated with PHA (figure 4.1A: lanes 3 and 4) and 
these samples showed no expression of HLXB9  
 the last two samples were peripheral blood cells stimulated with PHA and synchronised 
with thymidine (figure 4.1A:lanes 5 and 6). These samples showed HLXB9 expression as 
seen as faint bands on the gel.  
o Non-stimulated and stimulated normal peripheral blood (matched samples): The 
expression of HLXB9 was analysed in three control peripheral blood samples (figure 4.1B). The 
samples were obtained and analysed by RT-PCR before and after stimulation with PHA (Sample 
ID: pbmc, con 41 and con 43). Two out of the three samples (pbmc and con 43) showed HLXB9 
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expression before stimulation with PHA. After PHA stimulation, all three patients showed HLXB9 
expression (figure 4.4B). The pbmc sample also showed an increase in the expression of HLXB9 
after stimulation with PHA, whilst con 43 showed the same level of expression before and after 
PHA stimulation. 
 
In summary, 40% of peripheral blood cells (non-stimulated with PHA) showed HLXB9 expression. In 
addition, 60% peripheral blood samples stimulated with PHA showed HLXB9 expression. Both samples 
stimulated with PHA and synchronised with thymidine also showed HLXB9 expression. Although the 
results obtained were mixed, they suggest HLXB9 might be expressed in peripheral blood cells. There is 
also a possibility that HLXB9 expression might increase after stimulation with PHA, although these results 
have to be confirmed by qRT-PCR. These results also show HLXB9 is expressed upon thymidine 
synchronisation of lymphocytes in culture. However, due to the small number of samples (n=2), this 
cannot be stated conclusively. 
 
b) HLXB9 was expressed in control bone marrow cells 
Five non-cancer bone marrow samples were screened for HLXB9 expression to ascertain if the 
expression of HLXB9 in progenitor blood cells was different to mature blood cells circulating in the 
peripheral blood. All five samples studied show HLXB9 expression (figure 4.1D). The reason for the 
variation in expression between bone marrow cells and peripheral blood cells is yet to be 
determined. However, the results obtained suggest that HLXB9 may have a function associated with 
proliferation in blood cells. Therefore HLXB9 was expressed uniformly in bone marrow cells, cells 







Figure 4.1: Agarose gel electrophoresis analysis of RT-PCR products in control samples.RT-PCR products were electrophoresed in 1.2% Agarose gel at 80 Volts. Amplified products at 660bp 
obtained using primers for β-actin was used as both quality and quantity control. The β-actin PCR products in each sample were analysed before the HLXB9 RT-PCR was carried out to make sure cDNA 













Figure 4.1A: Agarose gel electrophoresis analysis 
of RT-PCR products in control (non-cancer) 
peripheral blood samples. Whole blood sample 
(n=2); whole blood stimulated with 
phytohaemagglutinin (n=2); and whole blood 
samples stimulated with PHA and treated with 
thymidine (n=2). 
LANES: 
M= peqGOLD DNA SIZER XI, Lane 1= whole 
peripheral blood cells (WBC) sample 1, Lane 2= 
WBC sample 2, Lane 3= WBC sample 3 stimulated 
with PHA, Lane 4=WBC sample 4 stimulated with 
PHA, Lane 5= WBC sample 4 stimulated with PHA 
and treated with thymidine (thy), Lane 6= WBC 
sample 5 stimulated with PHA and treated with 
thymidine, Lane 7= (top) negative control- cDNA 
negative / (bottom) positive control K562 cell line, 
Lane 8 = negative control mastermix 
Lane *= Sample not included as part of this study, 
patient with constitutional abnormality of 7q 
 
(Bottom) Gel of RT-PCR reaction using HLXB9 
primers showing the amplified product at 
359bp. Lanes 1-4 were negative for HLXB9 
expression (no bands in lane on gel), Lane 5 and 6 
show faint bands. (Top) RT-PCR control gel showing 
the quality of cDNA samples using β-actin primers.  
Figure 4.1B: Agarose gel electrophoresis 
analysis of RT-PCR products in matched 
control peripheral blood samples before 
and after stimulation with PHA.  
LANES: 
M= peqGOLD DNA SIZER XI, Lane 1= 
control peripheral blood mononuclear cells 
(pbmc), Lane 2= pbmc stimulated with 
PHA, 
Lane 3= control peripheral blood (pb) 
sample-control 41, Lane 4= control 41 
stimulated with PHA, Lane 5= control pb 
sample-control 43, Lane 6= control 43 
(npb) stimulated with PHA 
Lane 7= positive control-K562 cell line, 
Lane 8= negative controls 
 
(Bottom) Gel of RT-PCR reaction using 
HLXB9 primers showing the amplified 
product at 359bp. Before PHA 
stimulation, two out of three pb control 
samples showed HLXB9 expression (pbmc 
and 41). After PHA stimulation, all three 
peripheral blood samples showed HLXB9 
expression. (Top) RT-PCR control gel show 
the quality of cDNA samples using β-actin 
primers.  
 
Figure 4.1C: Agarose gel 
electrophoresis analysis of RT-PCR 
products in lymphoblastoid cell 
lines GM00893 and GM17208B. 
 
LANES: 
M= peqGOLD DNA SIZER XI, Lane 1= 
GM00893, Lane 2= 17208B, Lane 3= 
(top) negative control-negative 
cDNA/ (bottom) positive control-
K562 cell line, Lane 4= negative 
control- master mix 
 
(Bottom) Gel of RT-PCR reaction 
using HLXB9 primers showing the 
amplified product at 359bp. Both 
lymphoblastoid cell lines show (Top) 
RT-PCR control gel showing the 





Figure 4.1D: Agarose gel electrophoresis 
analysis of RT-PCR products in five bone 





M= peqGOLD DNA SIZER XI, Lane 1= 
control bone marrow cells (BM 1), Lane 
2= BM2, Lane 3= BM3, Lane 4= BM4, Lane 
5= BM5, Lane 6= (top) negative control-
negative cDNA/(bottom) positive control-
K562 cell line, Lane 7= negative control-
master mix 
 
(Bottom) Gel of RT-PCR reaction using 
HLXB9 primers showing the amplified 
product at 359bp. All five bone marrow 
samples showed HLXB9 expression. (Top) 
RT-PCR control gel showing the quality of 









Figure 4.2: Agarose gel electrophoresis analysis of RT-PCR products in leukaemia (K562, GFD-8, GDM1) and lymphoma (CRL 2632 and 2630) derived cell lines. Lanes: M= peqGOLD 
DNA SIZER XI , Lane 1= K562, Lane 2 = GF-D8, Lane 3 = GDM-1, Lane 4 = CRL 2632, Lane 5 = CRL 2630, Lane 6 = cDNA negative control. (Bottom) gel of RT-PCR reaction using HLXB9 primers 




Figure 4.3: Agarose gel electrophoresis analysis of RT-PCR products in patients diagnosed with various haematological disorders. 12 out of the 48 patients diagnosed with various 
haematological malignancies showed HLXB9 expression. Patients 1029, 1030, 1033, 1040, and 1042 were not included in the analysis due to low RNA yield and subsequent failure of cDNA 
synthesis and RT-PCR experiments. * Samples not included in this study as they are breast cancer cell lines. Lanes: M= peqGOLD DNA SIZER XI, negative controls (-ve) cDNA negative or master 
mix and K562 was used as positive controls (+ve)
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c) HLXB9 was expressed in control lymphoblastoid cell lines: GM00893 and GM17208B 
HLXB9 expression was also examined in two control lymphoblastoid cell lines, GM00893 and 
GM17208B. Lymphoblastoid cell lines are obtained from Epstein Barr Virus transformation of resting 
B cells from peripheral blood. They are commonly used as controls in place of lymphocytes in 
research (Hussain and Mulherkar 2012). Lymphoblastoid cell lines, unlike mature lymphocytes are 
able to undergo cell division and are grown in culture without become tumorigenic (Hussain and 
Mulherkar 2012). Both lymphoblastoid cell lines examined showed HLXB9 expression (figure 4.1C). 
These results implies a function for HLXB9 linked to proliferation in these cells  
 
 HLXB9 expression in leukaemia and lymphoma derived cell lines II.
Four out of five cell lines investigated expressed HLXB9 
HLXB9 expression was also examined in five leukaemia or lymphoma derived cell lines described in table 
4.1 and shown in figure 4.2. The two lymphoma derived cell lines analysed had no chromosome 7 
abnormality and both showed HLXB9 expression. In contrast, the three leukaemia cell lines analysed had 
confirmed abnormality of chromosome 7. Two out of the three leukaemia derived cell lines showed 
HLXB9 expression. These results indicate that HLXB9 expression can occur independently of the presence 
of chromosome 7 abnormalities.  
 










Complex karyotype including 4 copies of 
chromosome 7 (Gribble et al. 2000) 
Yes  Yes  
GF-D8  Acute Myeloid 
Leukaemia 
(AML) -M1 FAB 
subtype. 
Complex karyotype including 3 copies of 
chromosome 7 
including)t(5;7)t(7;15),inv(7)x2, der(7)t(7; 
15)del(7) t(7;12) (Tosi et al. 1999) 
Yes  No  
GDM-1  AML  48,XX, der (2) 
t(2;12)(q36;q13);t(6;7)(q23;q36) (Nagel et 
al. 2005) 
Yes  Yes  
CRL 2632  Non-Hodgkin’s 
B cell 
lymphoma  
Complex karyotype including t(14:18) 
(Laulier et al. 2011)  
No  Yes   
CRL 2630  Non Hodgkin’s 
B cell 
lymphoma  
Trisomy of chromosome 11 as published in 
Gabay et al. 1999 however no trisomy of 
chromosome 11 was detected in cells in our 
lab (data not shown) 
No  Yes  
Table 4.1: Four out of the five cell lines investigated expressed HLXB9. HLXB9 expression in cell lines derived 
from leukaemia/lymphoma patients showing karyotype published in literature or obtained experimentally. 
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 HLXB9 expression in patients with various haematological malignancies III.
25% of patients analysed showed HLXB9 expression 
48 patients diagnosed with various haematological malignancies were screened for HLXB9 expression 
(figure 4.3). 12 patients out of the 48 patients studied showed HLXB9 expression (25%). Patient’s 
diagnosis and karyotype were checked after obtaining the RT-PCR results to prevent bias in the results 
from the expression experiments. As the study was interested in expression of HLXB9 in patients 
harbouring del 7q, patients were categorised into two groups by karyotype (figure 4.4):  
 patients with chromosome 7 abnormalities (n=35)  
 patients without chromosome 7 abnormalities (n=8)  
The karyotype of five patients analysed were unknown. Seven out of 35 patients with confirmed 
chromosome 7 abnormality showed HLXB9 expression (20%). Three out of eight patients without 
chromosome 7 abnormalities showed HLXB9 expression (37.5%). Two out of five patients with an 
unknown karyotype showed HLXB9 expression (40%). There was no significant difference in the 
proportion of patients showing HLXB9 gene expression when patients with chromosome 7 abnormalities 
were compared to patients without chromosome 7 abnormalities (P=0.290, Pearson chi squared test). 
These findings suggest that HLXB9 expression in haematological malignancies is not limited to patients 
harbouring chromosome 7 abnormalities. 
 
Figure 4.4: The proportion of patients with haematological disorders that showed HLXB9 expression. (Total 
number of patients analysed n=48). Patients were categorised by karyotype into two groups; patients with 
chromosome 7 abnormalities (n=35) and patients without chromosome 7 abnormalities (n=8). The karyotypes of five 
patients were unknown. 25% of all patient sampled show HLXB9 expression, 20% of patients with confirmed 
abnormality of chromosome 7 show HLXB9 expression, 37.5% of patients without abnormality of chromosome 7 
show HLXB9 expression and 40% with an unknown karyotype showed HLXB9 expression. There was no significant 
difference between the proportion of patients with chromosome 7 abnormality showing HLXB9 expression and the 
patients without chromosome 7 abnormality showing expression (P=0.290, Pearson chi squared test). This implies 
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During the study, a sample from two time points for one of the patients studied was screened. The two 
time points are represented by samples 1005 and 1007. Sample 1007 was taken at follow up a year after 
sample 1005 was taken. Sample 1005 showed HLXB9 expression whilst sample 1007 was negative for 
HLXB9 suggesting that HLXB9 expression has been lost in this patient. Two different samples 1028 and 
1032 were also taken from another patients obtained at the same time and both show HLXB9 expression. 
The results from this patient validate the result obtained from the experimental design as the same 
results were obtained independently. 
 
A greater proportion of patients diagnosed with MDS or MPD showed HLXB9 expression compared to 
patients diagnosed with other haematological malignancies.  
 
The diagnosis was available for 39 of the patients analysed. Figure 4.5 below categorises the patients 
analysed by the type of haematological disorder diagnosed. Four out of the nine (44%) patients diagnosed 
with myelodysplastic/myeloproliferative neoplasms (MDS or MPD) showed HLXB9 expression. Two out 
of six (33%) patients diagnosed with acute lymphoblastic leukaemia (ALL) show HLXB9 expression. Two 
of the 23 (9%) patients with acute myeloid leukaemia (AML various FAB-subtypes) show HLXB9 
expression; and the only patient diagnosed with chronic myeloid leukaemia screened did not show HLXB9 
expression.  
 
Figure 4.5: Proportion of patients with HLXB9 expression categorised by the type of haematological disorder 
diagnosed. 44% of the patients diagnosed with MDS and MPD show HLXB9 expression, 33% ALL patients show 
HLXB9 expression, 6% AML patients studied show HLXB9 expression and the one CML patient sampled did not show 
HLXB9 expression.  
 
The proportion of patients diagnosed with MDS/MPD expressing HLXB9 was compared to the proportion 
of patients diagnosed with AML expressing HLXB9 using a Pearson chi squared test. The difference in 
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frequently in MDS/MPD compared to AML. MDS or MPD can be described as premalignant conditions 
because a proportion of patients go on to develop acute myeloid leukaemia (Björkholm et al. 2014). 
 
The MDS/MPD patients that showed HLXB9 expression had different types of chromosome 7 
abnormalities with heterogeneous breakpoints. Examination of the five patients diagnosed with MDS or 
MPD that did not show HLXB9 expression revealed no overlap between the type of chromosome 7 
abnormalities present or the breakpoints on chromosome 7. Interestingly, patient 1005 who was 
diagnosed with MDS had both an interstitial and terminal deletion of chromosome 7 and showed HLXB9 
expression. When the blood sample from this patient was collected a year later (1007), there was an 
evolution in the karyotype of this patient gaining additional abnormality of chromosome 3 and 12 and a 
loss of HLXB9 expression. 
 
The incidence in the proportion of HLXB9 expression in MPD/MDS patients in addition to the evolution of 
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HLXB9 expression in patients diagnosed with haematological disorders was not limited to patients 
that harboured chromosome 7 abnormalities.  
 
12 out of the 48 patients studied show HLXB9 expression. The diagnosis and karyotype of patients that 
showed HLXB9 expression are summarised in table 4.2.  
















1005** 46,XY, add(7)(p10), add (7)(q?22) Interstitial and 
terminal deletion 
MDS 
1012 47,XY, r(7)(p22q22),del(20)(q11q13) 
 
Ring Chromosome MPD 
1019 46, XX, add (7), i(9) q10, t(10;11) (p12;q21) [20] 
46, XX [10] 
Add 7 ALL 






1049 Full karyotype unknown with t(3;7)(unknown 
breakpoint) 
Translocation Unknown 







1026 46, XY, t(5;11) (q31;q23) 
 
None ANLL-M2 
1027 46,XX, t(6;11) (q13;p13) 
 
None ALL- ref 
V1001 45-46,XY,-14,+mar[CP2]/46,XY (patient 10 in 















1032* Unknown Unknown Unknown 
Table 4.2: Clinical and cytogenetic data of patients positive for HLXB9 expression in our study. Results are 
categorised into three groups: patients with known chromosome 7 abnormalities (seven patients out of 35 showed 
HLXB9 expression), patients without chromosome 7 abnormalities (three out of eight showed HLXB9 expression) and 
patients with unknown karyotype and clinical details (two out of five showed HLXB9 expression) * Patients 1028 and 
1032 are two blood samples obtained from the same patient at the same time. ** Patient 1005 and patient 1007 are 
samples obtained from the same patient, however, sample 1007 was taken a year later; interestingly patient 1005 
expresses HLXB9 but a year later when sample 1007 was taken no longer show expression of HLXB9. Pt v1001 was 
published as pt 10 in Ballabio et al. 2009. 
 
Three out of the eight patients without chromosome 7 abnormalities show HLXB9 expression. The first 
patient, pt V1001 had been previously described as showing HLXB9 expression by our group (Ballabio et 
al. 2009). The patient karyotype was: 45-46, XY,-14,+mar[CP2]/46,XY. In this study, two additional 
patients without chromosome 7 abnormality, pt 1026 and pt 1027 showed HLXB9 expression. Both 
patients had a translocation-involving chromosome 11 with different breakpoints. Pt 1026 with t(5;11) 
(q31;q23) was diagnosed with ANLL-M2 (AML) whilst pt 1027 with t(6;11) (q13;p13) was diagnosed 
with ALL-ref. Two of five patients with an unknown karyotype showed HLXB9 expression. In the group of 
patients with chromosome 7 abnormalities that showed HLXB9 expression, the breakpoints on 
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chromosome 7 were heterogeneous and the type of chromosomal abnormality was varied. In addition, a 
correlation between patients that showed HLXB9 expression and harboured deletions of 7q could not be 
identified  
A hypothesis of this study was that patients with interstitial deletions of chromosome 7 might be more 
likely to express HLXB9 compared to patients without interstitial deletions of chromosome 7. The 
proportion of patients with an interstitial deletion of 7q that expressed HLXB9 (three out of seven) was 
compared to the proportion of patients without interstitial deletion of 7q that expressed HLXB9 (six out of 
36). There was no significant difference in the proportion of patients showing HLXB9 expression 
indicating that patients with interstitial deletions of chromosome 7 are not more likely to express HLXB9 
(result of Pearson Squared chi test, P=0.119).  
 
In summary, due to the variability in HLXB9 expression shown in the controls and patient samples, the 
difference in the expression of HLXB9 observed probably differs for reasons yet to be determined. 
Therefore, further research is required to understand why these patients showed HLXB9 expression.  
 
 
75% of patients diagnosed with haematological malignancies did not show HLXB9 expression 
 
36 out of the 48 patients analysed were negative for HLXB9 expression. The results, diagnosis and 
cytogenetic data from these patients are categorised in table 4.3 into three main groups: patients with 
unknown karyotype (n=5); patients without chromosome 7 abnormalities (n=8) and patients with 
abnormalities of chromosome 7 (n=35). 






3 out of 5 patients with unknown 
karyotype did not show HLXB9 
expression 
1020 N/A N/A 
1045 N/A N/A 
1047 N/A N/A 
5 out of 8 patients without 
chromosome 7 abnormality did 
not show HLXB9 expression  
1021 46,XX, der(11)(q23) ANLL-M1 
1022 6,XX, t(2;11) (q31;p15) ANLL-M5 
1023 46,XY,t(4;11) (p12;p15) AML-M1 
1024 46,XX,del (15q) AML 
1025 45,XY,-Y, t(8;21)(q22q22)/45, idem, add(3) 
(q?26),del(5)(q?33)/46, XY 
ANLL-M5 




of 7q did not 
show HLXB9 
expression 
9 had terminal 





1014 46,XY,del(7)(q22) [18] 
46,XY,ins(11;X)(q23;q13q?23) [4]  
46, XY,ins(11;X),t(8;10) (q21;q26) [2]  
46, XY [16] 
ANLL 
1017 46,XXadd (7)(q22)  AML 
1036 46,XY,del(7)(q22),t(8;21) AML 







1043 Complex karyotype +del(7)(q13) ALL 
1051 del(7q)(unknown breakpoint) MDS to AML 
1052 Complex karyotype+del(7)(q11q32) ALL 
4 had interstitial  
deletions of 7(q) 
1003 47,XY,dic(5;17)(q11;p11),del 
(7)(q22q?),+11,+13,-15,+mar [1] /46,idem,-3 
[5] /46,idem,-3,+8,-13 [22] /46,XY [2] 
? 
1016 46, XX, del 7 (q22-? q34) AML-M0 
1055 46,XY,?del (7)(q22q22) [16]/46,XY [4] MPD 
K1001 46,XY,del(7) (q22q36) MDS/AREB 
6 had interstitial 
and terminal 
deletion of 7(q) 
 
1007** 46,XY,add (7) (p10), add (7) (q?22) [18]  
46, idem,del (3) (q2?1), ins (12;?) (q13;?) [12] 
MDS 
1008 46,XX, t(9;22) (q34;q11) [3]/ 46,XX, t(7;8) 






1009 46?XX,dic (5;17)(q11; p11),-






q33)[ 28] /46, XY [2] 
ANLL 
1013 46,XY,inv(11) (q13q22),inv (16)(p13q22) [2]/ 
46, XY,idem,del (7) (q22) [20]/ 
46,XY,idem, t(3;17) (q2?1;q21), del 7(q32) [8]  
AML 
1051 Complex karyotype+del(7)(q ?) AML 
1 had deletion 











1 had an  
add7(q) 
1034 46,XX,add(7) (q22) AML 




1002 46, XY, +mar.ish -7, del (7) (D7Z1+) MDS 
1006 43,X,dic(?Y;16)(q11;q13),-5,der(7)inv 
(7)(p11q22) del (7) (q22q32),-12,der (15) 
t(15;?17)(p11;q21) add(19)(p13),-20,+2 mar 
[29]/46,XY?? [1] 
MDS 
1015 46,XX,Inv (7) (q31q33-34) AML 
1035 46, XX, der(7),+mar (ish)7WCP+ (unbalanced 
translocation of chromosome 7) 
AML-M5 
1037 46,XY,+X,-7,add(9) (p22),der(12) t(7;12) 
(q11;p13),del(14)(q13)/47,XY,idem+mar/46,XY 
ALL 
1039 Complex+del 7(q32)? +add 7q N/A 
1053 46,XY,r(7)(p22q22) ANLL-M1 
Table 4.3: Table showing the clinical and cytogenetic data of patients negative for HLXB9 expression. Results 
are categorised into three groups, patients with known chromosome 7 abnormalities (28 patients out of 35 in this 
group did not show HLXB9 expression), patients without chromosome 7 abnormalities (5 out of 8 did not show 
HLXB9 expression) and patients with unknown karyotype and clinical details (3 out of 5 did not show HLXB9 
expression). ** Patient 1005 and patient 1007 were samples obtained from the same patient however sample 1007 
was taken a year later, interestingly the patient had HLXB9 expression when sample 1005 was collected positive and 
a year later has no expression of HLXB9, this coincides with an evolution of the patient karyotype. 
 
The group of patients with chromosome 7 abnormalities that did not show HLXB9 expression included 
nine patients with terminal deletion of chromosome 7 (table 4.3). This result was expected as HLXB9 
maps to 7q36 and is likely to be lost during a deletion involving the terminal region of 7q. Others 
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abnormality of chromosome 7 observed included interstitial deletion of 7q and addition of 7q. The 
breakpoints of these abnormalities were heterogeneous. 
 
Patients without chromosome 7 abnormalities that did not show HLXB9 expression included: one patient 
with a structural abnormality of the MLL gene, two patients with translocations involving NUP 98 and one 





4 4.2. Nuclear Localisation of HLXB9 in non-cancer samples and patients diagnosed with 
haematological malignancies 
 
The nuclear localisation of HLXB9 was analysed in patients diagnosed with various haematological 
malignancies identified as either expressing HLXB9 or habouring interstitial deletion of 7q. The rationale 
for these experiments was to determine if the nuclear localisation of HLXB9 was altered upon its 
expression or due to the deletion and rejoining of 7q as observed in interstitial deletions. 2D FISH 
experiments were carried out using a probe containing HLXB9, and erosion script analysis of the resulting 
FISH images was used to determine the nuclear localisation of the gene. The nuclear localisation of HLXB9 
was also determined in a number of controls commonly used in research.  
I. Nuclear localisation of HLXB9 in control (non-cancer) blood cells 
 
The nuclear localisation of HLXB9 was analysed in non-cancer peripheral blood cells, bone marrow cells 
and lymphoblastoid cell lines; these cells are commonly used as controls in leukaemia research. The 
nuclear localisation in these samples were analysed to determine the localisation of HLXB9 in non-cancer 
cells. 
a) HLXB9 had an intermediate nuclear positioning in non-cancer bone marrow cells 
The nuclear localisation of HLXB9 was examined in five mononuclear bone marrow cells, which are 
mostly comprised of progenitor blood cells. These cells were found to express HLXB9 by RT-PCR. 
HLXB9 was found to have an intermediate nuclear position in all five samples of control bone 
marrow mononuclear cells analysed (figure 4.6). There was no significant difference in the nuclear 
positioning of the HLXB9 gene in the bone marrow samples studied using a one-way ANOVA and 
Bonferroni post hoc test.  
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Figure 4.6: HLXB9 had an intermediate nuclear localisation in bone marrow mononuclear cells. 2D FISH was 
performed on bone marrow samples fixed in methanol: acetic acid. FISH images were analysed by erosion script 
analysis. The histograms display the average probe intensity (normalised by DAPI staining) on the y-axis and the 
number of nuclei studied on the x-axis. The standard error bars represent the standard error of the mean for each 
nuclear position. There was no significant difference in the nuclear positioning of the HLXB9 gene in the bone marrow 




b)  HLXB9 had an intermediate nuclear positioning in control (non-cancer) peripheral blood cells 
 
As previously discussed, due to their limited proliferative capacity, PHA (a plant mitogen) is 
regularly used to culture lymphocytes in peripheral blood cells in the laboratory. Upon 
stimulation with PHA, the nuclear volume of lymphocytes is known to increase as shown in figure 
4.7 (Branco et al. 2008; Ioannou et al. 2015). Therefore, the nuclear localisation of HLXB9 was 
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Figure 4.7: Nuclear localisation of HLXB9 in control peripheral blood samples with or without stimulation 
with PHA. There was an increase in the nuclear volume of peripheral blood samples stimulated with PHA (Left): non-
stimulated peripheral blood samples (right): stimulated peripheral blood samples. 2D FISH images of peripheral 
blood samples, nuclei counterstained in DAPI (blue), HLXB9 was labelled with FITC (green). Scale bar= 5µM  
 
 
I. Control (non-cancer) peripheral blood cells (non-stimulated with PHA) 
HLXB9 had an intermediate nuclear positioning in the three control (non-cancer) peripheral 




















Non-stimulated peripheral blood 
samples 
Peripheral blood samples stimulated 
with PHA 
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in the localisation of the HLXB9 gene between the three control samples (results obtained from a 
one-way ANOVA and Bonferroni post hoc test). 
In order to determine if there was a difference in the nuclear localisation of HLXB9 between 
peripheral blood cells and bone marrow cells, their nuclear localisation of HLXB9 were compared 
using a one-way ANOVA and Bonferroni post hoc test. The nuclear localisation of HLXB9 in the 
non-stimulated peripheral blood cells was similar to the bone marrow cells analysed. This 
indicates the nuclear localisation of HLXB9 was conserved in blood cell regardless of cell maturity 
and suggests that regulation of HLXB9 expression in these cells is probably not a result of a 
position effect regulation of expression. 
  




Figure 4.8: HLXB9 had an intermediate nuclear localisation in peripheral blood mononuclear cells before and 
after PHA stimulation. After PHA stimulation, there was an increase in the proportion of gene signals in the nuclear 
periphery in the three samples. However, this increase was only statistically significant in sample pbmc and con 41 
samples only. 2D FISH was performed on peripheral blood cells. FISH images were analysed by erosion script 
analysis. The histogram displays the average probe intensity (normalised by DAPI staining) on the y-axis and the 
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II. Stimulated control (non-cancer) peripheral blood cells 
HLXB9 also had an intermediate nuclear positioning in the cells after stimulation with PHA 
(figure 4.8). There was no significant difference in the localisation of the HLXB9 gene between the 
three stimulated peripheral blood samples (results obtained from a one-way ANOVA and 
Bonferroni post hoc test).  
 
The nuclear localisation of HLXB9 in peripheral blood samples before and after stimulation with 
PHA was compared by a paired student t-test. There was an increase in proportion of genes 
localised in the nuclear periphery in the pbmc and con 41 samples after stimulation with PHA (as 
shown in table 4.4). In these two samples, HLXB9 expression increased post stimulation with 
PHA (figure 4.1B). There was no difference in the nuclear localisation in the con 43 before and 
after PHA stimulation. This may be because the level of HLXB9 expression in the non-stimulated 
con43 sample and the stimulated sample con 43 was similar.  
Non-stimulated 
controls vs. 
PBMC Con 41 Con 43 
Stimulated with PHA 
(paired student t-
test) 
Increase in proportion of genes 
localised in peripheral shell 
upon stimulation with PHA ***. 
Increase in proportion of genes 
localised in peripheral shell upon 
stimulation with PHA *. 
No difference in 
gene localisation in 
nuclei. 
Table 4.4: Comparison of the nuclear localisation of HLXB9 in three peripheral blood samples before 
and after PHA stimulation using a paired student t-test. There was an increase in the proportion of 
HLXB9 gene signal localised in the nuclear periphery in the PBMC and con 41 samples after stimulation with 
PHA. No difference was observed in the nuclear localisation of HLXB9 in the con 43 before and after PHA 
stimulation. Results of unpaired student t-test, *P  0.05, ** P 0.01, *** P 0.001 
 
 
c) HLXB9 had a peripheral-Intermediate nuclear localisation in peripheral blood cells stimulated 
with PHA and synchronised with thymidine 
 
The nuclear localisation of HLXB9 in healthy peripheral blood cells stimulated with PHA and synchronised 
with thymidine were also analysed as HLXB9 expression was observed in these samples. HLXB9 had a 
peripheral-intermediate nuclear positioning in these cells (figure 4.9). There was no significant difference 
in the nuclear localisation of HLXB9 between two samples analysed (results of an unpaired student t-test). 
 
The nuclear localisation of HLXB9 in these samples was then compared to the peripheral blood control 
samples: pbmc, con 41 and con 43 by a one-way ANOVA and Bonferroni post hoc test (table 4.5). Upon 
stimulation with PHA and addition of thymidine, there was an increase in the proportion of genes in the 
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nuclear periphery in both samples. This means there was a change in the nuclear localisation of HLXB9 to 
the nuclear periphery after stimulation with PHA and treatment with thymidine.  
 
The nuclear localisation of HLXB9 in these controls: con 6 and con 7 were also compared to peripheral 
blood samples stimulated with only PHA. There was no significant difference in the nuclear localisation of 
HLXB9 between the two conditions. 
 
Samples stimulated 
with PHA and 
thymidine vs  
PBMC Con41 Con 43 
Control 6 Increase in proportion of genes 
in the nuclear periphery *** 
Increase in proportion of 
genes in the nuclear 
periphery *** 
Increase in proportion of 
genes in the nuclear 
periphery. * 
Control 7 Increase in proportion of genes 
in the nuclear periphery. *** 
Increase in proportion of 
genes in the nuclear 
periphery. *** 
Increase in proportion of 
genes in the nuclear 
periphery. ** 
Table 4.5: Comparison of the nuclear localisation of HLXB9 in peripheral blood samples stimulated with PHA 
and thymidine (con 6 and con7) to three peripheral blood samples (pbmc, con 41 and con 43). The results 
indicate a thymidine specific change in gene positioning of HLXB9. There was an increase in the proportion of HLXB9 
gene signal localised in the nuclear periphery in pbmc, con 41 and con43. Results of a one-way ANOVA and 
Bonferroni post hoc test. *P  0.05, ** P 0.01, *** P 0.001 
 
   
 
 
Figure 4.9: HLXB9 had a peripheral-intermediate nuclear localisation in peripheral blood cells stimulated 
with PHA and synchronised with thymidine. 2D FISH was performed on peripheral blood cells in methanol: acetic 
acid fixative. FISH images were analysed by erosion script analysis. The histogram displays the average probe intensity 
(normalised by DAPI staining) on the y-axis and the number of nuclei studied on the x-axis. The standard error bars 
represent the standard error of the mean for each nuclear position. There was no significant difference in the nuclear 
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d) HLXB9 had an intermediate nuclear positioning in the two lymphoblastoid cell lines 
analysed 
  
HLXB9 had an intermediate nuclear positioning in the two lymphoblastoid cell lines analysed-
GM17208B, GM00893 (figure 4.10). There was no significant difference in the nuclear positioning of 
HLXB9 between the lymphoblastoid cell lines studied (results of an unpaired student t-test). 
As lymphoblastoid cell lines are derived by EBV transformation of b-lymphocytes in the peripheral 
blood, the nuclear localisation of HLXB9 in lymphoblastoid cell lines was compared to the peripheral 
blood cells analysed (pbmc, con 41 and con 43). There was no significant difference in the nuclear 
localisation of HLXB9 between the two groups (results obtained from a one-way ANOVA and 
Bonferroni post hoc test).This implies the nuclear positioning of HLXB9 in the lymphoblastoid cell 
lines was similar to the localisation of HLXB9 in peripheral blood cells. 
 
  
Figure 4.10: HLXB9 had an intermediate nuclear localisation lymphoblastoid cell lines analysed. 2D FISH was 
performed on lymphoblastoid cells in methanol: acetic acid fixative. FISH images were analysed by erosion script 
analysis. The histogram displays average probe intensity (normalised by DAPI staining) on the y-axis and the number 
of nuclei studied on the x-axis. The standard error bars represent the standard error of the mean for each nuclear 
position. There was no significant difference in the nuclear positioning of the HLXB9 gene between the two 




II. Nuclear localisation of HLXB9 in patients with haematological disorders 
 
The nuclear localisation of HLXB9 was analysed in seven patients diagnosed with various haematological 
malignancies. The patients were selected based on either confirmed expression of HLXB9 or the presence 
of interstitial deletion of 7q (refer to table 4.6). The selection of the patients was carried out in this 
manner in order to determine if a change in the nuclear localisation of HLXB9 is dependent on its 
expression or the presence of chromosomal 7 abnormalities. Nuclear localisation of HLXB9 was analysed 
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a. Patients found to express HLXB9 without chromosome 7 abnormalities  
b. Patients diagnosed with various haematological disorders with an interstitial deletion in 7q 
(del 7q). 
The nuclear localisation of HLXB9 in patients was only compared to control bone marrow samples as the 
patients’ samples analysed were bone marrow samples. 
 
Table 4.6: Clinical and cytogenetic characteristics of patients analysed for nuclear localisation of HLXB9. 
 
 
a. Patients without chromosome 7 abnormality with confirmed expression of HLXB9  
 
The nuclear localisation of HLXB9 was analysed in three patients without chromosome 7 
abnormalities that showed HLXB9 expression by RT-PCR. Two of these patients were diagnosed with 
AML whilst the third patient was diagnosed with ALL. The nuclear localisation of HLXB9 in these 
patients was investigated to determine if a change in the nuclear localisation of HLXB9 occurred due 
to expression of HLXB9. 
 
o HLXB9 had an intermediate nuclear localisation in AML patients without chromosome 7 
abnormalities 
 
HLXB9 had an intermediate nuclear position in the bone marrow cells of the two AML 
patients (pt 1026 and ptV1001) without chromosome 7 abnormalities analysed. There was 
no significant difference in the nuclear localisations between the two patients (result of an 
unpaired student’s t-test). 
Patient 
ID 








1026 ANLL-M2 46, XY, t(5;11) (q31;q23) None +ve Intermediate 
V1001 AML 45-46, XY,-14+mar None +ve 
(Pt 10 in Ballabio 
et al. 2009) 
Intermediate 
1027 ALL 46,XX, t(6;11) (q13;p13) None  +ve Peripheral 
C1001 AML-M5 45,XX,del 7(q22q?)/ 46,xx, del 
7(q22q?) 
Interstitial 




46, XY, del (7) (q22q36) Interstitial 
deletion of 7q 
-ve Intermediate 
to interior 
S1001  MDS 45,XX,del(5) (q14),del (7) (q22),del 
(9)(q22),-17 
Interstitial 
deletion of 7q 
N/A Intermediate 
to interior 
9001 CMML 46, del 7q [25/30]/ 45,-7 [5/30] 
 
Interstitial 
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Figure 4.11: HLXB9 had an intermediate nuclear localisation in the two AML patients without chromosome 7 
abnormalities with confirmed expression of HLXB9. 2D FISH images were analysed by erosion script analysis. The 
histogram displays average probe intensity (normalised by DAPI staining) on the y-axis and the number of nuclei 
studied on the x-axis. The standard error bars represent the standard error of the mean for each nuclear position. 
There was no significant difference in the nuclear positioning of the HLXB9 gene between the two AML patients 
without chromosome 7 abnormalities analysed (result of student t-test) 
 
Additionally, HLXB9 had a similar nuclear localisation in these patients (pt 1026 and pt 
V1001) to the control bone marrow cells analysed (result obtained from a one-way ANOVA 
and Bonferroni post hoc test).  
 
o HLXB9 had a peripheral nuclear localisation in an ALL patient without chromosome 7 
abnormalities  
 
An ALL patient without chromosome 7 abnormalities was found to express HLXB9 by RT-
PCR. Although HLXB9 was expressed in this patient, HLXB9 was localised in the nuclear 
periphery. 
 
The nuclear localisation of HLXB9 in this ALL patient was statistically different to the control 
bone marrow cells (result obtained from a one-way ANOVA and Bonferroni post hoc test). 
There was a statistical significant increase in the proportion of HLXB9 gene signals in the 
nuclear periphery in this patient compared to the control bone marrow samples. This implies 
the HLXB9 nuclear localisation in this patient was different from the nuclear localisation of 
HLXB9 observed in control bone marrow cells This suggests an ALL specific nuclear 
localisation of HLXB9. However as only one sample was analysed, further studies with a 
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Figure 4.12: HLXB9 had a peripheral nuclear localisation in patient 1027, an ALL patient without 
chromosome 7 abnormalities. This patient had a different nuclear localisation of HLXB9 compared to control bone 
marrow and peripheral blood samples analysed. 2D FISH images were analysed by erosion script analysis. The 
histogram displays average probe intensity (normalised by DAPI staining) on the y-axis and the number of nuclei 
studied on the x-axis. The standard error bars represent the standard error of the mean for each nuclear position.  
 
 
b. Nuclear localisation of HLXB9 in patients diagnosed with haematological disorders 
harbouring an interstitial deletion of chromosome 7 
 
In a previous study, the nuclear localisation of HLXB9 was analysed in paediatric AML patients with a 
translocation t(7;12) (q36; p13). In the study, the translocated HLXB9 was localised in the nuclear 
interior compared to the non-translocated HLXB9 (Ballabio et al. 2009). Due to that finding, the nuclear 
localisation of HLXB9 was analysed in AML patients with interstitial deletions of chromosome 7. This is 
because, similar to a translocation event, an interstitial deletion also results in the re-joining of 
chromosome, which might alter the nuclear localisation of HLXB9. 
In this study, the nuclear localisation of HLXB9 was analysed in bone marrow cells of four AML patients 
with interstitial deletions of chromosome 7. The deletions had various breakpoints (as shown in table 
4.8).  
 
All four patients (K1001, C1001, 9001 and S1001) analysed had a similar distribution of HLXB9 gene 
signals in the nuclei (result obtained from a one-way ANOVA and Bonferroni post hoc test). 
 
Only one patient, C1001 showed a different nuclear localisation of HLXB9 compared to the bone marrow 
cells investigated (results in table 4.9). There was a significant reduction in the proportion of gene signals 
in the nuclear periphery of pt C1001 compared to three out of the five bone marrow samples analysed 
(BM2, BM3 and BM4). There was also a reduction in the proportion of the genes signals localised in the 
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an interstitial deletion with an unknown breakpoint therefore the reason for the change in nuclear 
localisation could not be determined.  
  
  
Figure 4.13: Nuclear localisation of HLXB9 in AML patients with interstitial deletions of chromosome 7 (del7q). Four AML 
patients with interstitial deletions of HLXB9 (various breakpoint see table 8) were analysed by erosion script analysis of 2D FISH. 
The histogram displays average probe intensity (normalised by DAPI staining) on the y-axis and the number of nuclei studied on the 
x-axis. The standard error bars represent the standard error of the mean for each nuclear position. Three of the four patients 
(C1001, pt 9001 and S1001) analysed had the same distribution of HLXB9 gene signals in the nuclei (results of an unpaired student 
t-test). Patient K1001 had an increased proportion of HLXB9 gene signal in the nuclear periphery compared to the other three 
patients analysed.  
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Table 4.7: Comparison of the nuclear localisation of HLXB9 in Pt C1001 to control bone marrow samples. There was a 
significant reduction in the proportion of HLXB9 gene signals in the nuclear periphery and intermediate in pt C1001 compared to 
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4.5. Discussion 
 
One of the main hypothesis for this study was the deletion in 7q might lead to expression of HLXB9 as 
seen in translocations involving 7q such as t(7;12) (q36; p13) and t(6;7) (q23, q36) (Nagel et al. 2005; 
von Bergh et al. 2006; Ballabio et al. 2009; Wildenhain et al. 2010; Wildenhain et al. 2012). To investigate 
this hypothesis, HLXB9 expression was investigated in leukaemia and lymphoma derived cell lines and 
patients diagnosed with various haematological malignancies. However, prior to the investigation of 
HLXB9 expression in cancer samples, HLXB9 expression was examined in control (non-cancer) bone 
marrow and peripheral blood cells. 
 
HLXB9 was expressed in all control bone marrow samples and a proportion of control peripheral 
blood samples 
 
Although the HLXB9 gene was first discovered in B-lymphocytes, there remains a lack of consensus about 
whether HLXB9 is expressed by bone marrow cells or peripheral blood cells (Harrison et al. 1994). 
Deguchi and colleagues previously reported HLXB9 expression in CD34 positive enriched bone marrow 
cells and in unfractionated bone marrow cells (Deguchi and Kehrl 1991). However since their study, other 
groups have been unable to detect HLXB9 expression in healthy CD34+ bone marrow cells or 
CD34+peripheral blood cells by RT-PCR (Nagel et al. 2005; von Bergh et al. 2006; Wildenhain et al. 2012). 
In this study, HLXB9 was expressed by all five control unfractionated bone marrow samples analysed. 
This finding was in line with results obtained by Deguchi and Kehrl (Deguchi and Kehrl 1991). The 
function of HLXB9 in blood cell development in the bone marrow is unknown, however, it has been 
suggested to be associated with maintaining stem cell niche by regulating cell adhesion or cell-to-cell 
interaction genes (Wildenhain et al. 2012) 
 
HLXB9 was also expressed in two out of five of the peripheral blood cells analysed. All samples analysed 
were unfractionated white blood cells isolated from peripheral blood. Therefore, the variability in 
expression of HLXB9 observed might indicate either variability in the expression of HLXB9 between 
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Reagents routinely used in culturing lymphocytes from peripheral blood might have an effect on 
HLXB9 expression  
 
PHA and thymidine are two reagents routinely used in the laboratory to prepare lymphocytes from 
peripheral blood for cytogenetic analysis. As PHA stimulation has been observed to alter the 
transcriptional profiles of lymphocytes, the expression of HLXB9 was investigated in control peripheral 
blood samples after stimulation with PHA (Branco et al. 2008; Ioannou et al. 2015). HLXB9 expression 
was found to increase in two of the three patients analysed. However quantitative PCR experiments are 
needed to confirm or accurately quantify the change in expression observed.  
 
HLXB9 expression was also examined after peripheral blood cells were treated with thymidine. The two 
samples treated with thymidine showed HLXB9 expression. However, this observation was made 
analysing only two samples, therefore further studies using more samples will be required to confirm this 
finding. 
 
These results suggests that HLXB9 expression is induced by reagents used in culturing lymphocytes from 
blood and implies that HLXB9 may have a function associated with proliferation in blood cells.  
 
HLXB9 was expressed by four out of five leukaemia/lymphoma cell lines analysed 
HLXB9 was found expressed in four of the five cell lines investigated. Three of the five cell lines 
investigated harboured chromosome 7 abnormalities (GDM-1, K562 and GF-D8). Out of these three cell 
lines, two showed HLXB9 expression (GDM-1 and K562). HLXB9 was expressed in the GDM-1 cell line, a 
cell line derived from an AML-M4 patient with a complex karyotype that includes the translocation t(6;7) 
(q23;q36). This cell line had been previously shown to overexpress HLXB9 (Nagel et al. 2005). HLXB9 was 
also found expressed in the K562 cell line; this cell line was developed from a CML patient and has a 
complex karyotype with ~ 66-72 chromosomes with four copies of chromosome 7. Chromosome 7 
specific chromosomal abnormalities in this cell line include i(7)(q10) (del(7) (q31.2;q36);del (7) 
(q21;q36) (Gribble et al. 2000). This cell line was chosen for investigation because the deletion of 
chromosome 7 in this cell line is proximal to HLXB9 but does not disrupt the gene. Another leukaemia cell 
line chosen for this study was the GF-D8 cell line. This cell line was derived from an AML-M4 patient with 
a complex karyotype. This cell lines has three abnormal copies of chromosome 7; two copies have an 
inversion of 7 (breakpoint distal to 7q36) and the third copy has an unbalanced translocation between 
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chromosome 7 and 15. As the HLXB9 gene is not deleted, this cell line was expected to express HXLB9; 
however, this was not the case. This might be because the deletion or rearrangement of chromosome 7 in 
GF-D8 does not result in the juxtaposition of HLXB9 with an enhancer or a regulatory element. 
 
Two non-Hodgkin lymphoma derived cell lines were also analysed as part of this study (CRL 2630 and 
CRL 2632). CRL 2630 is a cell line derived from non-Hodgkin B cell lymphoma patient with a diploid 
karyotype plus trisomy 11, whilst CRL 2632 is a cell line from a non-Hodgkin B cell lymphoma patient 
with t(14;18)(q32;q21). Both cell lines showed HLXB9 expression, although there were no known 
chromosome 7 abnormalities in the cell lines. These results suggest that HLXB9 expression can occur 
independently of the presence of chromosomes 7 abnormality.  
 
However, as these results were obtained from cell lines grown in culture, the possibility of HLXB9 
expression being a result of an evolution in the cell lines or by introduction of artefacts during culturing 
could not be ruled out. Therefore, HLXB9 expression in patient’s samples was analysed.  
 
25% of patients diagnosed with haematological malignancies showed HLXB9 expression. 
Bone marrow cells of patients diagnosed with various haematological disorders were investigated for 
HLXB9 expression. 12 of the 48 patients investigated showed HLXB9 expression. This result indicates that 
HLXB9 was not expressed by a majority of patients diagnosed with haematological malignancies. 35 of the 
48 patients analysed harboured chromosome 7 abnormalities, and 20% of these patients showed HLXB9 
expression. However, a larger proportion of patients without chromosome 7 abnormalities showed 
HLXB9 compared to these patients (37.5%). This finding confirms that HLXB9 expression is not limited to 
patients harbouring chromosome 7 abnormalities.  
 
44% of patients diagnosed with MPS/MPD (pre-malignant haematological disorders) showed HLXB9 
expression compared to 14% of patients diagnosed with leukaemia suggesting that HLXB9 expression 
might occur early on in leukaemogenesis. Only 6% of AML patients showed HLXB9 expression compared 
to 33% of ALL patients. This result was contrary to expectation as HLXB9 expression in leukaemia had be 
mainly associated with AML patients. Moreover, in previous research, HLXB9 expression had only been 
specifically associated with a subset of infant AML patients harbouring the translocation t(7;12) (q36; 
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p13) (von Bergh et al. 2006; Ballabio et al. 2009; Park et al. 2009; Wildenhain et al. 2012). These results 
thereby indicate that HLXB9 expression in AML is not limited to t(7;12) patients. 
 
As translocation involving 7q had previously been associated with expression of HLXB9, patients with 
interstitial deletion of 7q were investigated for HLXB9 expression. The rationale for selecting these 
patients was because, similar to a translocation event, the deletion of 7q results in the re-joining of 
chromosome 7 that might lead to expression of HLXB9 as observed in the translocation previously 
discussed. It was expected that a significant proportion of patients harbouring interstitial deletions of 7q 
(del 7q) would show HLXB9 expression compared to patients without del7q. However, this was not the 
case. In fact a larger proportion (40%) of patients with other chromosome 7 abnormalities showed 
HLXB9 expression compared to del 7q patients. A unifying characteristic between the three patients with 
interstitial deletions of 7q that showed HLXB9 expression could not be identified. Additionally, a common 
characteristic could also not be identified in patients with interstitial deletion of 7q that did not show 
HLXB9 expression. These results suggest the interstitial deletions of 7q do not always give rise to 
expression of HLXB9. This may be because the re-joining event on chromosome 7 does not result in a 
juxtaposition of HLXB9 with an enhancer or regulatory element. 
 
Finally, an unsuccessful attempt was made to identify a common characteristic between patients that 
showed HLXB9 expression or between patients that did not show HLXB9 expression. These patients 
analysed showed different abnormalities and various breakpoints. The lack of consensus also suggests a 
chromosome 7 independent mechanism of gene expression in patients that showed HLXB9 expression.  
 
HLXB9 has an intermediate nuclear positioning in control (non-cancer cells) 
The second hypothesis for this study was that the nuclear localisation of HLXB9 might become altered due 
to a chromosome 7 abnormality as seen in t(7;12) AML patients. Therefore, the nuclear localisation of 
HLXB9 was examined and compared in control samples, patients expressing HLXB9 without chromosome 
7 abnormality and patients harbouring interstitial deletion of 7q.  
 
HLXB9 was found to have an intermediate nuclear positioning in the control peripheral blood cells ,bone 
marrow cells and lymphoblastoid cells analysed. The nuclear localisation of HLXB9 in bone marrow cells 
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was similar to the peripheral blood cells analysed. This suggests a conserved nuclear localisation of 
HLXB9 in blood cells independent of cell maturity. The results also indicates a conserved nuclear 
localisation of HLXB9 between healthy indiduals. This result was in line in findings from two studies that 
showed no variation in the nuclear localisation of genes in healthy individuals (Wiech et al. 2005; 
Meaburn et al. 2009). 
 
Reagents routinely used in culturing lymphocytes from peripheral blood affected HLXB9 nuclear 
localisation  
 
The nuclear localisation of HLXB9 was also examined in peripheral blood cell after treatment with 
lymphocyte culturing reagents PHA and thymidine. This was to investigate if HLXB9 nuclear positioning 
changes upon lymphocyte stimulation. HLXB9 was found to have an intermediate nuclear positioing in 
cells stimulated with PHA. In addition, there was also a significant increase in the proportion of gene 
signals in the nuclear periphery in two out of three samples indicating a shift in HLXB9 localisation after 
stimulation with PHA. This finding was not suprising as previous research had identified an increase in 
the nuclear volume of lymphocytes upon stimulation with PHA (Branco et al. 2008; Ioannou et al. 2015). 
Ioannou and colleagues also found a PHA-stimulated reorganisation of the nucleus (Ioannou et al. 2015).  
 
The addition of thymidine resulted in a significant shift in the nuclear localisation of HLXB9 to the nuclear 
periphery. HLXB9 in peripheral blood cells stimulated with PHA and treated with thymidine showed a 
peripheral- intermediate nuclear positioning of HLXB9. 
 
HLXB9 had an intermediate nuclear localisation in AML patients without chromosome 7 
abnormalities that expressed HLXB9 
 
The nuclear localisation of HLXB9 in bone marrow cells of two AML patients that showed HLXB9 
expression without chromosome 7 abnormalities was investigated. HLXB9 had an intermediate nuclear 
positioning in these patients. These patients were also shown to express HLXB9 by RT-PCR. When 
compared to the control bone marrow cells, HLXB9 was found to have a similar nuclear localisation in 
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HLXB9 had a peripheral nuclear localisation in an ALL patient without chromosome 7 abnormalities 
that expressed HLXB9  
 
HLXB9 had a peripheral nuclear positioning in bone marrow cells of the only ALL patient investigated. 
This ALL patient showed HLXB9 expression by RT-PCR. This finding was interesting as HLXB9 was 
previously suggested to be silenced in the nuclear periphery in patients bone marrow cells (Ballabio et al. 
2009). The nuclear localisation of HLXB9 in this patient was different when compared to the control bone 
marrow and peripheral blood cells analysed. This result indicates an ALL specific nuclear localisation of 
HLXB9. However, due to the small sample size, further studies with a larger number of samples will be 
needed to confirm this finding. 
 
Only one patient (C1001) with an interstitial deletion of 7q showed a nuclear relocalisation of HLXB9  
 
Only one of the four patients harbouring interstitial deletion of 7q showed a significant change in the 
nuclear localisation of HLXB9 compared to the bone marrow cells. This interstitial deletion in this patient 
had an unknown breakpoint so the reason for the alteration in nuclear localisation of HLXB9 could not 
determined.  
 
HLXB9 nuclear positioning and expression 
 
Aberrant expression of HLXB9 has been found to be a unifying characteristic of AML patients harbouring 
t(7;12), who showed dismal clinical outcomes. These patients have also been observed to have an altered 
nuclear localisation of HLXB9, therefore it has been hypothesised that a change in the nuclear localisation 
of this gene is responsible for the altered expression in HLXB9 observed (Ballabio et al. 2009). 
Additionally, alteration in HLXB9 nuclear localisation linked to increased expression has also been 
observed in neuronal cells where increased expression of HLXB9 is associated with cellular differentiation 
(Leotta et al. 2014). Therefore, the main hypothesis for this study was that a change in the nuclear 
localisation of HLXB9 could result in the ectopic expression of this gene.  
 
Although there was variability in HLXB9 expression in the control peripheral blood and bone marrow 
samples analysed, HLXB9 had a similar nuclear localisation. Therefore, no link could be found between 
expression of HLXB9 and the nuclear localisation in the control samples.  
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In peripheral blood cells, stimulation with PHA was observed to result in an increased expression of 
HLXB9 with an associated increase in the proportion of HLXB9 gene signal in the nuclear periphery. The 
change in nuclear localisation of HLXB9 might be indicative of an increased expression of HLXB9. 
However, there remains a possibility that a change in the nuclear localisation of HLXB9 could be a result 
of PHA specific genome reorganisation. A previously study has showed that stimulation with PHA induced 
a random PHA specific nuclear reorganisation of the genome of lymphocytes (Ioannou et al. 2015). 
 
Only one patient diagnosed with a myeloid lineage haematological disorder showed a difference in the 
nuclear localisation of HLXB9, unfortunately the expression status of HLXB9 in this patient was unknown. 
In other patients, there were differences in the expression of HLXB9, but no change in nuclear localisation 
of HLXB9. This suggests that HLXB9 expression is not dependent on its nuclear localisation and there are 
other mechanism/(s) for the regulation of HLXB9 gene expression. This finding, although contrary to 
expectation is not completely surprising as previous studies have shown epigenetic regulation of HLXB9 




In conclusion, a majority of patients diagnosed with haematological disorders do not express HLXB9. The 
expression of HLXB9 was found to occur independently of the presence of chromosome 7 abnormalities in 
cell lines and patients diagnosed with various haematological disorders. HLXB9 expression occurred 
more frequently in MDS/MPD patients than AML patients, which indicates the possibility of aberrant 
HLXB9 expression being an early event in leukaemogenesis.  
 
The nuclear localisation of HLXB9 was conserved in healthy individuals even though variability in gene 
expression was observed. The nuclear localisation of HLXB9 in control samples investigated was also 
similar to most of the patients analysed although differences in expression was also observed.  Therefore, 
a clear indication from this study is that HLXB9 expression was not solely regulated by a position effect 
mechanism. Therefore, further investigation is required to fully understand the regulation of HLXB9 in 
leukaemia patients that show aberrant expression of this gene. The role of HLXB9 in blood cell 
development or leukaemogenesis remains unknown. Although this study attempted to understand the 
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mechanism by which HXLB9 becomes deregulated in leukaemia, the impact of its deregulation is 
unknown. Therefore, further studies to understand the biological significance of HLXB9 deregulation 
particularly in MDS/MPD patients is recommended. Investigating the expression and function of HLXB9 in 

















Chapter 5: Investigating the differential 
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5.1. Introduction 
 
The number of homeobox genes discovered to be aberrantly expressed in cancer continues to increase 
and is particularly significant in cancer research as the deregulation of these genes can initiate a cascade 
of events that supports cancer development and progression (Miller et al. 2016; Abate-Shen 2002; Olsen 
et al. 2016). HLXB9, a homeobox gene, has been found to be aberrantly expressed in various cancers 
(Almstrup et al. 2005; Ballabio et al. 2009; Wilkens et al. 2011; Hu et al. 2012; Shi et al. 2013; Bailey et al. 
2016). 
The development of methods that can be used to measure whole genome gene expression such as 
microarray, RNA Sequencing (RNA-Seq) and next generation sequencing (NGS) has led to the deposition 
of data from these experiments into data banks. These data banks such as gene expression omnibus 
(GEO), the cancer genome atlas (TCGA) and the international cancer genome consortium (ICGC) can be 
accessed by the wider scientific community for data analysis. Databases have now been developed, and 
these can be used to interrogate datasets from various sources to aid the study of differential gene 
expression in disease states. Whole genome gene expression has been particularly useful in cancer 
research leading to the identification of potential targets for therapy, genomic subtypes of diseases and 
genes whose expression correlate with cancer development and progression (Rhodes et al. 2009; Bailey 




The main aim of this study is to determine whether HLXB9 could be used as a biomarker in cancer. In 
order to achieve the aim, the following objectives will be pursued by: 
I. Identifying cancers with differential expression of HLXB9 using a number of freely available 
transcriptomics databases; 
II. Analysing the identified differential expression of HLXB9 to determine if it is associated with 
particular cancer types and stages; 
III. Evaluating the results obtained from objectives I and II to determine if aberrant HLXB9 
expression is an indicator of prognosis or disease progression. 
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5.3. Methods 
 
In order to investigate HLXB9 expression in various cancers, the following gene expression databases 
were analysed and compared: Oncomine, Gene expression across normal and tumour tissue (GENT), 
FIREBROWSE and BioXpress.  
Oncomine (Rhodes et al. 2004; Rhodes et al. 2007) 
Oncomine (Research Edition) is a web-based cancer microarray database. It contains datasets on 
approximately 18,000 microarray studies for more than 20 different cancer types. Oncomine has three 
freely available analytical tools: the normal to cancer analysis tool can be used to compared gene 
expression in non-cancer and cancer samples; the cancer histological tool can be used to compare 
differential gene expression between histological subtypes of cancer; and the gene outlier tool which can 
be used to identify subpopulations of low and high expression in a cancer type. Used together, these tools 
can provide insights into the differential expression of genes in cancer. 
In this study, to reduce the possibility of including false positives and artefacts, the parameters used in 
the normal to cancer analysis, cancer histology analysis and outlier analysis was set stringently at P value 
of ≤ 0.001, gene expression fold change of ≥2 and gene rank of top 10 per cent over/under expressed 
genes. In the outlier analysis, an outlier of 90-percentile expression value was categorised as 
overexpression and an outlier of 5-percentile expression value was categorised as underexpression.  
GENT (Shin et al. 2011)  
GENT is a web based cancer microarray database that can be used to identify outliers of gene expression, 
especially overexpression in a subset of the cancer populations. The database has microarray data across 
two different Affymetrix platforms i.e. the U133A microarray platform, which has a smaller number of 
gene probes, and the U133 Plus 2 platform, which has a more comprehensive number of gene probes. The 
gene expression values for HLXB9 could be found on both platforms. In GENT, raw expression and 
transformed values are presented as boxplots. The transformed log2 value is more useful compared to the 
raw values as the data has been normalised without removing the relationship between the datasets. This 
enables a direct comparison of the minimum, lower quartile, median, upper quartile maximum expression 
and outlier expression values can be made between normal and cancer samples. By comparing these 
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expression values between the normal and cancer samples, cancers with outliers of expression of 
HLXB9/MNX1 can be identified. The GENT database holds over 34,000 tissue samples with 9,000 cancer 
samples and 4,000 normal samples on the U133A platform and over 18,000 cancer samples and 3400 
normal samples on the U133 Plus 2 platform. Datasets on HLXB9 gene expression from both microarray 
platforms were downloaded and analysed using IBM SPSS Statistics v20 (see table 5.3 and table 5.4). Fold 
change was calculated as average expression levels of cancer samples divided by average probe 
expression level of control samples. The log2 values of the obtained fold change was also calculated and 
presented in the aforementioned tables.  
FIREBROWSE http://firebrowse.org/ (no associated publication) 
FIREBROWSE is also a web based gene expression viewer database developed by the Broad Institute and 
is based on the cancer genome atlas (TCGA) datasets. This database has experimental data from RNA-Seq 
experiments on samples from over 11,000 cancer patients. Utilising a ‘view expression profile’ tool, gene 
expression can be compared between normal and cancer samples in the database. The results from the 
analysis are presented as box plots with values for the lower quartile, median, upper quartile and number 
of samples in analysis. In this database, cancers with a fold change of ≥2 compared to normal samples 
were considered to overexpress HLXB9 whilst cancers with a fold change of ≤ 0.5 were considered to 
underexpress HLXB9. 
BioXpress (Wan et al. 2015) 
BioXpress v 1.0 is a gene expression database with RNA-Seq data on 64 cancer types and over 6000 
patient samples from different resources such as the TGCA, ICGC, the expression atlas and research 
publications. This database can be used to compare differential gene expression between normal and 
cancer samples and the frequency of the observed change by cancer types. The results are presented in a 
graph showing the percentage of overexpression and underexpression observed. HLXB9 expression in a 
cancer sample was compared to its matched normal sample pair and classified into overexpression or 
under expression using the following method: overexpression was determined to be a fold change of 
greater than zero compared to its matched normal sample pair and underexpression was determined to a 
fold change of less than zero compared to its matched normal sample pair. The change in expression 
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observed was then analysed to determine its statistical significance. The frequency of statistically 
significant change in expression was presented in a graph as shown in figure 5.7.  
5.4. Results  
 
HLXB9 expression in various cancers was analysed using the previously mentioned online databases in 
order to identify cancers with differential expression of HLXB9. Results from these analyses are divided 
into two sections. Section I, provides an overview on HLXB9 expression in various cancers according to 
database whilst Section II discusses the results obtained according to cancer type. 
I. Overview on HLXB9 expression in cancer according to database 
Results on differential expression of HLXB9 expression in various cancers are discussed by the database 
they were obtained from in this section. 
 
a. Oncomine 
Using the normal to cancer tool in Oncomine, eleven cancer types with altered expression of HLXB9 were 
identified. Out of the eleven cancer types, eight (brain and central nervous system cancer, breast cancer, 
cervical cancer, oesophageal cancer, kidney cancer, lung cancer, lymphoma and melanoma) showed 
upregulation of HLXB9 indicating a pro-oncogenic role for HLXB9 in most cancers identified. 
Downregulation of HLXB9 was found in kidney cancer, leukaemia and pancreatic cancer suggesting a loss 
of tumour suppressor function of HLXB9 in these cancers. These results are summarised in Table 5.1. 
 
Interestingly, both upregulation and downregulation of HLXB9 was found in kidney cancer implying that 
accurate regulation of HLXB9 expression in the kidney is important to prevent cancer development and 
progression. Previous studies on HLXB9 expression by cancer type have also identified both 
overexpression and underexpression of HLXB9 in patients (Tosi et al. 2003, von Bergh et al. 2006; 
Ballabio et al. 2009; Park et al. 2009, Ferguson et al. 2011). In leukaemia, overexpression of HLXB9 was 
found in a subset of AML patients whilst underexpression was identified in ALL. Additionally, in 
pancreatic cancer, overexpression of HLXB9 has been reported in insulinomas, whilst underexpression 
has been found in pancreatic adenocarcinomas (Shi et al. 2013; Desai et al. 2014, Bailey et al. 2016). 
These findings suggest HLXB9 might function differently in different cell types originating from a common 
multipotent progenitor. This difference in expression levels in subtypes within cancer types might mask 
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some of the results obtained from this study. For instance, from Oncomine, it could be incorrectly 
deduced that HLXB9 was underexpressed in leukaemia, which is most likely an artefact of the small 
population of AML patients that overexpress HLXB9. Therefore an attempt was made to analyse cancers 
by subtypes where possible.  
Other genes that have been observed to show overexpression in some cancers and underexpression in 
other cancers include HOXA9, which has been found to be upregulated in colorectal carcinomas but 
downregulated in breast cancer and HOXD8 which is downregulated in colorectal cancer whilst being 
overexpressed in lung cancer  (Bhatlekar et al. 2014).  
Cancer Type Number of studies where HLXB9 expression was altered by Cancer 
type (P ≤ 0.001, fold change ≥ 2 and gene rank of top 10%)  
Brain and Central Nervous 
System Cancer 
1 out of 13 datasets showed HLXB9 overexpression 
Breast Cancer  5 out of 11 datasets showed HLXB9 overexpression 
Cervical Cancer 1 out of 6 datasets showed HLXB9 overexpression 
Oesophageal Cancer 3 out of 7 datasets showed HLXB9 overexpression 
Kidney Cancer  1 out of 7 datasets showed HLXB9 overexpression 
2 out of 7 datasets showed downregulation of HLXB9 
Leukaemia  2 out of 11 datasets showed downregulation of HLXB9 
Lung Cancer 3 out of 12 datasets showed HLXB9 overexpression 
Lymphoma  1 out of 8 datasets showed HLXB9 overexpression  
Melanoma 1 out of 4 datasets showed HLXB9 overexpression 
Ovarian Cancer  1 out of 8 datasets showed HLXB9 overexpression 
Pancreatic Cancer  1 out of 9 datasets showed downregulation of HLXB9 
Table 5.1: Eleven cancer types where analysis identified populations of patients with aberrant expression of 
HLXB9. (Oncomine) . Datasets in Oncomine are obtained from published or unpublished microarray experiments 
deposited into the database. All datasets available per cancer type were analysed. Normal to cancer analyses were 
conducted on datasets available using the following parameters gene expression fold change of ≥2, P ≤ 0.001 and 
gene rank of the top 10% of gene altered. Studies with increased fold change of ≥2 are defined as overexpression 
whilst studies with decreased fold change of ≥2 are defined as showing underexpression/downregulation. 
The Oncomine database also has a cancer histology tool, which compares gene expression changes in 
different histological subtypes within a cancer type; eight cancers with altered HLXB9 expression 
between cancer subtypes were identified using this tool. They were sarcoma, leukaemia, melanoma, 
breast cancer, kidney cancer, leukaemia, melanoma, ovarian cancer and sarcoma. Some of these cancer 
types: breast cancer, kidney cancer, leukaemia, and ovarian cancer were previously identified using the 
normal to cancer tool. This suggests in these particular cancer types, not only does differential expression 
of HLXB9 occur in cancer states from normal; there are also subtypes that show significant differential 
expression. The results from these analyses are examined in more detail in table 5.7. 
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This database also allows users to carry out another analysis known as ‘outlier analysis’. This analysis can 
be used to identify genes with very low or very high expression in a subset of samples (sub population) 
within the total population for a cancer type. This analysis is crucial as differential expression of genes 
might occur in a small subset of a cancer type, which could go undetected using a standard normal to 
cancer analysis. The cancer types with outlier expression of HLXB9 were brain and central nervous 
system cancer, adrenal carcinoma, kidney cancer, leukaemia, lymphoma, lung cancer, sarcoma, liver 
cancer, breast cancer, ovarian cancer, prostate cancer. The results from some of these analyses are 
categorised by cancer type and examined in detail in table 5.7. 
 
In summary, HLXB9 expression was altered in a minority of cancers types in the Oncomine database, with 
most of the cancer types showing upregulation of HLXB9. Combining the analyses from the three freely 
available tools in Oncomine, differential expression of HLXB9 might be particularly significant in breast 
cancer, kidney cancer, leukaemia and ovarian cancer. 
 
b. Gene Expression across Normal and Tumour Tissue- GENT 
 
The GENT database has samples from two different microarray platforms so the results were split into 
two to represent each platform; please see figure 5.1 and 5.3 for samples on the U133A platform and 
figure 5.2 and 5.4 for samples on the U133Plus 2 platform. In this database, comparing boxplots of normal 
and cancer samples can be used to identify outliers of gene expression in various cancers. Raw expression 
values are plotted as boxplots for normal and cancer samples in figure 5.1 and 5.2.  
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Figure 5.1: Boxplots showing differential expression of HLXB9 in cancer originating from various tissues. 
These boxplots are raw values of HLXB9 using the datasets under the U133A platform from the GENT database. The 
plot shows nineteen different normal and cancer matched samples.  
 
Figure 5.2: Boxplots showing differential expression of HLXB9 in cancer originating from various tissues. 
These boxplots are raw values of HLXB9 using the datasets under the U133 Plus2 platform from the GENT database. 
The plot shows twenty-five different normal and cancer matched samples.  
 
Although comparing box plots of the raw values provides a suggestion of cancers with differential 
expression of HLXB9, comparing boxplots of the log2 transformed value between normal and cancer 
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samples is more meaningful as transformation of the raw values normalises the variation between 
datasets enabling an accurate judgment of the differential expression between normal and cancer 
samples (figures 5.3 and 5.4; tables 5.3 and 5.4).  
 
It should be noted that some of the cancers originating from tissues such as adrenal gland and vaginal in 
this database had small sample size; therefore results obtained on this cancer type on HLXB9 expression 
may not be truly representative of the cancer type. For details on sample size of cancers in this database 
please see table 5.2.  
Origin 
U133Plus2 U133A 
Cancer Normal Cancer Normal 
Adipose 1 59 0 12 
Adrenal gland 14 5 0 0 
Bladder 39 14 87 15 
Blood 7786 847 3130 1099 
Brain 838 667 592 1627 
Breast 2662 267 2635 91 
Cervix 113 12 64 34 
Colon 1994 287 256 27 
Endometrium 72 75 0 9 
Oesophagus 48 9 24 28 
Eye 63 0 0 0 
Gastrointestinal stromal tumours 66 0 0 0 
Head and Neck 202 14 21 2 
Kidney 573 130 366 66 
Liver 194 50 156 52 
Lung 547 336 582 364 
Muscle 0 217 0 331 
Ovary 902 51 341 9 
Pancreas 174 62 13 8 
Prostate 314 51 244 83 
Sarcoma 520 0 0 0 
Skin 302 141 499 59 
Small intestine 13 6 0 22 
Spleen 0 6 0 0 
Stomach 311 57 46 18 
Testis 4 9 184 13 
Thyroid 62 25 44 25 
Tongue 0 11 0 4 
Uterus 155 12 0 24 
Vagina 3 5 0 0 
Vulva 21 14 0 0 
Heart 0 0 0 41 
Myometrium 0 0 0 24 
Total 18,004 3,439 9,284 4,087 
Table 5.2: Number of samples in the GENT database across the U133A and U133 Plus 2 platforms 
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Figure 5.3: Boxplots showing differential expression of HLXB9 in cancer originating from various tissues (U133A microarray platform). Box plot are log2 transformed raw 
values for the same nineteen normal cancer samples in figure 5.1. Please see tables 5.3a and b for detailed analysis of box plots. 
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Origin 












log2 values log2 values 
Breast 271 4.09 5.21 6.13 2658 5.32 6.95 8.11 
Bladder 15 7.01 7.29 8.45 87 6.51 7.13 7.56 
Brain 1627 3.81 4.52 5.39 592 4 5.75 7.29 
Blood 1099 4.81 5.93 7.38 3165 4.09 5.13 6.13 
Cervix 34 3.7 5.27 6.37 64 5.88 6.78 7.57 
Colon 27 7.29 7.87 8.62 256 8.06 8.67 9.14 
Oesophagus 28 3.97 5.13 5.75 24 4.88 6.67 7.9 
Head and Neck 2 5.17 5.19 NA 21 4.45 5.83 6.45 
Kidney 66 4.75 5.82 8.86 366 4 5.04 6.72 
Liver 52 2.81 3.91 5.42 165 3.86 4.81 5.87 
Lung 364 3.81 4.75 5.7 582 5.61 6.49 7.08 
Ovary 9 2.85 4.58 7.16 341 3.58 4.58 6.18 
Pancreas 8 7.94 8.75 9.01 13 6.71 8.03 8.96 
Prostate 83 5.46 6.52 7.56 244 4.95 6.39 7.77 
Skin 59 4.09 4.7 5.64 499 4.52 5.52 6.64 
Stomach 18 5.49 7.25 7.99 46 7.47 7.9 8.17 
Testis 13 6.29 7.45 7.64 184 6.56 7.25 8.66 
Thyroid 25 3.64 4.58 5.11 44 3.52 4.49 5.3 
Table 5.3a: Box plots of HLXB9 expression in control and cancer samples from U133A microarray 
platform in the GENT database. 
 
Origin 








Mean SD SEM 
n 
Mean SD SEM 
log2 values log2 values 
Breast 271 5.08 1.37 0.08 2658 6.62 1.9 0.04 2.19 1.13 <0.0001 
Bladder 15 7.48 1.12 0.29 87 6.87 1.21 0.13 0.67 -0.58 0.07 
Brain 1627 4.62 1.23 0.03 592 5.68 1.87 0.08 2.79 1.48 <0.0001 
Blood 1099 5.98 1.69 0.05 3165 5.13 1.41 0.03 0.51 -0.98 <0.0001 
Cervix 34 4.98 1.55 0.27 64 6.57 1.39 0.17 2.91 1.54 <0.0001 
Colon 27 7.83 1.08 0.21 256 8.59 1.06 0.07 1.78 0.83 0.0005 
Oesophagus 28 4.99 1.37 0.26 24 6.36 1.94 0.4 3.46 1.79 0.0045 
Head and Neck 2 5.19 0.03 0.02 21 5.58 1.19 0.26 1.72 0.78 0.65 
Kidney 66 6.48 2.12 0.26 366 5.43 1.95 0.1 0.54 -0.90 <0.0001 
Liver 52 4.16 1.95 0.27 165 4.97 1.49 0.12 0.55 -0.86 0.002 
Lung 364 4.8 1.35 0.07 582 6.31 1.19 0.05 2.49 1.32 <0.0001 
Ovary 9 4.92 2.39 0.8 341 4.88 1.74 0.09 0.76 -0.39 0.95 
Pancreas 8 8.54 0.52 0.19 13 7.74 1.37 0.38 0.75 -0.41 0.13 
Prostate 83 6.34 1.42 0.16 244 6.25 1.75 0.11 1.13 0.18 0.67 
Skin 59 4.74 1.09 0.14 499 5.65 1.45 0.06 2.37 1.24 <0.0001 
Stomach 18 6.7 1.68 0.39 46 7.85 0.57 0.08 1.53 0.62 0.0001 
Testis 13 7.07 0.96 0.27 184 7.36 1.58 0.12 1.70 0.77 0.51 
Thyroid 25 4.48 0.97 0.19 44 4.35 1.24 0.19 1.01 0.02 0.65 
Table 5.3b: Comparison of HLXB9 expression in control samples to cancer samples using the U133A 
microarray platform in the GENT database. P ≤0.05 was considered significant, results of independent student 
test. Fold change calculated as average expression levels of cancer samples divided by average probe expression 
level of control samples. Fold change of ≥2 in HLXB9 expression between control and cancer samples are defined as 
overexpression. Fold change of ≤0.5 in HLXB9 expression between control and cancer samples are defined as 
underexpression. Rows highlighted in red represent cancer types with statistically significant overexpression of 
HLXB9 whilst rows highlighted in blue represent statistically significant underexpression of HLXB9. 
 
 
From the fold change and t-test analysis, cancer originating from eight organs showed 
differential expression of HLXB9. Six of the eight showed statistically significant overexpression 
of HLXB9: these were breast, brain, cervix, oesophagus, lung and skin (fold change ≥2, P≤0.05). 




Figure 5.4: Boxplots showing differential expression of HLXB9 in cancer originating from various tissues (U133 Plus 2 microarray platform). Box plot are log2 transformed 
expression raw values for the same twenty-five normal cancer samples as in figure 5.2. See tables 5.4a and b for more detailed analysis of box plots. 
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Origin 












log2 values log2 values 
Adrenal gland 5 1.29 2.32 3.25 14 2.81 4.36 5.25 
Bladder 14 3.75 4.78 5.4 39 6.13 7.39 7.91 
Blood 855 4.09 5.09 6.55 7836 3.91 5.04 6.11 
Brain 668 3.91 4.7 5.64 874 3.58 4.64 6.00 
Breast 91 4.52 5.43 6.32 2635 4.95 6.29 7.41 
Cervix 12 3.82 5.04 6.23 113 5.36 6.54 7.55 
Colon 293 8.43 8.91 9.24 1839 8.58 8.96 9.35 
Endometrium 75 4.39 5.86 7.22 72 6.43 7.79 8.72 
Oesophagus 9 4.2 5.04 5.72 48 6 6.77 7.29 
Head and Neck 14 4.48 5.4 6.2 202 5.24 6.11 6.92 
Kidney 130 4.09 4.7 5.36 573 4.39 5.67 7.1 
Liver 50 3.17 3.64 4.54 194 3.17 4.09 5.91 
Lung 381 3 3.91 5.13 547 5.91 7.04 8.04 
Ovary 51 2.59 3.91 4.86 902 3.46 4.91 6.34 
Pancreas 62 8.19 9.02 9.42 174 8.13 8.73 9.64 
Prostate 51 2.59 4.25 5.61 314 4.44 5.82 7.54 
Skin 141 4.17 5.09 5.75 302 4.09 5.59 7.08 
Small Intestine 6 5.49 9.19 9.58 13 5.16 7.32 8.9 
Stomach 57 7.17 7.75 8.24 311 7.73 8.24 8.81 
Testis 9 6.41 7.36 7.92 4 6.09 7.1 8.89 
Thyroid 25 4.76 6.52 6.93 62 4.07 5.13 6.78 
Uterus 12 2 2.45 3.88 155 4.64 7.33 8.3 
Vagina 5 4.7 5 5.83 3 5.46 7.19 NA 
Vulva 14 4.19 5.15 5.78 21 4.45 5.78 7.13 
Table 5.4a: Box plots of HLXB9 expression in normal samples to cancer samples from the U133Plus 2 microarray platform 
in the GENT database. 
 
 
From the U133Plus 2 microarray platform, overexpression of HLXB9 was found in cancers originating 
from the adrenal gland, bladder, breast, cervix, endometrium, oesophagus, kidney, liver, lung, ovary, 
prostate, skin, uterus and vagina (fold change ≥2, P≤0.05, as shown in table 5.4b).  
 
The results obtained from both microarray platforms on GENT were compared. Five cancer types from 
both platforms showed statistically significant overexpression of HLXB9; these were breast, cervix, 
oesophagus, lung and skin.  Additionally underexpression of HLXB9 was found in leukaemia in both 
platforms (U133A, fold change 0.51. U133Plus2, fold change 0.58), although only the result obtained from 
the U133A platform met the parameters of this study (underexpression defined as fold change ≤ 0.5). 
Conflicting results were obtained on expression of HLXB9 in two cancer types, kidney cancer and prostate 
cancer. Underexpression of HLXB9 was obtained in the U133A platform whilst overexpression was 
observed in the U133Plus2 platform. This result was similar to the results obtained from the Oncomine 
database and will be explained in the discussion section.  For prostate cancer, the result from the U133A 
platform the fold change was insignificant (n=244), whilst the result from the U133Plus2 platform was 
significant (n=314) which may be due to an increase in sample size. 
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A number of the cancer types had samples in only the U133Plus2 platform such as adrenal gland, 












Mean SD SEM 
n 
Mean SD SEM 
log2 values log2 values 
Adrenal gland 5 2.28 0.45 1.00 14 4.42 0.47 1.77 8.82 3.14 0.022 
Bladder 14 4.7 1.07 0.29 39 7.03 1.23 0.2 5.20 2.38 <0.0001 
Blood 855 5.43 1.91 0.07 7836 5.06 1.53 0.02 0.67 -0.58 <0.0001 
Brain 668 4.82 1.29 0.05 874 4.87 1.86 0.06 1.72 0.78 0.55 
Breast 91 5.42 1.07 0.11 2635 6.13 1.64 0.03 3.81 1.93 <0.0001 
Cervix 12 4.91 1.42 0.41 113 6.34 1.57 0.15 3.14 1.65 0.003 
Colon 293 8.77 0.83 0.05 1839 8.88 0.87 0.02 1.09 0.12 0.043 
Endometrium 75 5.65 1.6 0.18 72 7.31 1.77 0.21 3.17 1.67 <0.0001 
Oesophagus 9 4.81 1.47 0.49 48 6.46 1.52 0.22 3.39 1.76 0.004 
Head and Neck 14 5.25 1.09 0.29 202 5.97 1.24 0.09 1.79 0.84 0.035 
Kidney 130 4.73 0.98 0.09 573 5.74 1.7 0.07 3.04 1.60 <0.0001 
Liver 50 3.8 1.04 0.15 194 4.76 2.21 0.16 5.71 2.51 0.003 
Lung 381 4.1 1.46 0.07 547 6.79 1.65 0.07 5.29 2.40 <0.0001 
Ovary 51 3.7 1.68 0.24 902 5.07 2.02 0.07 4.00 2.00 <0.0001 
Pancreas 62 8.52 1.52 0.19 174 8.8 1.25 0.1 1.26 0.33 0.15 
Prostate 51 3.88 2.12 0.3 314 5.82 2.1 0.12 3.54 1.83 <0.0001 
Skin 141 4.86 1.18 0.1 302 5.44 1.88 0.11 2.33 1.22 0.0008 
Small Intestine 6 7.89 2.49 1.02 13 7.2 3.2 0.89 2.43 1.28 0.65 
Stomach 57 7.55 1.07 0.14 311 8.07 1.27 0.07 1.47 0.56 0.004 
Testis 9 7.13 1.06 0.35 4 7.36 1.49 0.74 1.45 0.54 0.75 
Thyroid 25 5.87 1.36 0.27 62 5.29 1.65 0.21 0.98 -0.04 0.12 
Uterus 12 2.8 1.32 0.38 155 6.46 2.25 0.18 18.13 4.18 <0.0001 
Vagina 5 5.21 0.64 0.29 3 6.65 1.03 0.6 2.86 1.52 0.047 
Vulva 14 4.95 1.2 0.32 21 5.79 1.67 0.37 2.35 1.23 0.11 
Table 5.4b: Comparison of HLXB9 expression box plots in normal samples to Cancer samples using the U133Plus 
2 microarray platform in the GENT database. P ≤0.05 was considered significant, results of independent student 
test. Fold change calculated as average expression levels of cancer samples divided by average probe expression level 
of control samples. Fold change of ≥2 in HLXB9 expression between control and cancer samples are defined as 
overexpression. Fold change of ≤0.5 in HLXB9 expression between control and cancer samples are defined as 
underexpression. Rows highlighted in pink represent cancer types with statistically significant overexpression of 
HLXB9 whilst rows highlighted in blue represent statistically significant underexpression of HLXB9. 
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c. FIREBROWSE 
Cancer types identified as having overexpression of HLXB9 (fold change  2) from RNA-Seq experiments in this database were rectum, stomach, kidney, head and 
neck, lung, adrenal, breast, prostate, bladder, endometrial. Underexpression of HLXB9 (fold change of ≤ 0.5) was found in pancreatic and kidney cancer (as shown in 
figure 5.5 and table 5.5). 
 
Figure 5.5: Boxplots showing differential expression of HLXB9 (MNX1) in normal and cancer samples (FIREBROWSE). Overexpression of HLXB9 was found in stomach adenocarcinoma 
(STAD), rectum adenocarcinoma (READ), kidney cancer cohort (KIPAN), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), head and neck squamous 
cell carcinoma (HNSC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), pheochromocytoma and paraganglioma (PCPG), breast invasive carcinoma (BRCA), prostate 
adenocarcinoma (PRAD), uterine corpus endometrial carcinoma (UCEC) and bladder urothelial carcinoma (BLCA). Both pancreatic adenocarcinoma (PAAD) and kidney chromophobe 
(KICH), a kidney cancer subtype showed underexpression of HLXB9. Other cancers analysed included colon adenocarcinoma (COAD), colorectal adenocarcinoma (COADREAD), oesophageal 
carcinoma (ESCA), liver hepatocellular carcinoma (LIHC), stomach and esophageal carcinoma (STES), thyroid carcinoma (THCA) and thymoma (THYM), see table 5.5 for fold change for these cancer 
types. 
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change RNA-Seq by Expectation 
Maximization RSEM (log2) 
RNA-Seq by Expectation 
Maximization RSEM (log2) 
Normal sample (BLCA) 12 0.21 1.1 2.42 Bladder urothelial carcinoma (BLCA) 384 2.72 4.53 5.64 10.8 
Normal sample (BRCA) 94 -0.1 0.88 1.74 Breast invasive carcinoma (BRCA) 992 0.94 3.29 5.2 5.3 
Normal sample (COAD) 41 6.25 6.97 7.32 Colon adenocarcinoma (COAD) 459 7.05 7.52 7.93 1.5 
Normal sample (COADREAD) 51 6.24 6.89 7.27 Colorectal adenocarcinoma (COADREAD) 626 7.06 7.56 7.99 1.6 
Normal sample (ESCA) 11 1.38 5.42 6.02 Oesophageal carcinoma (ESCA) 180 2.75 5.33 6.78 0.9 
Normal sample (HNSC) 28 -1.02 0.03 1.12 Head and neck squamous cell carcinoma (HNSC) 452 0.61 1.98 3.17 3.9 
Normal sample (KICH) 23 0.17 1.31 1.99 Kidney chromophobe (KICH) 45 -1.15 -0.41 0.6 0.3 
Normal sample (KIPAN) 98 -0.5 0.54 1.74 All kidney cohort (KIPAN) 775 0.73 2.81 4.65 4.8 
Normal sample (KIRC) 52 -0.54 0.45 1.55 Kidney renal clear cell carcinoma (KIRC) 442 0.18 2.01 3.62 3 
Normal sample 23 -0.89 0.36 2.01 Kidney renal papillary cell carcinoma (KIRP) 288 3.08 4.63 5.9 19.3 
Normal sample (LIHC) 11 0.53 0.9 1.31 Liver hepatocellular carcinoma (LIHC) 170 -0.02 1.84 5.39 1.9 
Normal sample (LUAD) 49 -0.34 0.75 1.88 Lung adenocarcinoma (LUAD) 504 3.17 4.88 5.92 17.4 
Normal sample (LUSC) 42 -0.56 0.51 1.2 Lung squamous cell carcinoma (LUSC) 452 0.97 2.5 4.13 4 
Normal sample (PAAD) 3 6.99 7.79 7.84 Pancreatic adenocarcinoma (PAAD) 179 6.16 6.9 7.65 0.5 
Normal sample (PCPG) 2 -0.69 -0.54 -0.38 Pheochromocytoma and paraganglioma (PCPG) 149 -0.14 1.58 4.07 4.3 
Normal sample (PRAD) 41 -0.34 1.61 3.02 Prostate adenocarcinoma (PRAD) 492 3.21 4.91 6.22 9.9 
Normal sample (READ) 10 6.1 6.5 7.08 Rectum adenocarcinoma (READ) 167 7.07 7.66 8.15 2.2 
Normal sample (STAD) 4 3.8 5.46 5.67 Stomach adenocarcinoma (STAD) 37 5.54 6.66 7.21 2.3 
Normal sample (STES) 15 1.38 5.42 5.92 Stomach and esophageal carcinoma (STES) 217 3.15 5.58 6.87 1.1 
Normal sample (THCA) 23 -1.61 -0.71 -0.31 Thyroid carcinoma (THCA) 189 -1.53 -1.08 -0.25 0.8 
Normal sample (THYM) 2 -0.62 0.36 1.33 Thymoma (THYM) 107 -0.5 0.76 1.54 1.3 
Normal sample (UCEC) 21 -0.19 0.84 1.62 Uterine corpus endometrial carcinoma (UCEC) 508 4.53 6.29 7.24 43.9 
Table 5.5: Comparison of HLXB9 expression box plots in normal samples to cancer samples (FIREBROWSE). This table shows cancer type, sample size (n), lower quartile, 
median, upper quartile expression values and fold change in expression between normal and cancer values. Row highlighted in pink represent cancer types with 
differential overexpression of HLXB9 whilst rows highlighted in blue represent cancer types with differential underexpression of HLXB9. Overexpression of HLXB9 was 
found in stomach adenocarcinoma (STAD), rectum adenocarcinoma (READ), all kidney cancer cohort (KIPAN), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell 
carcinoma (KIRP), head and neck squamous cell carcinoma (HNSC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), pheochromocytoma and paraganglioma 
(PCPG), breast invasive carcinoma (BRCA), prostate adenocarcinoma (PRAD), uterine corpus endometrial carcinoma (UCEC), bladder urothelial carcinoma (BLCA). Pancreatic 
adenocarcinoma (PAAD) and kidney chromophobe (KICH) a type of kidney cancer showed underexpression of HLXB9.  
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As seen in the previous databases, most of the cancers identified as having differential expression of 
HLXB9 show overexpression of the gene suggesting a potential pro-oncogenic role for HLXB9 in most 
cancers identified. Additionally, some of the cancers showed very substantial increase in the expression 
of HLXB9 in the cancerous state such as prostate adenocarcinoma (PRAD, fold change=9.86), bladder 
urothelial carcinoma (BLCA, fold change=10.8), lung adenocarcinoma (LUAD, fold change=17.4), kidney 
renal papillary cell carcinoma (KIRP, fold change=19.3) and uterine corpus endometrial carcinoma 
(UCEC, fold change=43.9).  
 
One of the interesting findings from this database was the identification of different patterns of 
expression of HLXB9 within a cancer type such as in kidney cancer (also seen in Oncomine and GENT). 
In kidney cancer, two out of three subtypes; kidney renal clear cell carcinoma (KIRC) and kidney renal 
papillary cell carcinoma (KIRP) showed HLXB9 overexpression suggesting a possible pro-oncogenic 
function of HLXB9 for these kidney cancer subtypes. However, the third subtype kidney chromophobe 
(KICH) showed underexpression of HLXB9 suggesting a tumour suppressive function of HLXB9 in this 
kidney cancer subtype. This finding illustrates the importance of studying cancers by subtype when 
differential expressions of genes are being considered between normal and cancerous states.  
 
d. BioXpress v 1.0. 
 
In this database, HLXB9 expression in a cancer sample is compared to its non-cancer, matched pair 
sample. The change in expression between the two states was classified into overexpression or under 
expression. Overexpression was determined to be a fold change of greater than zero compared to its 
normal pair expression level and underexpression is a fold change less than zero compared to its normal 
pair; the results of this calculation are represented as a graph with a percentage frequency of over or 
under expression in observed in patients samples. 
The database then compares the expression of HLXB9 in the cancer sample to the non-cancer sample 
and calculates if the change observed between the two states was statistically significant. The frequency 
of statistically significant expression by cancer type was then represented graphically (figure 5.6). Six 
out of the eighteen cancer types analysed showed a statistical significant difference in the expression of 
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HLXB9. HLXB9 was found to be significantly upregulated in 10% of cases of prostate cancer (PRAD), 
6.67% of kidney renal papillary cell carcinoma (KIRP), 2% of cases of liver cancer (LIHC), 1.75% of cases 
of lung cancer (LUAD) and 0.88% of cases of breast cancer (BRCA). HLXB9 was also found to be 
significantly downregulated in 33% of pancreatic patient samples (PAAD).  
 
Figure 5.6: The frequency of significant differential expression of HLXB9 in cancer types (adjusted p value≤ 
0.05). HLXB9 was found to be significantly upregulated in 10% of cases of prostate cancer (PRAD), 6.67% of kidney 
renal papillary cell carcinoma cases (KIRP), 2% of cases of liver cancer (LIHC), 1.75% of cases of lung cancer 
(LUAD), and 0.88% of cases of breast cancer (BRCA). HLXB9 was found to be significantly downregulated in 33% of 
pancreatic patient samples (PAAD). 
 
Although only six out of eighteen cancer types analysed showed a statistical significant difference in the 
expression of HLXB9, it is worth noting that some of the other cancer types analysed may not have 
reached statistical significance due to the small number of samples analysed, as shown in table 5.6. 
Examples include cervical cancer and rectum cancer where the sample size was less than ten. However, 
there was a significant difference observed in pancreatic cancer although only four samples were 
analysed. This indicates that downregulation of HLXB9 might occur more frequently in pancreatic 
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Cancer Type No of patient 









DOID:5041_Esophageal cancer [ESCA] 10 77.78 22.22 0 
DOID:4362_Cervical Cancer [CESC] 4 100 0 0 
DOID:363_Uterine cancer [UCEC] 18 82.35 17.65 0 
DOID:3571_Liver Cancer [LIHC] 51 34 66 2 
DOID:263_Kidney cancer [KIRP] 128 96.67 3.33 6.67 
DOID:263_Kidney cancer [KIRC] 128 72.22 27.78 0 
DOID:263_Kidney cancer [KICH] 128 16 84 0 
DOID:219_Colon Cancer [COAD] 27 88.46 11.54 0 
DOID:1993_Rectum cancer [READ] 6 83.33 16.67 0 
DOID:1793_Pancreatic Cancer [PAAD] 4 33.33 66.67 33.33 
DOID:1781_Thyroid cancer [THCA] 60 32.2 67.8 0 
DOID:1612_Breast Cancer [BRCA] 114 69.03 30.97 0.88 
DOID:1324_Lung Cancer [LUSC] 108 68 32 0 
DOID:1324_Lung Cancer [LUAD] 108 94.74 5.26 1.75 
DOID:11934_Head and neck cancer [HNSC] 41 78.05 21.95 0 
DOID:11054_Urinary bladder cancer 
[BLCA] 
20 89.47 10.53 0 
DOID:10534_Stomach cancer [STAD] 31 76.67 23.33 0 
DOID:10283_Prostate Cancer [PRAD] 51 78 22 10 
Table 5.6: Cancer types, frequency of overexpression or underexpression and the frequency of statistical 
significance differential expression of HLXB9 in cancer samples. 
 
 
II. HLXB9 expression by cancer types 
Six cancer types were identified as having differential expression of HLXB9 from all four databases 
analysed. These were breast cancer, kidney cancer, liver cancer, lung cancer, prostate cancer and 
endometrial cancer. More details on the pattern of expression of HLXB9 in these cancer types are 
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HLXB9 expression: Overexpression (Up) or Underexpression (Down) 
Cancer Type Oncomine 




















U133A U133 Plus2 
Brain and central nervous 
cancer 
Up (3%)  Up (8%)  
Down (11%) 
    
Head and neck cancer    Up (1.7) Up (1.7) Up (3.9) Up 
Adrenal gland/cortex 
carcinoma 
  Up (3%) 
Down (3%) 
 Up (8.8)   
Pheochromocytoma and 
paraganglioma  
     Up (4.3)  
Thymoma      Up (1.3)  




Up (20%) Down (0.5) Up (3.0) Up (4.8)  
Kidney chromophobe 
(KICH) 
 Up (3%) 
Down (3%) 
   Down 
(0.3) 
Down 
Kidney renal clear cell 
carcinoma (KIRC) 
Down (5%) Down (3%) Up (7%)   Up (3.0) Up 




Up (5%)    Up (19.3) Up (6.7%) 




Down (0.5) Down (0.6)   
Lymphoma Up (3%)  Up (4%)     
Lung Cancer Up (11%)  Up (4%) Up (2.5) Up (5.3)   
Lung adenocarcinoma 
(LUAD) 
Up (11%)     Up (17.4) Up (1.8%) 
Lung squamous cell 
carcinoma (LUSC) 
     Up (4.0) Up 
Melanoma Up (20%) Up (33%)  Up (2.4) Up (2.3)   
Sarcoma   Up (4%) 
Down (4%) 
    
Bladder Cancer    Down (0.7) Down (5.2) Up (10.8) Up 
Pancreatic cancer  Down (8%)   Down (0.7) Up (1.3) (0.54) Down 
(33%) 
Liver cancer   Up (7%) Down (0.6) Up (5.7) Up (1.9) Down (2%) 
Oesophageal cancer Up (27%)   Up (3.5) Up (3.4) (0.9) Up 
Stomach cancer    Up (1.5) Up (1.5) Up (2.3) Up 
Stomach and oesophageal 
carcinoma (STES) 
     Up (1.1)  
Small intestine     Up (2.4)   
Colon cancer    Up (1.8) Up (1.1) Up (1.5) Up 
Colorectal 
adenocarcinoma 
     Up (1.6)  
Rectum adenocarcinoma      Up (2.2) Up 
Breast cancer Up (11%) Up (4%) 
Down (4%) 
Up (14%) Up (2.2) 
 
Up (3.8) Up (5.3) Up (0.9%) 




 Up (3%) 
Down (3%) 
  Up (3.2) Up (43.9) Up 




Up (0.8) Up (4.0)   
Prostate cancer   Up (12%) Up (1.1) Up (3.5) Up (9.7) Up (11%) 
Testicular cancer     Up (1.7) Up (1.5)   
Vagina cancer     Up (2.9)   
Vulva cancer     Up (2.4)   
Table 5.7: Overview on HLXB9 expression in various cancers by databases. Up represents overexpression, down 
represents underexpression. Blank cells indicates lack of data for cancer type in database. 
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Figure 5.7: HLXB9 expression in various cancer types. HLXB9 was aberrantly expressed in six cancers types 
from all four databases; these were breast, kidney, liver, lung, endometrial and prostate cancer. Up arrows indicate 
up regulation of HLXB9 whilst down arrows indicate downregulation of HLXB9. 
 
Upregulation of HLXB9 was identified in a proportion of breast cancer patients. This indicates the 
possibility of HLXB9 overexpression being pro-oncogenic in some breast cancer patients. In two of the 
databases (Oncomine and FIREBROWSE), HLXB9 overexpression was associated with invasive breast 
carcinoma suggesting a potential role for HLXB9 in breast cancer metastasis. In the Oncomine database 
only, HLXB9 overexpression was associated with invasive ductal breast carcinoma (IDC), when 
compared to other breast cancer subtypes in a study by Bitter 2005. This study also showed 
underexpression of HLXB9 in mucinous breast carcinoma compared to the other breast cancer subtypes 
studied. HLXB9 expression in breast cancer will be further investigated in Chapter 6.  
Upregulation of HLXB9 was also identified in a proportion of lung cancer patients. HLXB9 
overexpression was particularly significant in lung adenocarcinoma, a subtype of lung cancer (as shown 
in table 5.7). Although HLXB9 overexpression was also found in lung squamous cell carcinoma patients, 
the change in expression was not as significant when compared to the change observed in lung 
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adenocarcinoma patients. This implies a pro-oncogenic role for HLXB9 overexpression the lung 
adenocarcinoma subtype. 
Upregulation of HLXB9 in liver cancer was found in three out of the four databases investigated 
(Oncomine, GENT- U133Plus2 platform and FIREBROWSE) suggesting a pro-oncogenic role for HLXB9.  
Upregulation of HLXB9 has previously been reported in advanced stage (III, IV) heptocellular carcinoma, 
the most common type of liver cancer (Wilkens et al. 2011). However, downregulation of HLXB9 was 
found in BioXpress and GENT- U133A platform. This finding was contradictory to the aforementioned 
results and most likely indicates the heterogeneity of gene expression within subpopulations of a cancer 
type such as difference in tumour grade.  Alternatively, the conflicting results obtained might indicate 
that HLXB9 expression was not altered in liver cancer.  
The expression of HLXB9 in kidney cancer was interesting. Three of the databases (Oncomine, Gent and 
FIREBROWSE) analysed all types of kidney cancers together. From analysing all kidney cancer patients 
together, HLXB9 was found to be mostly upregulated in kidney cancer. Three of the databases also 
analysed kidney cancer by subtypes (Oncomine, FIREBROWSE, and BioXpress). However, when the 
subtypes were investigated separately, a different pattern of expression emerged. Upregulation of 
HLXB9 was mostly observed in KIRP and KIRC, and downregulation of HLXB9 was mostly found in KICH 
(as shown in table 5.7). 
Finally HLXB9 was found to be upregulated in prostate and endometrial cancer, suggesting that HLXB9 
overexpression might be pro-oncogenic in these cancers. 
5.5. Discussion 
 
Experimental data from scientific literature suggested that differential expression of HLXB9 would be 
identified in a large proportion of cancer types and patients. However, the results obtained using a 
number of transcriptomic databases were contrary to this expectation and imply that HLXB9 is not 
differentially expressed in a majority of cancer types and patients. 
It was also expected that by using this approach, patients previously characterised as overexpressing 
HLXB9 such as infant AML patients harbouring translocation t(7;12)would be identified in this study. 
However, this was not the case and may be explained by the low incidence of these patients. Infant AML 
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patients harbouring t(7;12) represent approximately 4.8 cancer cases per million diagnosed (Ballabio et 
al. 2009; Tosi et al. 2015). Another tumour type previously described as showing HLXB9 overexpression 
are insulinomas (Shi et al. 2013). Insulinoma is a rare type of pancreatic cancer, with an incidence of 1-4 
cases per million cancer cases diagnosed (Okabayashi et al. 2013). Patients diagnosed with poorly 
differentiated grade III and IV hepatocellular carcinoma (HCC) patients have also been previously 
reported as showing HLXB9 overexpression (Wilkens et al. 2011). However, apart from a review by 
Paradis who reported that most diagnosed HCC cases are grade II and III tumours, the incidence of 
grade III or IV tumours in HCC could not be determined (Paradis 2013).  
There were limitations encountered in some of the database used. In Oncomine and for some cancer 
types in BioXpress, there were a small number of non-cancer and cancer samples, which means results 
obtained from this analysis may not be truly representative of the whole population. There was also an 
overlap in datasets used. For example, the TGCA datasets is freely available and is used in all databases 
analysed. This might introduce a bias in some of the results obtained, as there was a possibility of the 
same samples being interrogated repeatedly. Another limitation of this study was the lack of datasets on 
a number of cancer types in the databases analysed (as shown in table 5.7). Therefore, it is possible that 
differential expression of HLXB9 important in the development and progression of cancers have not 
been identified in this study. In fact, aberrant expression of HLXB9 previously reported in leukaemia 
(Ballabio et al. 2009; Wildenhain et al. 2010; Ferguson et al. 2011) was only found in two of the four 
databases analysed.  
Despite these limitations, aberrant expression of HLXB9 was identified in a proportion of patients 
diagnosed with six different cancer types. This suggests HLXB9 may contribute to cancer development 
and progression from two different mechanisms. These are underexpression indicating a loss of tumour 
suppressor activity or overexpression indicating a pro-oncogenic role. This finding demonstrates that 
accurate regulation of this gene is crucial. In this study, differential HLXB9 expression was found in 
cancer types previously reported in literature as showing aberrant expression of HLXB9 these were: 
breast cancer and hepatocellular carcinoma. 
HLXB9 was found upregulated in breast cancer suggesting a pro-oncogenic role for HLXB9 in breast 
cancer. However, in contrast to this finding, earlier studies analysing HLXB9 expression in breast cancer 
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had reported HLXB9 as being downregulated suggesting loss of HLXB9 reduces its tumour suppressor 
function in breast cancer (Tommasi et al. 2009; Lian et al. 2012; Siletz et al. 2013b; Siletz et al. 2013a). 
Our finding although contradictory to previous research may be attributed to a difference in the 
subtypes or subpopulations of breast tumours investigated. This is because results from both Oncomine 
and GENT suggest a subpopulation or subtypes of breast tumours might underexpress HLXB9. 
HLXB9 was found upregulated in liver cancer (hepatocellular carcinoma) in three of the four database 
analysed. This result suggests a pro-oncogenic function of HLXB9 in a subpopulation of hepatocellular 
carcinoma (HCC) patients. This finding was supported by previously published research by Wilkens and 
colleagues: in their study, HLXB9 was found to be upregulated in a subset of HCC patients (grade III, IV) 
(Wilkens et al. 2011). In these patients, upregulation of HLXB9 was associated with dedifferentiated HCC 
subtypes and poor patient prognosis (Wilkens et al. 2011).  
This study also uncovered differential expression of HLXB9 in cancer types not previously associated 
with aberrant expression of HLXB9 such as lung cancer, kidney cancer and endometrial cancer. These 
findings highlight a new avenue of research in understanding these cancer types. The result obtained 
from kidney cancer analyses was particularly interesting.  
There are three main subtypes of kidney cancer: kidney clear cell carcinoma (KIRC) representing 65% of 
diagnosed cases, kidney papillary cell carcinomas (KIRP) representing 20% of diagnosed cases and 
kidney chromophobe (KICH) representing 5% of diagnosed cases (Cairns 2011; Chen et al. 2016). Out of 
these subtypes, kidney chromophobe is a low-grade tumour subtype and has a favourable prognosis 
while KIRC and KIRP are mostly high-grade tumours, which have very poor prognosis. Additionally, 
most diagnosed metastatic kidney cancers are KIRC (Cairns et al 2011). HLXB9 was upregulated in KIRP, 
a subtype of kidney cancer associated with poor prognosis. HLXB9 expression can also be suggested to 
be upregulated in KICH; a subtype of kidney cancer with poor prognosis and associated with metastasis, 
although a subpopulation of patients diagnosed with this kidney cancer subtype also showed a 
significant downregulation of HLXB9 (Oncomine only). This discrepancy in expression of HLXB9 
observed in KICH might be indicative of difference in tumour grade therefore more research is needed 
to fully understand HLXB9 expression in this kidney subtype. 
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HLXB9 expression was found to be downregulated in KICH, a kidney cancer subtype with favourable 
outcome. Therefore, these results imply HLXB9 overexpression is pro-oncogenic in KIRC and KIRP, two 
kidney cancer subtypes that are associated with poor prognosis, whilst underexpression in KICH is 
associated with a favourable outcome. This finding implies HLXB9 expression in kidney cancer should be 
further explored to elucidate its function in the development and/or progression in this tumour type. 
This study also highlighted the heterogeneity of cancers and the importance of studying tumours by 
subtypes during gene expression profiling experiments. For instance, HLXB9 has been previously 
reported to be overexpressed in insulinomas, a subtype of pancreatic cancer, however in this study 
HLXB9 was found underexpressed in pancreatic adenocarcinoma, the most common subtype of 
pancreatic cancer (Shi et al. 2013; Desai et al. 2014). Insulinomas, which are endocrine tumours, 
originate from b-cells from the Islets of Langerhans and are usually benign tumours. Whereas pancreatic 
adenocarcinomas are mostly exocrine tumours mostly originating from cells lining the pancreatic ducts 
are generally invasive and associated with a poor prognosis.  
Additionally, the lack of categorisation of cancers types into subtypes as seen in the GENT database and 
for some cancer types in BioXpress and FIREBROWSE database was found to obscure the differential 
expression of HLXB9 in some cancer types. For example, in kidney cancer by investigating only GENT or 
the all kidney cancer cohort in FIREBROWSE, an inaccurate conclusion could be reached that HLXB9 was 
overexpressed in kidney cancer. However, when kidney cancer was sub-divided into subtypes like in 
BioXpress and FIREBROWSE, HLXB9 was shown to be overexpressed in two subtypes (KIRP and KIRC) 
whilst underexpressed in one subtype (KICH). 
Another finding from this study was that differential expression of HLXB9 observed in cancers of 
organs/tissue solely or partially derived from the endodermal germ layer such as pancreas, rectum, 
lung, liver, bladder, stomach, and oesophagus. This indicates that HLXB9 expression has to be correctly 








In conclusion, this study highlighted that a small proportion of cancer types and patients showed 
differential expression of HLXB9. However, there is a possibility that HLXB9 expression may be 
implicated in cancer progression in some cancer types e.g. breast cancer, kidney cancer. Thereby, 
further research into characterising HLXB9 expression in these specific cancer types and identifying 
HLXB9 target genes and pathways maybe prove beneficial for improving patients’ outcome. 
Another avenue for further research would be to interrogate patient outcome in cases where HLXB9 
differential expression occurs, as this would provide insight into whether HLXB9 expression could have 
prognostic significance in these patients. Although differential expression of HLXB9 was identified in a 
number of cancer types, there remains a gap in knowledge of the function of HLXB9 in these tissues and 
organs. Therefore it would be useful to understand the function of this gene in relation to the identified 
tissues and organs and how dysregulation may contribute to cancer development and progression. 
  













6. Investigating HLXB9 expression as a 
biomarker in breast cancer 
  




In the UK, breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer 
deaths in women (Cancer Research UK). Genetically, breast cancer is a heterogeneous disease, with 
aberrations in expression of many genes. The identification of the increased expression of oestrogen 
(ER), progesterone (PR) and human epidermal growth factor 2 (HER2) receptors, proteins that mediate 
the increase in proliferation of breast cells observed in breast cancer has led to the categorisation of 
breast tumours into four main molecular subtypes: luminal A, luminal B, basal and HER2 amplified. 
These subtypes are now used routinely in making treatment decisions in clinic (Perou et al. 2000; Sorlie 
et al. 2003; Parker et al. 2009). 
Apart from these molecular subtypes, other factors that have prognostic significance in breast cancer 
treatment include tumour grade, lymph node involvement and tumour response to treatment. However, 
there remains a need to identify new biomarkers to improve patients’ outcome. For instance, 
biomarkers that can be used for early diagnosis, evaluate prognosis, monitor disease progression and 




The aim of this chapter is to investigate HLXB9 as a possible biomarker in breast cancer by: 
 Using quantitative RT-PCR and indirect immunofluorescence to investigate the expression of 
HLXB9 in non-tumorigenic breast cells and breast cancer cell lines 
 Using FISH and erosion analysis of FISH images to compare the nuclear localisation of HLXB9 in 
non-tumorigenic and breast cancer cell lines to determine if there is a difference in the nuclear 
localisation of HLXB9 in breast cancer  
 Investigating the effect of the nuclear localisation of HLXB9 in non-cancer and breast cancer cell 
lines on expression of HLXB9  
 Examining HLXB9 expression in terms of breast cancer molecular subtypes to determine if there 
is a relationship between these subtypes and HLXB9 expression 
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 Evaluating the prognostic significance of HLXB9 expression in breast cancer patients’ outcome 
using widely available survival databases. 
 
6.3. Materials and Methods 
 
The materials and methods used in this chapter are described in Chapter 2. 
 
6.4. Results 
I. HLXB9 expression in non-cancer mammary cells and breast cancer cell lines by RT-PCR 
 
Several breast cancer cell lines were screened to identify cell lines that could be studied to investigate 
the function of HLXB9 overexpression in breast cancer. RT-PCR using primers for HLXB9 and β-actin 
(loading control) were carried out on the following cells/cell lines: 
 Non-cancer cells/cell lines: two primary human mammary epithelial cells (HMEC) 184D and 
240L, and a non-tumorigenic epithelial cell line MCF 10A were used as non-cancer controls in 
this study. 
 Breast cancer cell lines: breast cancer cell lines screened in this study were GI-101, MDA-MB-
361, MDA-MB-157, T47D, SKBR3, MDA-MB-231, and BT474. 
 Transformed derived cell lines from the non-tumorigenic MCF 10A cell line; MCF 10A-T1K and 
MCF 10A-CA1h were also analysed. 
After the RT-PCR experiments, agarose gel electrophoresis analysis of amplified PCR products was 
carried out on a 1.2% agarose gel run at 80 volts. 
HLXB9 was expressed by non-cancer mammary cells  
 
Samples from six different passages of HMEC 184D cells (primary mammary epithelial cells) were 
provided by Dr Yasaei and investigated for HLXB9 expression. A sample of HMEC 184D cells was taken 
at early passage (passage 7); at midpoint passage (passage 10) and at late passage (passage 14) when 
these cells start to senescence due to p16 accumulation (stress induced senescence) (Garbe et al. 2014; 
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Garbe et al. 2009). All three samples showed HLXB9 expression and there was no observable difference 
in the level of expression of HLXB9 (figure 6.1a, lane 1, 2 and 3). 
The other three HMEC 184D samples were obtained after the cells were treated with Nickel (II) 
Chloride-NiCl2, a carcinogen that rescues cell growth by helping them bypass senescence at passage 14. 
The samples at passage 14, passage 19 and passage 25 were also examined to investigate how HLXB9 
expression changes as cells bypass their normal cell division control mechanism. These samples of 
HMEC 184D also show HLXB9 expression and there was no observable difference in the level of 
expression of HLXB9 (figure 6.1a, lane 4, 5 and 6).  
HMEC 240L, the other human mammary epithelial cell analysed also expressed HLXB9 (figure 6.1b). 
Finally, HLXB9 expression was investigated in MCF 10A, an immortalised non-tumorigenic epithelial cell 
line widely used as a control (non-cancer) sample in breast cancer studies. MCF 10A cells also express 
HLXB9 (figure 6.1c). 
 
All breast cancer cell lines screened expressed HLXB9 
 
Seven breast cancer cell lines were screened for HLXB9 expression (as shown in figure 6.2a and b). The 
molecular characteristics of the cell lines investigated are described in table 6.1. The cell lines 
investigated were GI-101, MDA-MB-361, MDA-MB-157, T47D, SKBR3, MDA-MB-231, and BT474. All cell 
lines examined expressed HLXB9 (figure 6.3a and b).  
Cell Line Molecular 
subtypes 
HER2 PR ER HLXB9 expression 
confirmed by RT-
PCR experiments 
GI-01 Basal  + - +/-* Yes 
MCF 10A Basal  - - - Yes 
MDA-MB-361 Luminal A + + + Yes 
MDA-MB-157 Basal  - - - Yes 
MDA-MB-157+BRK Basal  - - - Yes 
T47D Luminal A - + + Yes 
SKBR-3 HER2 amplified ++ - - Yes 
MDA-MB-231 Basal  - - - Yes 
BT474 Luminal B ++ + ++ Yes 
Table 6.1: Table showing the molecular subtypes, expression profile of the biomarkers currently used in 
categorising breast tumours on cell lines studied and results of HLXB9 expression experiments. Cell line 
phenotype determined by the genes expressed by cell line. Human epidermal growth factor receptor 2 (HER2), 
Progesterone receptor (PR), Estrogen receptor (ER), (-) no expression, (+) expression, (++) overexpression, (+/-*) 
differing reports in research articles with expression observed in some studies (Neve et al. 2006,Mackay et al. 2009, 
Subik et al. 2010; Lacroix and Leclercq 2004) 
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Cell lines that showed other amplified bands other than band representing HLXB9 at 359bp were MDA-
MB-157 and MDA-MB-157 stably transfected with breast tumour kinase (BRK). These additional bands 
suggest there might be a different isoform of HLXB9 being amplified or may represent artefacts from the 
PCR reaction. However, further investigations to identify these additional bands were unnecessary in 
this study as these experiments were designed to confirm HLXB9 expression. 
HLXB9 was also expressed by MCF 10A derivatives 
 
MCF 10A and transformed cell lines derived from MCF 10A were used as a model to study the 
progressiveness of cancer development. In this study, MCF 10A and two of the three cell lines derived 
from MCF 10A; MCF 10A-T1K and MCF 10A-CA1h were analysed for HLXB9 expression. MCF 10A-T1K is 
a pre-malignant cell line obtained by transforming the MCF 10A cell line with HRAS (Kadota et al. 2010, 
Wendt and Shiemann 2009). It is the first stage of the MCF 10A cancer progression model. MCF 10A-
CA1h, a well differentiated metastatic tumour cell line derived from MCF 10A-T1K, is the next stage in 
the cancer progression model (Kadota et al. 2010, Wendt and Shiemann 2009). Unfortunately, the third 
stage in this model was not available therefore was not analysed as part of this study. 
This breast cancer progression model is ideal for investigating the expression of HLXB9 as cells become 
more tumorigenic. MCF 10A and its derivatives were found to express HLXB9 by RT-PCR (figure 6.1c). 
There was also no observable difference in the quantity of HLXB9 amplified indicated by the intensity of 
the bands obtained in the agarose gel
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Figure 6.1: Agarose gel electrophoresis analysis of RT-PCR products in control (non-cancer) samples and MCF 10A cancer derivatives. RT-PCR products were 
electrophoresed in 1.2% Agarose gel at 80 Volts. Amplified products at 660bp obtained using primers for β-actin was used as both quality and quantity control. The β-actin PCR 
products in each sample was analysed before HLXB9 RT-PCR was carried out to make sure cDNA template from samples did not show signs of degradation or contamination. The β-













A                                                                                                        B                                                                                          C 
Figure 6.1A: Agarose gel electrophoresis analysis of RT-PCR 
products showed HLXB9 was expressed by HMEC 184D cells 
at different passages (n=3) 
Lanes: M= peqGOLD DNA SIZER XI, Lane 1= HMEC 184D passage 7, 
Lane 2= HMEC 184D passage 10, Lane 3= HMEC 184D passage 14, Lane 
4= HMEC 184D passage 14 after treatment with NiCl2, Lane 5= HMEC 
184D passage 19 after treatment with NiCl2, Lane 6=184D passage 25 
after treatment with NiCl2, Lane 7= (Top) positive control (K562 cell 
line)/ (Bottom) negative control (negative cDNA), Lane 8= negative 
control (PCR mastermix).  
(Top) Gel of RT-PCR reaction using HLXB9 primers showing the 
amplified product at 359bp. Lane labelled with purple numbers 
represent HMEC 184D samples after treatment with NiCl2 to help cells 
bypass p16 mediated cell senescence. There was no observable 
difference in the quantity of HLXB9 amplified indicated by the intensity 
of the bands obtained before and after treatment with NiCL2.  
(Bottom) RT-PCR control gel showing the quality of cDNA samples 
using β-actin primers. The amplified products at 660bp showed the 
cDNA used in experiments were of good quality as there were no signs 
of degradation or contamination. The bands for each sample also 
show that the same starting amount of cDNA was used in the 
PCR reaction.  
Figure 6.1B: Agarose gel electrophoresis 
of RT-PCR product showed HLXB9 was 
expressed by HMEC 240L cells (n=3). 
Lanes: M= peqGOLD DNA SIZER XI, Lane 1= 
HMEC, Lane 2= negative control (negative 
cDNA), Lane 3= negative control (PCR 
mastermix) 
(Top) Agarose gel of RT-PCR reaction using 
HLXB9 primers showing the amplified product at 
359bp. 
(Bottom) RT-PCR control gel showing the quality 
of cDNA sample using β-actin primers. The 
amplified products at 660bp showed the cDNA 
used in experiment was of good quality as there 





Figure 6.1C: Agarose gel electrophoresis of RT-PCR 
products showed HLXB9 was expressed by MCF 10A and 
its cancer derivatives: MCF 10A-TK1 and MCF 10A Ca1h 
(n=3).  
Lanes: M= peqGOLD DNA SIZER XI, Lane 1= MCF 10A Lane 2= MC 
10A-TK1, Lane 3= MCF 10A-Ca1h, Lane 4= positive control (K562 
cell line), Lane 5=negative control (negative cDNA), Lane 6= 
negative control (PCR mastermix) 
(Top) Gel of RT-PCR reaction using HLXB9 primers showing the 
amplified product at 359bp. There was no observable difference 
in the quantity of HLXB9 amplified indicated by the intensity of the 
bands obtained 
(Bottom) RT-PCR control gel showing the quality of cDNA samples 
using β-actin primers. The amplified products at 660bp showed 
the cDNA used in experiments were of good quality as there were 
no signs of degradation or contamination. The bands for each 
sample also showed that the same starting amount of cDNA was 
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Figure 6.2: Agarose gel electrophoresis analysis of RT-PCR products in breast cancer cell lines. RT-PCR products were electrophoresed in 1.2% Agarose gel at 80 Volts. 














Figure 6.2A: Agarose gel electrophoresis analysis of RT-PCR products 
showed HLXB9 was expressed by the breast cancer cell lines investigated. 
Lanes: M= peqGOLD DNA SIZER XI, Lane 1= Gi-101, Lane 2= MCF 10A, Lane 
3= MDA-MB-361, Lane 4= MDA-MB-157 transfected with a control vector, 
Lane 5= MDA-MB-157 transfected with BRK, Lane 6= T47D, Lane 7= SKBR 3, 
Lane 8= positive control K562 (top image)/ control negative cDNA (bottom 
image), Lane 9=negative control PCR mastermix 
(Top) Gel of RT-PCR reaction using HLXB9 primers showing the amplified 
product at 359bp. Cell lines that showed other amplified bands other than 
band representing HLXB9 at 359bp were MDA-MB-157 and MDA-MB-157 
stably transfected with breast cancer kinase. These additional bands might 
represent the detection of a different isoform of HLXB9 or artefacts from the 
PCR experiments. 
(Bottom) RT-PCR control gel showing the quality of cDNA samples using β-
actin primers. The amplified products at 660bp showed the cDNA used in 
experiments were of good quality as there were no signs of degradation or 
contamination. The band for each sample also showed the same starting 
amount of cDNA was used in the PCR reaction.  
Figure 6.2B: Agarose gel electrophoresis analysis of RT-PCR 
products showed HLXB9 was expressed by non- cancer cells/cell 
lines and breast cancer cell lines further analysed by qRT-PCR 
(n=3) 
Lanes: M= peqGOLD DNA SIZER XI, Lane 1=HMEC 184D passage 7, 
Lane 2=HMEC 240L Lane 3=T47D, lane 4=MDA-MB-231, Lane 
5=BT474, Lane 6= control mastermix  
(Top) Gel of RT-PCR reaction using HLXB9 primers showing the 
amplified product at 359bp. There was no observable difference in the 
quantity of HLXB9 amplified indicated by the intensity of the bands 
obtained between non cancer cells and breast cancer cell lines 
investigated.  
(Bottom) RT-PCR control gel showing the quality of cDNA samples 
using β-actin primers. The amplified products at 660bp showed the 
cDNA used in experiments were of good quality as there were no signs 
of degradation or contamination. The band for each sample also 
showed the same starting amount of cDNA was used in the PCR 
reaction.  
A                                                                                                                                                                                  B 
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II. Sequencing of RT-PCR products 
 
The next step in the investigation of HLXB9 expression in breast cancer was to determine if there was a 
differential expression between normal breast cells and breast cancer cell lines by quantitative RT-PCR 
(qRT-PCR). Therefore, cDNA from non-cancer breast cells/cell lines and breast cancer cell lines were sent 
to our collaborator, Professor Saccone.  
The antisense HLXB9 mRNA- HLXB9-AS2 was detected in the cell lines analysed 
However, as the primers had only been used in qRT-PCR in neuronal cell lines, RT-PCR experiments using 
the primers were carried out to determine the specificity of the primers for amplifying HLXB9 in breast 
cells. Upon agarose gel electrophoresis analysis of the RT-PCR products, an expected band at 98bp 
representing HLXB9 transcript variant one and two was observed. An additional unexpected band above 
800bp was also detected in the MCF 10A, T47D, MDA-MB-231, and BT474 cell lines. 
 
Figure 6.3: HLXB9 transcript variants 1 and 2 at 98bp and an additional band above 800bp in breast cancer cell 
lines analysed. An additional band was observed in MCF 10A, T47D, MDA-MB-231, and BT474 cell lines. Lanes: M= 
Peqlab 100bp ladder, Lane 1= HMEC 184D passage 7, Lane 2= HMEC 240L, Lane 3= MCF 10A, Lane 4= T47D, Lane 5= 
MDA-MB-231, Lane 6= BT474 and Lane 7= negative control, PCR mastermix. 
 
In order to determine the identity of the unexpected band, the primer sequences were analysed through 
primer blast (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The results from primer blast indicated 
the possibility of unspecific detection of GNL3L using the primers. Therefore, the PCR product from the 
T47D cell line was sent to Beckman Coulter Genomics Inc. UK for sequencing. The resulting sequence was 
analysed using nucleotide blast search (https://blast.ncbi.nlm.nih.gov). The result obtained from the 
sequencing reaction indicated the unexpected product above 800bp was most likely an anti-sense HLXB9 
RNA encoded by HLXB9-AS2.  
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III. Quantification of HLXB9 expression in non-cancer mammary cells and breast 
cancer cells 
Professor Saccone (University of Catania, Italy) provided the results described in this section. Sybr green 
Real Time PCR experiments using primers for HLXB9 and Tubulin (control gene) were carried out in non-
cancer and cancer breast cell lines. The relative concentration of HLXB9 in the samples of interest to the 
control gene was obtained from the 2-ΔΔCt formula (fold change between HLXB9 expression to control 
gene). GDM1 and SK-N-BE cell lines were used as positive control for HLXB9 expression. The GDM1 cell 
line is a leukaemia derived cell line known to overexpress HLXB9 (Nagel et al. 2005). The SK-N-BE cell 
line is a neuroblastoma cell line that expresses HLXB9 during proliferation, adding retinoic acid (RA) to 
this cell line increases HLXB9 expression to induce neural differentiation. The increase in HLXB9 
expression is particularly significant five days after the addition of RA when HLXB9 expression increases 
fivefold (Leotta et al. 2014). 
Non-cancer primary HMEC cells showed a variable level of HLXB9 expression.  
There was variability in the expression of HLXB9 in the two samples of HMEC cells analysed. HMEC 240L 
cells showed a lower level of HLXB9 expression compared to HMEC 184D cells (figure 6.4).  
The expression of HLXB9 in HMEC 184D cells was sampled at three time points in culture. These were: an 
early time point in culture (passage 7), mid-point in culture (passage 10) and a late time point in culture 
after treatment with NiCl2, (passage 25). HLXB9 was found to increase at passage 10 (mid-point) and 
decreases at passage 25 (late passage) to almost the same level at passage 7. Interestingly at passage 10,  
HLXB9 expression in HMEC 184D cells was almost comparable to the GDM1 cell line. The GDM1 cell line is 
a leukaemia cell line known for HLXB9 overexpression. Therefore HLXB9 expression was found to increase 
as mammary cells become more proliferative and then reduce as the cells lose their proliferative ability. 
This indicates a role for HLXB9 associated with proliferation in mammary cells. 
The variability of HLXB9 expression observed between the different HMECs samples studied (240L and 
184D) might be due to of a number of reasons. One of these might be because the sample from the HMEC 
240L cell line was taken at a late passage. Results from the HMEC 184D cell line suggests mammary cells 
lose HLXB9 expression when their proliferative potential reduces at late passage. Other reasons include a 
variation in HLXB9 expression between healthy individuals or a difference in patient’s characteristics. The 
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HMEC 184D cells are derived from a patient undergoing reduction mammoplasty at 21 years old and the 
240L derived from a patient undergoing reduction mammoplasty at 19 years old (Garbe et al. 2014). 
HLXB9 was downregulated as cells became tumorigenic (results from MCF 10A and its transformed 
derivatives) 
The expression of HLXB9 was measured in the MCF 10A cell line and its transformed derivatives (figure 
6.4). The MCF 10A cell line and its derivatives are used as a model to study cancer development as the 
cells go from non-tumorigenic MCF 10A to MCF 10A-TK1, a premalignant cell line to MCF 10A- CA1h, a 
well differentiated metastatic tumour cell line. HLXB9 expression was highest in the non-tumorigenic 
MCF 10A cell line, whilst HLXB9 expression reduced when the MCF 10A cell line becomes transformed 
(MCF 10A- TK1 cell line). HLXB9 expression was at a similar level between the pre malignant MCF 10A-
TK1 cell line and the malignant MCF 10A-CA1h cell line. This suggests a downregulation of HLXB9 occurs 
early on in the cancer development, and this reduced expression of HLXB9 persists as cells become more 
tumorigenic. These results indicate a tumour suppressive function for HLXB9 in healthy mammary cells. 
HLXB9 was downregulated in breast cancer cell lines  
HLXB9 expression was measured in three breast cancer cell lines, T47D, BT474 and MDA-MB-231. There 
was a decrease in expression of HLXB9 in these cell lines compared to two control (non-cancer) cells 
analysed (HMEC 184D cell and MCF 10A cell lines). However, a similar level of expression was observed 
when comparing HMEC 240L cells to the three breast cancer cell lines. This might be because the HMEC 
240L cell were sampled at late passage when these cells are not actively proliferating (see figure 6.4). 
Comparison of the three breast cancer cell lines showed BT474, the luminal B type cell line had the least 
amount of HLXB9 whilst T47D (Luminal A) and MDA-MB-231 cell line (Basal) had a similar level of 
expression of HLXB9. The reduced expression of HLXB9 in the breast cancer cell lines indicates a loss of 
tumour suppressive function of HLXB9 in cancer. This finding although contradictory to results presented 
in Chapter 5 was not surprising as other studies have also found downregulation of HLXB9 in breast 
cancer (Tommasi et al. 2009; Lian et al. 2012; Siletz et al. 2013b; Siletz et al. 2013a).  
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Figure 6.4: Histograms of HLXB9 expression in controls and breast cancer cell (n=2). There was a reduction in 
the level of HLXB9 in the breast cancer cell lines compared to two of the control non cancer cells/cell line (HMEC 
184D and MCF 10A). However, a similar level of HLXB9 expression was observed in the HMEC 240L cells compared to 
the breast cancer cell lines. The SK-N-BE and the GDM1 cell lines are used as positive controls. GDM1 is a leukaemia 
cell line known for very high levels of HLXB9 expression. The SK-N-BE cell line is a neuronal cell line that expresses 
HLXB9 during proliferation; upon stimulation with retinoic acid (RA) to induce differentiation, this cell line increases 
its HLXB9 expression fivefold. Bars represent of 2-ΔΔCt values of expression level normalised to TBP expression. 
 
IV. HLXB9 expression and cellular localisation in breast cancer cell lines by indirect 
immunofluorescence (IF) 
HLXB9 mRNA was found downregulated in breast cancer, Immunofluorescence (IF) experiments to detect 
the protein were carried out. Antibodies for HLXB9, β-actin and tubulin were used to identify and 
determine the cellular localisation of the HLXB9 protein in non-cancer MCF 10A cell lines and three 
breast cancer cell lines: T47D, BT474 and MDA-MB-231 (figure 6.5). It was impossible to determine the 
specificity of the HLXB9 antibody used, as no negative controls for HLXB9 protein expression were 
readily available. Additionally, due to time and resource constraints, knocking down the expression of 
HLXB9 by siRNA to determine the specificity of the antibody was also not possible.  
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HLXB9 was downregulated in breast cancer cell lines 
The MCF 10A cell line (control non-tumorigenic cell line) had the greatest staining intensity (expression) 
of HLXB9. HLXB9 was present uniformly in the cell nucleus and cytoplasm in these cells.  
The T47D (Luminal A) cell line also expresses HLXB9, however compared to the MCF 10A cell line, the 
staining intensity was reduced and there was a presence of protein aggregates (foci) in the nucleus. The 
MDA-MB-231 (Basal) cell line also expresses HLXB9, however compared to both control cell lines and the 
T47D, there was a reduction in the staining intensity with some cell nuclei having no staining for HLXB9. 
There were also foci of protein aggregates in nuclei when staining was observed. The BT474 cell line had 
the least amount of HLXB9 in the cytoplasm and the nuclei; HLXB9 was present as foci in the nucleus with 
some staining in the cytoplasm.  
These results indicate a correlation between the levels of HLXB9 mRNA and protein in these cells. The 
results also showed a downregulation of HLXB9 protein suggesting a tumour suppressive function for 
HLXB9 in non-cancer mammary cell lines. Additionally, the organisation of HLXB9 as foci in the nucleus in 
the breast cancer cell lines (not observed in control) might be indicative of perturbed activity of HLXB9 in 
these cells. 
The results obtained, although contrary to results obtained in chapter 5 were not surprising because a 
previous study had identified downregulation of HLXB9 in breast cancer (Neufing et al. 2003). The 
downregulation of HLXB9 observed might be due to variations within subtypes of breast cancers and 
might indicate that the spectrum of cell lines investigated was not comprehensive.  
Unfortunately, due to time constraints, experiments to accurately quantify HLXB9 expression using a 
method such as Enzyme-linked Immunosorbent assay (ELISA) were not possible.  
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Figure 6.5: HLXB9 was downregulated in the breast cancer cell lines analysed. The MCF 10A cell line had the most 
HLXB9 expression (staining intensity). The MCF 10A also had a uniform expression of HLXB9 in the nucleus and the 
cytoplasm. Compared to the MCF 10A cell lines, the T47D had a reduced expression of HLXB9. HLXB9 localisation was 
also different in the T47D cell lines; HLXB9 was present as foci in the nucleus and surrounding the cytoplasm. The 
MDA-MB-231 cell line also had a reduced expression of HLXB9 compared to the control cell lines; HLXB9 was also 
present as foci in these cells. Finally, the BT474 cell had the least amount of HLXB9 compared to control and other 
cell lines investigated. HLXB9 was also present as foci in these cells. βeta-Actin in CY3 (red), HLXB9 in FITC 
(green) and nuclei counterstained with DAPI (blue). 
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V. Cytogenetic characterisation of non-cancer breast cells and breast cancer cell lines by 
FISH and/or G-banding 
Breast cancer cell lines have been shown to harbour extensive chromosomal abnormalities that are known to 
evolve in culture (Rondón-Lagos et al. 2014; Watson et al. 2004). Therefore an attempt was made to characterise 
the cell lines used in this study with a particular focus on the number of HLXB9 alleles present in each cell line. 
This was performed in conjunction with the nuclear localisation of the HLXB9 gene in these cell lines.  
Non-cancer cell lines had two copies of HLXB9 gene 
The non-cancer cells/cell lines: HMEC 184D, HMEC 240L and MCF 10A used in this study were analysed by FISH 
and had two copies of the HLXB9 gene (as shown in figure 6.6). 
    
   
  
Figure 6.6: Fluorescence in situ hybridisation patterns observed in the metaphases and nuclei of non-cancer HMEC 
184D, HMEC 240L and MCF 10A cells. Left: HLXB9 in green (FITC labelled), and nucleus counterstained with DAPI. Right: 
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T47D cells also had two copies of HLXB9 
The T47D cell line was analysed by G- banding and found to have a near triploid number of chromosomes 
(n= 32, modal number of 63 chromosomes as shown in figure 6.7B). Additional information on the type of 
chromosome abnormality could not be ascertained from the G-banded images. However, due to time and 
cost constraints, multiplex fluorescence in situ hybridisation (M-FISH) or spectral karyotype (SKY) could 
not be carried out on this and other cell lines used. A range of 48-65 chromosomes was observed. T47D 
similar to the control non-cancer cells used in the study had two HLXB9 alleles by FISH (figure 6.7A). 
                     
Figure 6.7A: Fluorescence in situ hybridisation patterns observed in the T47D cell line. (Left) HLXB9 in green 
(FITC labelled), and nucleus counterstained with DAPI. (Right) Metaphase spread: chromosome counterstained in 
DAPI and HLXB9 in green (FITC labelled). 
 
Figure 6.7B: A representative image showing G banded T47D chromosome spread (n=63).  
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BT474 cells had a variable number of HLXB9 alleles (5-7n) 
The BT474 cell line was analysed by G banding (figure 6.8E). This cell line had a tetraploid number of chromosomes; a modal number of 92 chromosomes was 
observed (n=15) between a range of 49-101 chromosomes. There was also variability in the number of HLXB9 alleles in the BT474 nucleus from five to seven 
alleles (figure 6.8A-D); five alleles (19.2% of nuclei), six alleles (37.6% of nuclei) and seven alleles (43.2% of nuclei) by FISH. 
       
   
Figure 6.8: Fluorescence in situ hybridisation patterns observed in the metaphase and nuclei HLXB9 in green (FITC labelled), chromosome and nuclei counterstained with DAPI and 
representative g banding chromosome spread of BT474 cell line. (A) BT474 nucleus with 5 HLXB9 alleles. (B) BT474 nucleus with 6 HLXB9 alleles. (C) BT474 nucleus with 7 HLXB9 
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MDA-MB-231 cells had a variable number of HLXB9 alleles (2-5n) 
The MDA-MB-231 cell line was analysed solely by FISH. The cell line had a modal number of 73 chromosomes, a range of chromosomes 65-221 was observed 
(n=10) (Results used with permission from Dr Susan Wagland). There was also variability in the number of HLXB9 alleles in the MDA-MB-231 cell line, this ranged 
from two copies (6.3 percent of cells), three copies (51 percent of cells), four copies (15.8 percent of cells) to five copies (26.8 percent of cells) (figure 6.9A-F). 
    
                           
Figure 6.9: Fluorescence in situ hybridisation patterns observed in the metaphase and nuclei of MDA-MB-231 cell line HLXB9 in green (FITC labelled), and 
Nuclei/Chromosome counterstained with DAPI. (A) MDA-MB-231 nucleus with 2 HLXB9 alleles. (B) MDA-MB-231 nucleus with 3 HLXB9 alleles. (C) MDA-MB-231 nucleus with 4 
HLXB9 alleles. (D) MDA-MB-231 nucleus with 5 HLXB9 alleles. (E) Metaphase spread showing a cell with three copies of HLXB9. (F) Partial Metaphase spread showing a cell with five 
copies of HLXB9.
A
                                                                                     
B                                                                                       




  B 
C 
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VI. Nuclear localisation of the HLXB9 gene in non-cancer breast cells and breast 
cancer cells 
As HLXB9 expression has previously been linked to its nuclear localisation, the nuclear localisation of 
HLXB9 in the non-cancer cells/cell lines and breast cancer cell lines studied were analysed. The aim of 
these experiments was to determine if a change in the nuclear localisation of HLXB9 occurs in breast 
cancer. The results from the analysis are presented below and are shown in figure 6.10. 
 
A. Non-cancer breast cells/ cell lines  
HLXB9 was localised in the nuclear periphery of non-cancer primary human mammary epithelial 
cells (HMEC) 
The HLXB9 gene was localised in the nuclear periphery of both HMEC 184D cells (n=189) and HMEC 240L 
cells (n=191). There was no significant difference between the localisation of HLXB9 in both non-cancer 
HMEC cells studied using an unpaired student’s t-test. This result indicates the nuclear localisation of 
HLXB9 was conserved between healthy individuals. 
HLXB9 was also localised in the nuclear periphery of non-tumorigenic MCF 10A cells 
HLXB9 was localised in the nuclear periphery in the MCF 10A cell line (n=190). There was no significant 
difference in the nuclear localisation of HLXB9 in the MCF 10A cell line compared to the control HMEC 
cells studied (result of a one-way ANOVA and Bonferroni post hoc test). The result indicated that HLXB9 
nuclear localisation is conserved between healthy individuals. 
 
B. Breast cancer cell lines 
HLXB9 had a peripheral-intermediate nuclear localisation in T47D (Luminal A) cells 
HLXB9 had a peripheral to intermediate localisation in 126 nuclei analysed. Although there was a shift 
away of the HLXB9 gene from the periphery in this cell line, this shift was only significant when compared 
to one out of three control cell lines (figure 6.10). There was no significant difference in the localisation of 
HLXB9 in the T47D cell line compared to both HMEC cells analysed. However, there was a significant 
decrease in the proportion of gene signals localised in the nuclear periphery in the T47D cell line 
compared to the MCF 10A cell line (P=0.018), (as shown in table 6.2).  
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T47D (n=126)  
vs 
Proportion of Alleles in the Nuclear 
Periphery 
Proportion of Alleles 
in the Nuclear 
Intermediate 
Proportion of Alleles 




n.s.d  n.s.d  n.s.d  
HMEC 240L 
(n=191) 
n.s.d  n.s.d  n.s.d  
MCF 10A (n=190) Reduction in proportion of HLXB9 gene 
signals in the nuclear periphery (P 
=0.018) 
n.s.d  n.s.d  
Table 6.2: The nuclear localisation of HLXB9 in the T47D cell line compared to the two non-cancer HMEC cells 
and MCF 10A cell line analysed using a one-way ANOVA and Bonferroni post hoc test. There was no significant 
difference (n.s.d) in the localisation of the HLXB9 gene in the nucleus of T47D cell line compared to the HMEC 184D 
and 240L cells. There was a very significant reduction in the proportion of genes localised in the peripheral shell in 
the nucleus (P =0.018) of the T47D cell line compared to the MCF 10A cell line.  
 
HLXB9 had an intermediate nuclear localisation in BT474 cells (Luminal B) cells 
HLXB9 had an intermediate localisation in BT474 nucleus (n=257). In this cell line, there was a significant 
reduction in the proportion of alleles in the nuclear periphery compared to the non-cancer cells analysed. 
There was also a significant increase in the proportion of alleles in the nuclear interior compared to two 
out of the three non-cancer cells analysed (table 6.3). This indicates a change from the normal peripheral 





Proportion of Alleles in the 
Nuclear Periphery 
Proportion of Alleles in 
the Nuclear 
Intermediate 




Reduction in proportion of HLXB9 
gene signals in the nuclear 
periphery (P = 0.03) 





Reduction in proportion of HLXB9 
gene signals in the nuclear 
periphery (P =0.001) 
n.s.d  Increase in proportion of HLXB9 
gene signals in the nuclear interior 
(P < 0.0001) 
MCF 10A 
(n=190) 
Reduction in proportion of HLXB9 
gene signals in the nuclear 
periphery (P < 0.0001) 
n.s.d  Increase in proportion of HLXB9 
gene signals in the nuclear interior 
(P = 0.005) 
Table 6.3: The nuclear localisation of HLXB9 in the BT474 cell line compared to the two non-cancer HMEC 
cells and MCF 10A cell line analysed by a one-way ANOVA and Bonferroni post hoc test. There was a significant 
decrease in the proportion of gene signals observed in the nuclear periphery in the BT474 cell line compared to the 
non-cancer cell lines studied. There was also a significant increase in the proportion of gene signals in the BT474 cell 
line nuclear interior compared to two out of the three non-cancer cells analysed. This indicates a change in the 
localisation of HLXB9 from the nuclear periphery into the nuclear interior in the BT474 cell line.  
 
HLXB9 had an intermediate nuclear localisation in MDA-MB-231 (Basal) cells 
HLXB9 also had an intermediate position in the nucleus of MDA-MB-231 cells (n=272). In this cell line, 
there was a significant reduction in the proportion of HLXB9 alleles in the nuclear periphery in the MDA-
MB-231 cell line when compared to all non-cancer cells studied. There was also an increase in the 
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proportion of gene signals in the nuclear interior compared to HMEC 240L and MCF 10A only. This 
indicates a change from the normal peripheral position of the HLXB9 gene observed in the non-cancer 




Proportion of Alleles in the 
Nuclear Periphery 
Proportion of Alleles in the 
Nuclear Intermediate 
Proportion of Alleles in 
the Nuclear Interior 
HMEC 184D 
(n=189) 
Reduction in proportion of 
HLXB9 gene signals in the 
nuclear periphery (P =0.030) 
n.s.d  n.s.d  
HMEC 240L 
(n=191) 
Reduction in proportion of 
HLXB9 gene signals in the 
nuclear periphery (P =0.009) 
n.s.d  Increase in proportion of 
HLXB9 gene signals in the 
nuclear interior (P =0.007) 
MCF 10A (n=190) Reduction in proportion of 
HLXB9 gene signals in the 
nuclear periphery (P <0.0001) 
n.s.d  Increase in proportion of 
HLXB9 gene signals in the 
nuclear interior (P =0.050) 
Table 6.4: Comparison of the nuclear localisation of HLXB9 in MDA-MB-231 cell line to the two non-cancer 
HMEC cells and MCF 10A cell line analysed by a one-way ANOVA and Bonferroni post hoc test. There was a 
significant decrease in the proportion of gene signals observed in the nuclear periphery in the MDA-MB-231 cell line 
compared to the non-cancer cell lines studied. There was also a significant increase in the proportion of gene signals 
in the MDA-MB-231 cell line nuclear interior compared to HMEC 240L and MCF 10A only. This indicates a change in 
the localisation of HLXB9 from the nuclear periphery into the nuclear interior in the MDA-MB-231 cell line. 
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Figure 6.10: Nuclear localisation of HLXB9 gene in non-cancer breast cells/cell lines and Breast cancer cell lines studied. Controls: HLXB9 has a peripheral position in the control cells used 
HMEC184D, HMEC 240L and MCF 10A. Breast Cancer Cell lines: T47D: HLXB9 has a peripheral-intermediate position in this cell line, BT474 and MDA-MB-231: HLXB9 has an intermediate position in 
these cells. 2D FISH images were analysed by erosion script analysis to determine the nuclear localisation of HLXB9. The histogram displays the average probe intensity (normalised by DAPI staining) 
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VII. The effect of HLXB9 expression on breast cancer patients’ survival 
As HLXB9 potentially acts as a tumour suppressor in breast cancer, the prognostic significance of aberrant 
HLXB9 expression was evaluated in breast cancer patients using online databases: KM plotter and 
BreastMark (Gyorffy et al. 2013; Madden et al. 2013). In both databases, the patient cohort was divided 
into two groups by median gene expression. Patients with lower gene expression than the median were 
classified as showing low gene expression whilst patients with greater gene expression than the median 
were classified as showing high gene expression. A survival curve showing the patients’ outcome over 
time by level of gene expression was generated by the databases (as shown in figure 6.11). The difference 
in patients’ survival between the two groups was assigned a prognostic value (hazard ratio with 95% 
confidence intervals). Hazard ratio less than 1 indicated a positive impact on prognosis whilst hazard 
ratios greater than 1 indicated a negative impact on prognosis. The P value of the hazard ratio was also 
calculated. P values equal or less than 0.05 indicated the hazard ratio observed was statistically 
significant.  
Patients’ outcome were categorised into:  
 overall survival (OS), which is the time from either diagnosis or treatment that patients are alive; 
 relapse free survival (RFS) or disease free survival (DFS), which is the time after primary 
treatment that the patient survives without any sign and symptom of cancer returning in the 
original tumour site;  
 disease free metastatic survival (DFMS) or distant disease free survival (DDFS), which is the time 
after treatment or diagnosis that patients are alive without metastasis to secondary tumour 
site(s) and  
 post progression survival (PPS) which is the time after relapse or metastasis that patients are 
alive.  
Two multi-gene expression tests are now used clinically to determine the probability of disease 
reoccurrence in patients in low-grade tumours without lymph node involvement. (Madden et al. 2013; 
Marrone et al. 2015). These tests are Oncotype DX, a 21-gene panel test (5 control genes and 16 
oncogenes) and MammaPrint a 70-gene panel test. In the UK, Oncotype DX is approved by NICE for 
determining if patients should receive chemotherapy after surgery in ER positive, HER 2 negative, lymph 
node negative and early grade breast tumours (https://www.nice.org.uk/guidance/dg10). MammaPrint 
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is only approved for research purposes in the UK, although it is used in the US in patients under 61 years 
with grade 1or 2 tumours without lymph node involvement (Marrone et al. 2015).   
The 16 oncogenes in the oncotype DX panel is composed of five proliferation genes (KI67, STK15, Survivin, 
CCNB1 and MYBL2), two invasion genes (MMP11 and CTSL2), two HER2 associated genes (GRB7 and 
HER2), ER defining genes (ER, PGR, BCL2 and SCUBE2) and three other genes (GSTM1, CD68, BAG1). The 
expression of these genes are normalised to the control genes and then scored.  Proliferation genes have 
the highest impact on the overall score. In MammaPrint, 16 genes are associated with good prognosis 
whilst 45 genes are associated with poor prognosis (results could only be obtained on 43 out of 45 genes 
in BreastMark).  
Therefore, when HLXB9 has a statistically significant hazard ratio on patients’ survival in both KM plotter 
and BreastMark, the hazard ratio obtained will be compared to the panel of genes utilised in both tests. 
This will help determine if HLXB9 expression has better prognostic significance than some of the genes 
currently used and if it can be added to existing tests to improve their efficacy. 
 
High HLXB9 expression had a deleterious effect on breast cancer patients’ survival (RFS and OS) 
In this section, using both databases, the effect of HLXB9 expression was examined in breast cancer 
patients irrespective of tumour molecular subtype, tumour grade and lymph node involvement (see table 
6.5 and figure 6.11 for hazard ratios, P values and survival curves generated by both databases). 
In both databases, high expression of HLXB9 was found to significantly reduce the probability of overall 
survival (KM plotter: HR=1.52, P=0.0001; BreastMark: HR=1.42, p=5.1E-05). These results indicate breast 
cancer patients with high HLXB9 expression showed reduced survival time compared to patients with low 
HLXB9 expression. High expression of HLXB9 was also found to have a deleterious effect on patients’ 
survival when looking at DFS in both databases (KM plotter: HR=1.41, P=9.1E-07; BreastMark: HR=1.20, 
P=0.0021). These results suggest that high expression of HLXB9 significantly reduced the time breast 
cancer patients survived without relapse in the original site of the tumour. 
In KM plotter, high expression of HLXB9 was also found to significantly reduce breast cancer patient 
DMFS (HR=1.42, P=3.5E-04). However this effect was not significant in BreastMark (HR=1.16; P=0.079). 
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As the BreastMark database had a larger sample size, these results suggest that high expression of HLXB9 
probably has limited prognostic significance on breast cancer patients’ metastasis (DMFS).  
Data on PPS of breast cancer patients was only available in KM plotter. When the survival curve for PPS 
was analysed, overexpression of HLXB9 was deterimental to patient survival, HR: 1.32, P=0.024.  










Disease Free Survival (DFS/RFS) 3951 1.41 9.1E-10 2592 1.20 0.0021 
Distant Metastasis Free Survival (DMFS) 1746 1.42 3.5E-04 2223 1.16 0.079 
Post Progression Survival (PPS) 414 1.32 0.024 N/A N/A N/A 
Overall Survival (OS) 1402 1.52 0.0001 2091 1.42 5.1E-05 
Table 6.5: High HLXB9 expression is a negative prognostic indicator in breast cancer. In both databases, high 
expression of HLXB9 reduces the probability of disease free survival and overall survival. High expression of HLXB9 
significantly reduces the probability of distant disease free survival of patients in KM plotter but not in BreastMark 
(Gyorffy et al. 2013; Madden et al. 2013). Highlighted results have hazard ratios that were statistically significant. 
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Figure 6.11: HLXB9 overexpression is a negative prognostic indicator in breast cancer. Breast cancer survival curves from KM plotter and BreastMark (Gyorffy et al. 2013; 
Madden et al. 2013). In both databases, overexpression of HLXB9 reduces the probability of disease free survival and overall survival. Over expression of HLXB9 also significantly 
reduces the probability of distant metastasis free survival of patients in KM plotter only. This effect on patient survival was not observed in BreastMark as BreastMark analysed a 
larger number of sample for DMFS, high expression of HLXB9 probably has limited impact on DDFS survival of breast patients.
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The impact of HLXB9 expression on patients’ relapse free and overal l  survival 
compared to genes used in Oncotype DX and MammaPrint  
 
The impact of overexpression of HLXB9 on breast cancer patients’ relapse free and overall survival was 
found to be significant in both KM plotter and BreastMark.  Therefore, the hazard ratio obtained was 
compared to the panel of genes used in both the Oncotype DX and MammaPrint gene expression test. 
Oncotype DX 
From KM plotter, HLXB9 had the 5th most significant impact on breast cancer patients relapse free 
survival when compared to the 16 oncogenes used in the Oncotype DX test (performing better than the 
invasion genes MMP11 and CSTL2 in the panel). In BreastMark, HLXB9 ranked 9th in prognostic 
significance when compared to the same gene panel. Genes that had a better hazard ratio than HLXB9 in 
the Oncotype DX panel were genes associated with proliferation (KI67, STK15, Survivin, CCNB1 and 
MYBL2) and genes associated with invasion (MMP11 and CTSL2) as shown in table 6.6. These results 
indicate that HLXB9 has more prognostic significance than approximately half of the genes used in the 
panel.  
Entrez ID Gene 
Symbol 
BreastMark KM plotter 
HR P  (n) HR P  (n) 
3110 HLXB9 1.2 2.1E-03 2592 1.4 9.1E-10 3951 
Oncotype DX gene panel 
4288 KI67 1.4 1.9E-09 2652 1.4 7.2E-09 3951 
6790 STK15 1.5 2.5E-12 2652 1.9 1.0E-16 3951 
332 Survivin 1.6 1.6E-15 2652 1.7 1.0E-16 3951 
891 CCNB1 1.5 2.7E-10 2248 2.1 1.0E-16 1764 
4605 MYBL2 1.5 7.0E-12 2652 1.8 1.0E-16 3951 
4320 MMP11 1.3 1.7E-06 2592 1.2 6.2E-03 3951 
1515 CTSL2  1.5 4.7E-10 2592 1.4 1.8E-09 3951 
2886 GRB7  1.2 1.9E-04 2652 0.9 6.9E-03 3951 
2064 HER2  0.9 2.2E-01 2592 0.9 2.5E-01 1764 
2099 ER 0.9 2.1E-02 2592 0.7 2.7E-14 3951 
5241 PGR 0.7 3.2E-08 2652 0.5 1.2E-15 1764 
596 BCL2  0.8 4.5E-04 2592 0.6 1.0E-16 3951 
57758 SCUBE2 0.7 1.1E-04 1759 0.6 1.0E-16 3951 
2944 GSTM1 0.8 4.2E-03 1753 0.6 2.2E-16 3951 
968 CD68 1.1 3.4E-02 2652 0.8 1.8E-03 3951 
573 BAG1  0.9 3.1E-01 2652 0.8 6.7E-03 1764 
Table 6.6: Overexpression of HLXB9 is a better prognsotic indicator of relapse in breast cancer patients than 
a number of Oncotype DX genes. Results from analysing relapse free survival in KM plotter and BreastMark.  
The impact of HLXB9 overexpression on overall survival was also compared to genes in the Oncotype DX 
gene panel. HLXB9 had the 5th most significant impact on patient overall survival when compared to the 
16 oncogenes in the panel (KM plotter, 8th in BreastMark as shown in table 8.1 in appendix). These finding 
indicates that HLXB9 has more prognostic significance than a number of other genes in the panel. 
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Therefore HLXB9 overexpression is a better indicator of disease progression and outcome in breast 
cancer patients than those genes. 
MammaPrint 
As expected, genes associated with good prognosis had a hazard ratio of less than or equal to 1 whilst 
most genes associated with a poor prognosis had a hazard ratio greater than 1 when their impact on 
breast cancer patients’ RFS was compared in both KM plotter and BreastMark. When HLXB9 was added to 
the 43 genes associated with a poor prognosis, overexpression of HLXB9 was the 17th most significant 
indicator of poor prognosis in KM plotter (25th in BreastMark, as shown in Table 6.7).  
Entrez ID Gene 
Symbol 
BreastMark KM plotter 
HR P  (n) HR P  (n) 
3110 HLXB9 1.2 2.1E-03 2592 1.4 9.1E-10 3951 
Genes associated with good prognosis in MammaPrint 
8659 ALDH4 1.03 6.0E-01 2497 1 9.9E-01 3951 
8817 FGF18 0.93 2.6E-01 2652 0.64 1.8E-08 1764 
27113 BBC3 0.97 6.0E-01 2297 0.79 2.6E-05 3951 
57593 KIAA1442 0.70 6.5E-02 157 0.57 2.4E-12 3951 
57758 CEGP1 0.75 1.1E-04 1759 0.59 1.0E-16 3951 
146923 RUNDC1 0.76 3.3E-04 1238 0.51 1.0E-16 1764 
8840 WISP1 0.93 2.4E-01 2643 0.73 6.0E-05 1764 
2947 GSTM3 0.85 7.4E-03 2652 0.81 7.3E-03 1764 
151126 ZNF533 0.84 2.7E-02 1229 0.58 9.0E-12 1764 
146760 RTN4RL1 0.91 2.7E-01 1023 0.72 3.4E-05 3951 
10455 PECI 0.85 9.3E-03 2421 0.87 1.5E-02 3951 
7043 TGFB3  0.87 2.0E-02 2592 0.69 1.5E-11 3951 
55351 HSA250839 0.78 8.8E-05 2516 0.7 6.9E-11 3951 
58475 CFFM4 0.74 5.6E-05 1473 0.68 8.7E-07 1764 
163 AP2B1 0.99 9.1E-01 2592 0.73 1.8E-08 3951 
79132 LGP2 0.92 2.2E-01 2281 0.83 1.0E-03 3951 
Genes associated with poor prognosis in MammaPrint 
55321 C20orf46 1.11 8.0E-02 2576 0.86 5.2E-03 3951 
11082 ESM1 1.30 1.3E-05 2544 1.16 8.4E-03 3951 
9134 CCNE2 1.50 1.4E-10 2357 1.86 1.0E-16 3951 
54583 EGLN1 1.29 5.1E-05 2272 1.28 1.7E-03 1764 
1058 CENPA 1.54 6.6E-13 2652 1.7 1.0E-16 3951 
9055 PRC1 1.61 4.1E-15 2576 2 1.0E-16 3951 
445815 AKAP2  0.95 4.4E-01 1899 0.86 8.8E-03 3951 
10874 NMU 1.52 1.9E-12 2652 1.64 1.0E-16 3951 
3488 IGFBP5 1.13 4.8E-02 2592 1.1 2.2E-01 1764 
10531 MP1 1.10 1.9E-01 2004 1.32 5.1E-04 1764 
57110 LOC57110 1.36 5.2E-07 2516 1.54 8.2E-15 3951 
8577 TMEFF1 1.16 1.6E-02 2437 1.15 1.1E-02 3951 
4175 MCM6 1.56 8.8E-14 2652 1.36 9.8E-05 1764 
643008 LOC643008 NA NA  NA 1.02 8.0E-01 3951 
83879 CDCA7 1.26 3.2E-03 1238 1.57 1.0E-08 3951 
5984 RFC4 1.47 1.4E-10 2652 1.72 1.0E-16 3951 
23594 ORC6L 1.54 6.3E-13 2576 1.62 1.0E-16 3951 




1.09 1.8E-01 2297 
1.32 5.7E-07 3951 
79791 FBXO31 1.06 3.4E-01 2576 1.13 1.2E-01 1764 
1633 DCK 1.23 7.8E-04 2592 1.39 2.5E-09 3951 
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51514 L2DTL 1.54 1.4E-12 2516 1.82 6.6E-14 1764 
1284 COL4A2 1.16 2.0E-02 2297 1.15 1.3E-02 3951 
9833 KIAA0175 1.69 0.0E+00 2652 1.87 1.0E-16 3951 
92140 MTDH 1.26 1.1E-04 2592 1.32 3.9E-04 1764 
51377 UCH37 1.15 2.1E-02 2576 1.41 1.5E-05 1764 
51560 RAB6B 1.40 7.4E-08 2516 0.89 1.4E-01 1764 
160897 GPR180 1.24 9.1E-03 1127 0.89 1.6E-01 1764 
79888 FLJ12443 1.32 1.4E-05 2297 1.3 2.0E-06 3951 
8293 SERF1A 1.16 4.2E-01 169 0.71 8.8E-10 3951 
8476 PK428 1.10 1.2E-01 2652 1.2 9.9E-04 3951 
10403 HEC 1.30 1.1E-05 2652 1.92 1.0E-16 3951 
8833 GMPS 1.44 6.0E-09 2543 1.9 1.0E-16 3951 
1894 ECT2 1.39 3.8E-08 2576 1.23 9.7E-03 1764 
4318 MMP9 1.18 4.9E-03 2652 1.16 6.5E-03 3951 
5019 OXCT 1.08 1.9E-01 2652 1.12 3.7E-02 3951 
2781 GNAZ 1.14 3.4E-02 2592 0.91 7.5E-02 3951 
2321 FLT1 1.02 8.4E-01 1721 0.94 4.0E-01 1764 
2131 EXT1 1.13 3.9E-02 2652 1.05 4.3E-01 3951 
56942 DC13 1.53 1.2E-12 2576 1.84 1.0E-16 3951 
81624 DIAPH3 1.52 4.3E-10 2223 1.8 1.4E-13 1764 
169714 QSOX2 1.18 3.8E-02 1130 0.87 6.8E-02 1764 
286052 LOC286052 NA NA  NA 1.04 6.5E-01 3951 
51203 LOC51203 1.58 4.0E-14 2576 1.92 1.0E-16 3951 
85453 TSPYL5 1.01 8.2E-01 2288 1.12 1.0E-16 3951 
Table 6.7: Overexpression of HLXB9 is a better prognostic indicator of relapse in breast cancer patients than 
a number of MammaPrint genes. Results from analysing overall survival in KM plotter and BreastMark.  
 
The impact of HLXB9 overexpression on patients overall survival was also compared to genes in the 
MammaPrint gene panel. HLXB9 was the 14th most significant indicator of poor prognosis in KM plotter, 
23rd in Breast Mark (as shown in table 8.2 in appendix). These finding indicates that HLXB9 has more 
prognostic significance than a number of the other genes in the panel and would be a better indicator of 
disease progression and overall survival in breast cancer patients. 
In summary, these results indicate that high expression of HLXB9 was detrimental to breast cancer 
patients’ outcome especially in terms of relapse in the original origin of breast tumour and overall 
survival. The results obtained was contrary to expectations as results from experiments on breast cancer 
cell lines suggested HLXB9 functions as a tumour suppressor in breast cancer. Therefore, it was expected 
that high HLXB9 expression would have a favourable impact on breast cancer patients’ outcome. In 
comparison to genes from well-established multi gene expression panels Oncotype DX and MammaPrint, 
high expression of HLXB9 was a better indicator of poor prognosis (relapse and overall survival) than a 
number of the genes currently utilised. Therefore HLXB9 could be added to the tests to improve their 
efficacy.  
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The effect of HLXB9 expression on breast cancer patients’ survival was then analysed by well-known 
prognostic factors in breast cancer such as tumour grade, lymph node status and tumour intrinsic 
subtype.  
a) HLXB9 expression on breast cancer patients’ survival by tumour grade 
Histological tumour grade is also used as a prognostic marker in the treatment of breast tumours. It is a 
measure of tumour aggressiveness. There are three grades of breast tumours. Lower grade tumours are 
usually associated with better prognosis than higher grade tumours (Rakha et al. 2010; Weigelt et al. 
2010). In this section, patients’ survival was stratified by tumour grade in order to determine if HLXB9 
expression has a prognostic significance as tumour phenotype becomes more aggressive. 
Overexpression of HLXB9 had a negative prognostic significance on relapse free survival in patients 
diagnosed with grade 2 tumours 
HLXB9 expression had no effect on patient’s outcome when patients’ survival was stratified by tumour 
grade for grade 1 tumours in both databases. However, high expression of HLXB9 had prognostic 
significance in patients diagnosed with grade 2 tumours. Grade 2 breast tumours are usually associated 
with an intermediate reoccurrence risk but have been shown to include patients with both low and high 
risk of reoccurrence by gene expression profiling (Sotiriou et al. 2006). In KM plotter, high expression of 
HLXB9 reduced the probability of RFS in patients diagnosed with grade 2 tumours in both BreastMark and 
KM plotter HR: 1.61, P=0.001 and HR: 1.31, P=0.029 respectively. The DMFS in patients diagnosed with 
grade 2 breast tumours was also reduced by HLXB9 overexpression in BreastMark only (HR: 1.52, 
P=0.019). In BreastMark, high expression of HLXB9 also had a detrimental effect on the probability of 
overall survival of patients (HR: 1.67, P=0.01). Additionally in BreastMark only, overexpression of HLXB9 
was a negative prognostic indicator on RFS and DMFS in patients diagnosed with grade 3 tumours (HR: 
1.27, P=0.031 and HR: 1.52, P=0.019). 
The results obtained showed that high expression of HLXB9 has negative prognostic significance in 








Patients’ Outcome KM plotter BreastMark 
n Hazard 
Ratio 
P value n Hazard 
Ratio 
P value 
Grade 1 Relapse Free Survival 345 1.09 0.75 202 0.47 0.0973 
Distant Metastasis Free Survival 188 0.67 0.34 234 0.57 0.1964 
Post Progression Survival 34 0.73 0.53 N/A N/A N/A 
Overall Survival 161 0.65 0.37 164 0.74 0.6463 
Grade 2 Relapse Free Survival 901 1.31 0.029 577 1.61 0.00102 
Distant Metastasis Free Survival 546 1.55 0.014 811 1.29 0.06103 
Post Progression Survival 128 0.88 0.61 N/A N/A N/A 
Overall Survival 387 1.2 0.39 440 1.67 0.01273 
Grade 3 Relapse Free Survival 903 1.27 0.031 526 1.19 0.2325 
Distant Metastasis Free Survival 458 1.52 0.019 701 0.98 0.8606 
Post Progression Survival 165 1.33 0.14 N/A N/A N/A 
Overall Survival 503 1.36 0.066 352 1.177 0.3946 
Table 6.8: Overexpression of HLXB9 reduces the survival of breast cancer patients diagnosed with grade 2 
tumours. High expression of HLXB9 reduces the probability of the relapse free survival in patients diagnosed with 
grade 2 tumours (KM plotter), relapse free survival and overall survival (BreastMark) (Gyorffy et al. 2013; Madden et 
al. 2013). Highlighted results have hazard ratios that were statistically significant. 
 
The prognostic significance of HLXB9 overexpression on relapse (RFS) in patients diagnosed with grade 
two tumours was also compared to genes used in Oncotype DX and MammaPrint gene tests. HLXB9 was 
the 4th most significant indicator of poor prognosis in Oncotype DX (BreastMark, 7th in KM plotter as 
shown in table 8.3 in appendix). HLXB9 overexpression was a better indicator of poor prognosis than 
genes associated with invasion in the Oncotype DX from both databases. When compared to genes that 
indicate poor prognosis in MammaPrint, overexpression of HLXB9 was the 12th most significant indicator 
of poor prognosis (BreastMark, 22nd in KM plotter table 8.4 in appendix). 
 
b) HLXB9 expression on breast cancer patients’ survival by lymph node status 
Lymph node status, which is when tumour cells have spread from the breast into the lymph nodes, is also 
used as a prognostic marker. The presence of cancer cells in the lymph node is usually associated with a 
poor prognosis as it indicates the tumour has spread and there is a potential of metastasis to other 
organs. In this section, patients’ outcomes are stratified by lymph node involvement to determine if 
HLXB9 expression has a prognostic significant by lymph node status.  
HLXB9 overexpression reduced relapse free survival in lymph node positive patients 
High expression of HLXB9 reduced the probability of RFS in lymph node positive patients in both KM 
plotter (HR: 1.49, P=8.1E-05) and BreastMark (HR: 1.36, P=0.008). This indicates lymph node positive 
patients with high expression of HLXB9 are more likely to relapse in the original site of the breast tumour 
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than patients with low expression of HLXB9. Overexpression of HLXB9 was also found to be detrimental 
to patients with positive lymph nodes overall survival in KM plotter only (HR: 1.61, P=0.017). 
In KM plotter, overexpression of HLXB9 was unfavourable to relapse free survival (HR: 1.35, P=0.0005) 
and distant metastatic free survival (HR: 1.40, P=0.016) in lymph node negative patients. In BreastMark, 
the negative correlation of high expression of HLXB9 to patients’ survival seems to continue in terms of 
relapse free survival (HR: 1.21, P=0.076). However, this correlation was not statistically significant 















Relapse Free Survival 2020 1.35 0.00047 1155 1.213 0.07577 
Distant Metastasis Free Survival 988 1.40 0.016 900 1.089 0.5687 
Post Progression Survival 165 1.22 0.37 N/A N/A N/A 




Relapse Free Survival 1133 1.49 8.1E-05 719 1.356 0.0083 
Distant Metastasis Free Survival 382 1.27 0.22 749 1.047 0.7172 
Post Progression Survival 128 1.48 0.083 N/A N/A N/A 
Overall Survival 313 1.61 0.017 473 1.314 0.0676 
Table 6.9: High expression of HLXB9 reduced the relapse free survival of breast cancer patients with lymph node 
involvement. High expression of HLXB9 may also reduce on the relapse free survival and distant metastatic free 
survival of lymph node negative patients* (*KM Plotter only) (Gyorffy et al. 2013; Madden et al. 2013). Highlighted 
results have hazard ratios that were statistically significant. 
 
The prognostic significance of HLXB9 overexpression in lymph node positive patients was compared to 
genes used in both the Oncotype DX and MammaPrint gene tests. HLXB9 was the 6th most significant 
indicator of poor prognosis when compared to genes used in Oncotype DX (KM plotter, 8th in BreastMark, 
as shown in table 8.5 in appendix). When compared to genes that indicate poor prognosis in 
MammaPrint, HLXB9 was the 17th most significant indicator of prognosis (KM plotter, 19th in BreastMark, 
table 8.6 in appendix). 
Currently, both Oncotype DX and MammaPrint are used to determine prognosis in patients diagnosed 
with ER positive, lymph node negative tumours. Therefore, HLXB9 expression as a prognostic indicator 
was compared to genes used in both test in patients diagnosed with ER positive, lymph node negative 
tumours. In comparison to genes used in the Oncotype DX test, overexpression of HLXB9 was the 7th most 
significant indicator of poor prognosis (KM plotter, 8th in BreastMark, table 8.7 in appendix). In 
comparison to genes used in the MammaPrint test, HLXB9 ranked 22nd compared to the 43 genes that 
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indicate poor prognosis (KM plotter only). HLXB9 had no significant impact in BreastMark. However, this 
might be due to KM plotter having a larger same size (n=1256) than BreastMark (n=875). 
 
c) HLXB9 expression on breast cancer patients’ prognosis by tumour intrinsic subtypes 
Tumour intrinsic (molecular) subtypes are used as prognostic indicators and to inform treatment 
decisions in breast cancer. Patients’ outcomes were analysed by tumour intrinsic subtypes to determine if 
HLXB9 expression has a prognostic significance on particular tumour intrinsic subtypes (refer to table 
6.10 for hazard ratios and P values, and the appendix A1-A4 for survival curves). 
Overexpression of HLXB9 had a deleterious effect on the survival of patients diagnosed with luminal 
A molecular subtype breast tumours  
In both databases, overexpression of HLXB9 reduced the probability of RFS in patients diagnosed with 
luminal A tumours (KM plotter: HR=1.23, P=0.02; BreastMark: HR=1.24, P=0.04). In BreastMark only, 
overexpression of HLXB9 also reduced the probability of DDFS (HR=1.46, P=0.03) and OS (HR=1.43, 
P=0.030). These results imply that HLXB9 overexpression has a negative prognostic significance in 
patients diagnosed with luminal A subtype breast tumours particularly on RFS of these patients (as 
shown in figure A1 in appendix and table 6.10).  
The prognostic significance of HLXB9 overexpression in patients diagnosed with luminal A tumours was 
compared to genes used in both the Oncotype DX and MammaPrint gene tests. HLXB9 was the 7th most 
significant indicator of poor prognosis when compared with genes used in Oncotype DX (KM plotter, 8th in 
BreastMark, as shown in table 8.9 in appendix). When compared to genes that indicate poor prognosis in 
MammaPrint, HLXB9 was the 17th most significant indicator of prognosis (BreastMark, 21th in KM plotter, 
table 8.10 in appendix). 
Although the negative prognostic significance of overexpression of HLXB9 expression on patient survival 
was observed in the survival curves of patients diagnosed with luminal B subtype tumours, this 
observation did not reach statistical significance (as shown in figure A2 in appendix and table 6.10). 
In addition to this, the trend of negative prognostic significance of HLXB9 overexpression on survival of 
patients diagnosed with basal tumours was observed in the survival curves for RFS, DMFS, OS and PPS in 
both databases (as shown in figure A3 in appendix and table 6.10). However, the aforementioned trend 
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only reached statistical significance in the analysis of DFS, DMFS and OS in KM plotter (HR: 1:34, p=0.02, 
HR: 1.7, p=0.04 and HR: 1:85, p=0.02 respectively). 
Additionally, the trend of negative prognostic significance of high HLXB9 expression on survival of 
patients diagnosed with HER2 tumours was observed in the survival curves for RFS, DMFS and PPS in 
both databases (as shown in figure A4 in appendix and table 6.6). However, this trend did not reach 
statistical significance except in the analysis of OS in BreastMark. In this database, overexpression of 
HLXB9 significantly reduced the probability of overall survival in breast cancer patients diagnosed with 
HER2 amplified tumours (HR=1.65, p=0.04). 
When considering the effect of HLXB9 expression on patients’ survival by tumour intrinsic subtypes, it is 
worth noting that survival curves for all tumour intrinsic subtypes show a trend of negative correlation of 
HLXB9 overexpression to patient survival (figure A1, A2, A3 and A4 in appendix). However, this trend was 
probably not statistically significant due to the small numbers of samples obtained due to categorising 
patients by tumour intrinsic subtypes. This is supported by the results obtained for patients diagnosed 
with luminal A tumours, analyses on these patients reached statistical significance as this tumour subtype 
had the largest sample size (as shown in table 6.10). 
 In conclusion, overexpression of HLXB9 was found to reduce the probability of RFS in breast cancer 
patients diagnosed with luminal A tumours. Additionally, the possibility that HLXB9 overexpression was 




Patients’ Outcome KM plotter BreastMark 
n Number Hazard 
Ratio 
P value n Number Hazard 
Ratio 
P value 
Luminal A Relapse Free Survival 1933 1.23 0.017 1035 1.24 0.04041 
Distant Metastasis Free Survival 965 1.27 0.099 723 1.46 0.03176 
Post Progression Survival 179 0.9 0.58 N/A N/A N/A 
Overall Survival 611 1.18 0.34 812 1.43 0.02976 
Luminal B Relapse Free Survival 1149 1.22 0.044 617 1.21 0.08502 
Distant Metastasis Free Survival 430 1.21 0.28 904 0.91 0.4404 
Post Progression Survival 134 1.05 0.83 N/A N/A N/A 
Overall Survival 433 1.20 0.33 659 1.23 0.1468 
Basal Relapse Free Survival 618 1.34 0.022 394 0.90 0.5033 
Distant Metastasis Free Survival 232 1.7 0.043 341 1.15 0.4924 
Post Progression Survival 64 1.76 0.062 N/A N/A N/A 
Overall Survival 241 1.85 0.016 273 0.96 0.8488 
Her2 
amplified 
Relapse Free Survival 251 1.03 0.89 325 1.20 0.2512 
Distant Metastasis Free Survival 119 1.66 0.11 128 1.45 0.2517 
Post Progression Survival 37 1.37 0.53 N/A N/A N/A 
Overall Survival 117 1.37 0.34 200 1.65 0.04325 
Table 6.10: Overexpression of HLXB9 reduces the relapse free survival of patients diagnosed with luminal A 
molecular subtype tumours. High expression of HLXB9 reduces the probability of relapse free survival; distant 
- 155 - 
 
metastasis free survival and overall survival on breast cancer patients with diagnosed with luminal A tumours. It also 
reduces the probability of distance metastasis free survival in basal tumours** and overall survival of HER2 amplified 
tumours*. *BreastMark only, **KM plotter (Gyorffy et al. 2013; Madden et al. 2013). Highlighted results have hazard 
ratios that were statistically significant. 
 
In summary, HLXB9 overexpression was found to be detrimental to breast cancer patient’s survival. 
HLXB9 overexpression was also found to be a poor prognostic indicator on survival in breast cancer 
patients diagnosed with either luminal A, lymph node positive or grade2 tumours.  
In comparison to genes from well-established multi gene expression panel tests Oncotype DX and 
MammaPrint, high expression of HLXB9 was a better indicator of poor prognosis (relapse free survival) 
than a number of the genes currently utilised in patients diagnosed with luminal A, lymph node positive 
or grade 2 tumours. Therefore HLXB9 could be added to the tests to improve their efficacy. 
 
6.5. Discussion 
HLXB9 was downregulated in breast cancer cell lines 
HLXB9 expression was found in all control non-cancer cells and breast cancer cell lines analysed by RT-
PCR and qRT-PCR.  This result was not surprising as other homeobox genes have been found to be 
expressed and are known to play various roles in breast development (Chen & Sukumar 2003). The breast 
is also subject to many growth changes in a woman’s lifetime therefore dysregulation of these homeobox 
genes have unsurprisingly been implicated in breast cancer development and progression (Chen & 
Sukumar 2003; Yamamoto et al. 2011; Tommasi et al. 2009; Lian et al. 2012).  
As HLXB9 is expressed by normal breast, changes to its expression might be detrimental in breast cancer. 
To investigate this hypothesis, HLXB9 expression was compared in non-cancer breast cell and breast 
cancer cell lines by qRT-PCR. HLXB9 expression was found in variable levels in the two non-cancer 
primary human mammary epithelial cells (HMEC) sampled (see figure 6. 5). The level of expression of 
HLXB9 was also found to be potentially associated with proliferation in HMEC 184D suggesting that 
HLXB9 plays a tumour suppressive role in breast proliferation.  
The expression of HLXB9 in the non-tumorigenic cell line MCF 10A and its tumorigenic derivatives: MCF 
10A-TK1 and MCF 10A-Ca1h was also investigated. HLXB9 expression decreased as the cells became more 
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tumorigenic, which further suggests HLXB9 acts as a tumour suppressor in non-cancer breast cells. This 
hypothesis is supported by other studies that found HLXB9 was hypermethylated in breast cancer samples 
compared to normal breast samples (Yamamoto et al. 2011; Tommasi et al. 2009; Lian et al. 2012;). In 
addition, two studies into transcription factors activity in breast cancer by Siletz and colleagues found 
downregulation of HLXB9 contributes to breast cancer progression (Siletz et al. 2013; Siletz et al. 2013). In 
their first study on Epithelial-Mesenchymal Transition (EMT) in breast cancer, they found HLXB9 was 
downregulated in all the models of EMT they studied (Siletz et al.2013). EMT is a process which facilitates 
cancer progression as breast epithelial cells take on more mesenchymal cell characteristics such as loss of 
polarity and cell to cell adhesion enabling breast cancer cells migration and invasion. In their other study 
on breast carcinoma associated fibroblasts (CAF) pro-oncogenic cells that promote proliferation, invasion 
and angiogenesis, they found compared to normal healthy breast stroma, their model of CAF showed 
downregulation of HLXB9 compared to normal breast fibroblast (Siletz et al.2013).  
Seven breast cancer cell lines were initially screened for HLXB9 expression using RT-PCR, and all seven 
cell lines expressed HLXB9. Subsequently, qRT-PCR was carried out on three breast cancer cell lines: T47D 
(luminal A), BT474 (luminal B), and MDA-MB-231 (Basal). There was a decrease in expression of HLXB9 in 
all three breast cancer cell lines analysed compared to the two of the three non-cancer cell/cell lines 
analysed (HMEC 184D and MCF 10A). This suggests that HLXB9 expression was downregulated in breast 
cancer and that HLXB9 functions as a tumour suppressor in breast cancer. 
All breast cancer cell lines investigated also showed expression of the anti-sense non-coding RNA, HLXB9-
AS2. The function of this anti-sense mRNA has not been identified, however, anti-sense RNA has been 
implicated in many biological processes, which include DNA methylation, gene inactivation, splicing, RNA 
stability (Pelechano and Steinmetz 2013). This presence of HLXB9-AS2 RNA might explain the 
downregulation of HLXB9 observed in the breast cancer cell lines investigated. 
Although differential levels of gene expression is useful and is a characteristic of cancers, differential 
mRNA expression does not always correlate to differential protein levels of the genes, therefore HLXB9 
protein expression was analysed. HLXB9 protein expression in the breast cancer cell lines was analysed by 
indirect immunofluorescence (IF). HLXB9 was found to be downregulated in the breast cancer cell lines 
analysed compared to the MCF 10A cell line (control non-tumorigenic cell line). This finding was in line 
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with a previous study by Neufing et al. 2003 who found a decrease in the intensity of HLXB9 nuclei 
staining in tumour cells compared to matched control cells (Neufing et al. 2003). In addition, breast cancer 
cell lines showed nuclear protein aggregates of HLXB9 suggesting a functional role for HLXB9 in these 
cells. The nuclear protein aggregates observed in this cell line was similar to the protein aggregates of 
phosphorylated HLXB9 observed in insulinomas (Desai et al. 2015). In insulinomas, phosphorylated 
HLXB9 has an anti-apoptotic function, which contributes to cancer development and progression. 
There was a direct correlation in the level of HLXB9 mRNA expression and HLXB9 protein expression in 
two of the cell lines investigated (MCF 10A and BT474). In these cell lines, the MCF 10A cell line had the 
highest amount of mRNA expression, which corresponded to high protein expression. The BT474 cell line 
had the least amount of HLXB9 mRNA and protein expression. However, the T47D and MDA-MB-231 cell 
lines had similar levels of HLXB9 mRNA but different levels of protein expression with the T47D cell lines 
showing considerably more HLXB9 protein than the MDA-MB-231 cell line. This finding further indicates 
the possibility of an interaction between HLXB9 and estrogen in this cell line. 
In summary, both non-cancer breast cells and the breast cancer cell lines analysed express HLXB9. Some 
of the cell lines also expressed the anti-sense non-coding RNA. These results indicate a biological function 
for this gene in breast cell, which is dysregulated in cancer. As there seem to be variability in the 
expression of HLXB9 between healthy individuals, a better approach might be to compare the level of 
expression of HLXB9 between matched non-cancer and tumour sample in breast cancer patients. The 
expression of HLXB9 in patient’s samples could then be characterised to evaluate the link between 
expression and patient prognosis. Downregulation of HLXB9 was also found in the breast cancer cell lines 
analysed, suggesting a loss of the role of HLXB9 as a tumour suppressor in breast cancer. 
 
Nuclear localisation of HLXB9 in breast cancer 
The nuclear localisation of HLXB9 in non-cancer cells: HMEC 184D, HMEC 240L, MCF 10A cell line, and 
breast cancer cell lines: T47D, BT474 and MDA-MB-231 was analysed using a 2D FISH assay. In order to 
increase the reliability of our observations, no fewer than 120 nuclei were analysed per sample. 
The non-cancer HMEC cells and the MCF 10A cell line had two copies of the HLXB9 gene localised in the 
nuclear periphery in these cells. There was no significant difference in the localisation of HLXB9 between 
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these cells suggesting a conservation of gene positioning between healthy individuals. These results were 
in line with results from other studies that found no difference in gene positioning in healthy tissue of 
various individuals (Wiech et al. 2005; Meaburn et al. 2009). 
The T47D cell line (luminal A) had two copies of the HLXB9 gene; HLXB9 had a peripheral intermediate 
positioning in these cells. There was a reduction of gene signals found in the nuclear periphery in the cell 
line compared to the controls; however, this difference was significant compared to the MCF 10A cell line 
only. These results sugget a small population of T47D cells show an altered nuclear localisation of HLXB9 
compared to non-cancer cells. 
 The BT474 cell line (luminal B) had five to seven copies of the HLXB9 gene. The HLXB9 gene had an 
intermediate positioning in this cell line. Compared to the non-cancer cells analysed, there was a 
significant decrease in the proportion of gene signals in the nuclear periphery with a concomitant increase 
in proportion of gene signals in the nuclear interior (HMEC 240L and MCF 10A only). These results 
indicate a change in the nuclear localisation of HLXB9 from the nuclear periphery to the nuclear interior in 
this cell line. 
The MDA-MB-231 cell line (basal) showed variability in the number of HLXB9 alleles with two to five 
alleles observed. This variability in the number of alleles found is not unusual for this cell line as a study 
by Watson and colleagues identified three different strains of the MDA-MB-231 cell line grown in culture 
by their differing karyotype (Watson et al. 2004). HLXB9 had an intermediate nuclear positioning in this 
cell line. Compared to the non-cancer cells, there was a decrease in the proportion of gene signal in the 
nuclear periphery in this cell line compared to the three non-cancer cells and an increase in the 
proportion of gene signal in the nuclear interior compared to HMEC 240L and MCF 10A only. These results 
also indicate a change in the nuclear localisation of HLXB9 from the nuclear periphery to the nuclear 
interior in this cell line. 
As a proportion of the MDA-MB-231 cell nuclei had two alleles, this cell line is an ideal model to 
determine if a change in the number of alleles from the two copies affects the position of the HLXB9 gene. 
Unfortunately only seventeen nuclei with two copies of HLXB9 were present in our experiment and 
therefore was not a significantly representative sample size for further analysis. 
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In summary, these results showed a change in the nuclear localisation of HLXB9 in the two of the three 
breast cancer cell lines investigated. A previous study by Meaburn and colleagues showed a disease 
specific nuclear reorganisation in breast cancer (Meaburn et al. 2009; Meaburn & Misteli 2008). Disease 
specific nuclear reorganisation of genes has also been shown in prostate cancer (Leshner et al. 2016). 
However, the possibility the observed change in nuclear localisation of HLXB9 in the BT474 and MDA-MB-
231 cell lines being a result of additional copies of HLXB9 could not be ruled out in this study. 
  
HLXB9 nuclear localisation and its expression  
HLXB9 expression has been shown to be affected by its nuclear localisation. For instance, HLXB9 
expression has been linked to its expression during neuronal cell differentiation and in leukaemia patients 
(Ballabio et al. 2009, Leotta et al. 2014). Consequently, the nuclear localisation of HLXB9 was analysed in 
breast cancer to determine if a change in localisation was associated with gene expression. In the control 
cells, HLXB9 was localised in the nuclear periphery and this localisation was associated with active gene 
transcription (see figures 4 and 11). This finding indicates a breast specific method of regulating HLXB9 
expression in breast cells as previous studies had only shown the silencing of HLXB9 occurring at the 
nuclear periphery (Ballabio et al. 2009, Leotta et al. 2014). Although, there was a variation in levels of 
HLXB9 expression between our controls samples, there was no significant difference in the localisation of 
HLXB9 between these samples. This suggests a conserved localisation of HLXB9 in healthy individuals. 
This result also indicates the nuclear localisation of HLXB9 cannot be solely responsible for its regulation.  
In the breast cancer cell lines changes in the nuclear localisation of HLXB9 could not be linked to its 
expression. This suggests HLXB9 expression in breast cells is regulated by other mechanisms and is not 
dependent on nuclear positioning.  
 
Overexpression of HLXB9 is a negative prognostic indicator of breast cancer patient’s survival 
HLXB9 overexpression was found to have a detrimental impact on breast cancer patients’ overall survival 
and relapse free survival. These findings suggest that high HLXB9 expression could be useful in stratifying 
patients for treatment at diagnosis. Stratifying patients in this manner is likely to be beneficial to patients 
as one of the main aims of breast cancer research is identifying characteristics that could be used to judge 
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patients’ treatment options i.e. to prevent over treatment of patients leading to unwanted side effects or 
under treatment of patients leading to relapse and metastasis.  
Additionally, in comparison to genes from well-established multi gene expression panels Oncotype DX and 
MammaPrint, high expression of HLXB9, was a better indicator of poor prognosis (relapse and overall 
survival) than a number of the genes currently utilised. Therefore, HLXB9 could be added to the tests to 
improve their efficacy. 
Patient outcome was analysed by tumour grade to determine when HLXB9 expression has a prognostic 
significance during tumour progression. High expression of HLXB9 in patients with grade 2 tumours 
reduced the patients’ disease free survival. This is important as grade 2 tumours are characterised by 
cancer cells that are aggressive, and if left unchecked, these cells can proceed to grade 3 tumours. 
High expression of HLXB9 in lymph node positive patients (results from both databases) showed that high 
expression of HLXB9 had an adverse effect on relapse free survival indicating patients with high 
expression of HLXB9 are likely to relapse in the original site of the breast tumour. 
Patients’ outcome was also analysed by tumour intrinsic subtype to determine if HLXB9 expression had a 
prognostic significance dependant on tumour subtype. High expression of HLXB9 in patients diagnosed 
with luminal A subtype had a detrimental effect on relapse free survival in both databases. In BreastMark, 
this unfavourable effect also extends to distant disease free survival and overall survival in luminal A 
tumours. This finding suggests that high expression of HLXB9 might have an effect on estrogen receptors, 
a well known mediator of breast cancer growth. This result was not surprising as HLXB9 has been shown 
to interact with menin (MEN 1), a known binding partner of estrogen receptors in insulinomas (Shi et al. 
2013). However, HLXB9 must also interact with other proteins to mediate breast cancer as evidenced by 
its negative prognostic significance in basal and HER2 amplified breast tumours. High expression of 
HLXB9 had negative effect of distant metastasis free survival of patients diagnosed with basal tumours 
(KM plotter only) and overall survival of patients diagnosed with HER2 amplified tumours. Although a 
negative correlation was observed between high expression of HLXB9 and prognosis (as shown in the 
survival curve) in the other tumour intrinsic subtypes, the trend did not reach statistical significance 
probably due to low sample numbers.  
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Additionally, in comparison to genes from well-established multi gene expression panel tests Oncotype 
DX and MammaPrint, high expression of HLXB9, was a better indicator of poor prognosis (relapse free 
survival) than a number of the genes currently utilised in patients diagnosed with luminal A, lymph node 
positive or grade 2 tumours. Therefore, HLXB9 could be added to the tests to improve their efficacy. 
As downregulation of HLXB9 was observed in the breast cancer cell lines analysed, it was expected that 
high expression of HLXB9 would have a favourable impact on breast cancer patient’s prognosis. However, 
the results obtained suggest that high expression of HLXB9 was detrimental to patients’ survival. In 
previous research by Shi and colleagues, overexpression of HLXB9 in insulinomas was shown to inhibit 
the normal apoptotic function of HLXB9 in pancreatic b-cells (Shi et al. 2013; Desai et al. 2014; Desai et al. 
2015). This suggests that high expression of HLXB9 in breast cancer patients might have an anti-apoptotic 
function, which might be responsible for the poor prognosis observed in patients with high expression of 
HLXB9. It is also worth noting the expression of the anti-sense mRNA HLXB9-AS2 observed in breast 
cancer cell lines was not observed in primary mammary epithelial cells HMEC 184D and 240L. The HLXB9-
AS2 mRNA might be responsible for the down regulation of HLXB9 expression observed in breast cancer 
cell lines. Therefore, it is worth investigating the prognostic significance of HLXB9-AS2 gene expression on 
breast cancer patients’ outcome.  
Analysing the effect of mRNA expression on patient survival retroactively is a widely used approach in 
identifying candidate biomarkers as differential genes expression can be analysed in a large number of 
patients’ samples. Although this method of identifying biomarkers shows promising results for HLXB9, it is 
worth noting there are limitations to the methodology. These limitations include the possibility of the 
introduction of artefacts due to different laboratory protocols. Additionally, the use of median gene 
expression as a filter to differentiate expression might result in the concealment of significant populations 
with outlier expression values. From this study, HLXB9 overexpression was found to be deleterious to 
patients’ outcome suggesting HLXB9 overexpression is worth further investigation in the laboratory.  
6.6. Conclusion 
 
In this study, HLXB9 overexpression was shown to have a detrimental effect on breast cancer patients’ 
outcomes. Additionally, HLXB9 overexpression was a better prognostic indicator than a number of genes 
currently utilised in the Oncotype DX and MammaPrint gene expression test and could be added to them 
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improve their efficacy HLXB9 expression was also found in normal non-cancer breast samples suggesting a 
tumour suppressive role in normal breast cells. HLXB9 expression was found to be downregulated in the 
breast cancer cell lines analysed, which further supports the role of HLXB9 as a tumour suppressor in 
breast cancer. HLXB9 was found localised at the nuclear periphery of non-cancer breast cells where the 
gene is transcriptionally active. This is a new finding showing HLXB9 transcriptionally active in the 
nuclear periphery. This study also found that a change in the nuclear localisation of HLXB9 cannot be the 
sole mechanism for regulating HLXB9 expression. As both downregulation and upregulation of HLXB9 was 
analysed in this study, both states of dysregulation are worth further investigation in order to identify 
transcriptional targets of HLXB9. Hopefully this will shed some light into the function of HLXB9 in both 
breast cancer development and progression. Although the potential of HLXB9 as a biomarker in breast 
cancer is appealing, further work is needed to confirm the real value of this biological parameter in the 

















7. General Discussion 
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One of the main aims of cancer research is the identification and subsequent validation of biomarkers. 
Clinically, molecular biomarkers in cancer are routinely used to: classify risk for predisposition, diagnosis, 
monitoring disease status (including remittance and relapse), inform prognosis or as targets for therapy 
(Henry and Hayes 2012; Burke 2016). In leukaemia, specific chromosomal abnormalities are used as a 
biomarkers and are the most important indicators of patients’ prognosis (Betz and Hess 2010; Ferrara 
and Schiffer 2013; Estey et al. 2014). For example, deletions in the long arm of chromosomes 5 and 7 are 
associated with a poor prognosis in both acute myeloid leukaemia (AML) and the myelodyspstic 
syndromes (MDS) (van der Straaten et al. 2005).  
In breast cancer factors such as tumour grade, lymph node involvement, metastasis and tumour 
molecular subtypes that are used together as biomarkers. The identification of tumour molecular 
subtypes has been particularly significant in improving patients’ outcome in breast cancer as they 
provided new targets for therapy (Parker et al. 2009; Eroles et al. 2012; Tang et al. 2016). The basal 
molecular subtype of breast tumours best exemplifies the importance of identifying genetic biomarkers, 
as there are currently no genetic targets for therapy. Therefore, the standard course of treatment such as 
surgery, radiotherapy, immunotherapy, and chemotherapy are the only options available. 
In this project, HLXB9, a homeobox gene aberrantly expressed in a number of cancer types, was 
investigated to determine if it could be used as biomarker in cancer. 
A preliminary finding from this project is the possibility that alteration in HLXB9 expression is an early 
event in cancer development. HLXB9 expression was more frequently occurring in patients diagnosed 
with pre-leukaemic disorders states such as myeloproliferative disorders (MPD) and myelodysplastic 
syndrome (MDS). 44% of patients diagnosed with MPD and MDS showed HLXB9 expression compared to 
6% of AML patients (P=0.02). Additionally, downregulation in HLXB9 expression was found to occur early 
in breast cancer development (results obtained from MCF 10A and its derivatives). The first stage of the 
MCF 10A cancer progression model, pre malignant - MCF 10A TK1 showed a significant reduction in 
HLXB9 expression compared to the non-tumorigenic MCF 10A. This downregulation was then maintained 
in the malignant model MCF 10A –CA1h. This project was not the first to identify early deregulation of 
HLXB9 in cancer. In fact, hypermethylation of HLXB9 has been previously reported to be an early 
occurrence in breast cancer (Tommasi et al. 2009; Lian et al. 2012). Another tumour type showing early 
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HLXB9 deregulation is testicular cancer, where HLXB9 overexpression is observed in pre-invasive 
testicular carcinoma in situ (Almstrup et al. 2005; Almstrup et al. 2007; Novotny et al. 2007). Therefore 
the results obtained in this project, in conjunction with findings from other studies, suggest that 
deregulation of HLXB9 might have a potential as a biomarker of pre malignancy. 
Other results obtained from this project are discussed in the different chapters of this thesis and can be 
summarised as follows. 
7.1. Detection of t(7;12)(q36;p13) in paediatric leukaemia using dual colour 
fluorescence in situ hybridisation (FISH) 
 
One of the defining characteristics of a biomarker is that it can be accurately detected. It has been 
proven that consistent overexpression of HLXB9 is the consequence of a chromosomal rearrangement 
namely the t(7;12)(q36;p13) found in some infant leukaemia patients. In the first chapter of this 
thesis, a new probe set for the detection of the translocation-t(7;12)(q36;q13) was described. The 
probe set was validated in leukaemia patients using fluorescence in situ hybridisation as part of this 
thesis work. This approach for the detection of this translocation is advantageous over existing 
approaches because it only requires a fluorescent microscope equipped with three fluorescence filter 
sets, which is commonly available in laboratories. The accurate detection of this translocation is 
important for clinicians as its presence confers a very poor prognosis for patients.  
7.2. Investigating the expression and the nuclear localisation of HLXB9 in patients 
diagnosed with haematological malignancies 
 
The second study of this project continued the investigation into HLXB9 as a biomarker in leukaemia. 
In this study, HLXB9 expression and its nuclear localisation was investigated in a different patient 
cohort rather than the classic paediatric patients cohort harbouring t(7;12)(q36;p13) known to 
overexpress HLXB9. HLXB9 expression was investigated in 48 patients diagnosed with various 
haematological malignancies. 25% of the patients investigated showed HLXB9 expression. Patients 
chosen for this study included patients with normal copies of chromosome 7 and patients with 
chromosome 7 abnormalities (with a particular focus on patients harbouring interstitial deletions of 
7q).  
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Patients with interstitial deletion of chromosome 7 were chosen primarily because of the possibility of 
a similar mechanism for ectopic expression of HLXB9 observed in translocation t(7;12) (q36;p13) 
patients. This is because similar to a translocation event, an interstitial deletion of chromosome 7 
results in a disruption of the genomic region proximal to HLXB9 and the rejoining of that region with 
another part of the genome. We speculated this event could also result in the repositioning of the 
HLXB9 gene in the nucleus of the leukaemia cells harbouring the rearrangement, as this is seen in 
t(7;12) cases.  
In this study, there was no significant difference in HLXB9 expression in both groups of patients. 
HLXB9 was expressed in 37.5% of patients with normal chromosome 7 and 20% of patients with 
chromosome 7 abnormalities (P=0.290). To date, there has only been one other study that identified 
the expression of HLXB9 in a patient not harbouring a chromosome 7 abnormality. In that study, 
HLXB9 expression was found in patient with karyotype 45–46,XY,–14,+mar[cp2]/46,XY (pt 
10)(Ballabio et al. 2009). Therefore, this study confirms that HLXB9 expression in leukaemia is not 
limited to patients harbouring chromosome 7 abnormalities.  
Although HLXB9 was expressed in patients, the functional significance of HLXB9 expression in these 
patients remains unknown. Additionally, the prognostic significance of HLXB9 expression in these 
patients could not be determined as there was no clinical information on patients’ outcome. It would 
have been interesting to compare the clinical outcome of patients showing HLXB9 expression in this 
study to paediatric patients with t(7;12) to determine if a similar level of risk is observed in both 
groups. 
The nuclear localisation of HLXB9 was also investigated in both patients without chromosome 7 
abnormalities expressing HLXB9 and patients harbouring interstitial deletion of chromosome 7 in 
order to determine if its nuclear localisation is linked with expression. A majority of patients from 
both groups showed no difference in nuclear localisation from the control bone marrow cells 
investigated although there was a variation in gene expression. These results suggest the nuclear 
localisation of HLXB9 is not the mechanism of regulation of its expression in patients diagnosed with 
haematological disorders. 
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7.3. Investigating the differential expression of HLXB9 as a potential cancer 
biomarker by datamining online transcriptomics databases 
 
In this study on investigating HLXB9 expression as a cancer biomarker, the expression of HLXB9 was 
investigated in four publicly available databases. Differential expression of HLXB9 was identified in 
cancers not previously associated with its aberrant expression; these were lung cancer, kidney cancer 
and endometrial cancer, which could provide new avenues for research. The aberrant expression of 
HLXB9 in kidney cancer was particularly interesting as it was identified in three subtypes of kidney 
cancer. HLXB9 was upregulated in two kidney cancer subtypes. These were kidney clear cell 
carcinoma (KIRC) and kidney papillary cell carcinomas (KIRP), which are associated with poor 
prognosis. In contrast, HLXB9 was downregulated in kidney chromophobe (KICH), a kidney cancer 
subtype with better prognosis.  
Another key finding from this study was the differential expression of HLXB9 that was observed in 
cancers from organs/tissue solely or partially derived from the endodermal germ layer such as 
pancreas, rectum, lung, liver, bladder, stomach and oesophagus. This finding indicates HLXB9 
expression has to be correctly regulated in endodermal tissue derivatives after foetal development to 
maintain health. 
However, this study highlights the limitation of the datamining approach for the identification of new 
biomarkers. One of the limitations encountered was the small number of samples available or lack of 
data on particular cancer types. Additionally, although HLXB9 expression was identified in 
subpopulations of cancer type, further investigation into the clinical characteristics unifying these 
patients was not possible. There was also a lack of data on the patients’ outcome so the prognostic 
significance of identified aberrant expression of HLXB9 could not be determined.  
 
7.4. Investigating HLXB9 as a biomarker in breast cancer 
 
In the final study on investigating HLXB9 as a biomarker in breast cancer, HLXB9 expression was 
found to be downregulated in breast cancer cell lines by qRT-PCR and IF. This finding was in line with 
previous reports from other studies (Neufing et al. 2003; Tommasi et al. 2009; Lian et al. 2012; Siletz 
et al. 2013b; Siletz et al. 2013a). From the IF experiments, foci of HLXB9 protein aggregates were 
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observed in the nucleus of breast cancer cell lines investigated suggesting a function for HLXB9 in 
these cell lines, similar foci of HLXB9 protein aggregates have been previously observed in 
insulinomas (Desai et al. 2015). In insulinomas, these aggregates have been confirmed to be primarily 
composed of phosphorylated HLXB9, which has an anti-apoptotic function. However further 
investigation is required to confirm the identity and function of the protein aggregates observed in 
HLXB9 in breast cancer. 
The nuclear localisation of HLXB9 in breast cancer cell lines was also investigated. HLXB9 was 
localised in the nuclear periphery in control cells, however, the breast cancer cell lines showed a 
localisation of HLXB9 away from the nuclear periphery. This change in the nuclear localisation of 
HLXB9 was particularly significant in the MDA-MB-231 and BT474 cell line. However, the 
repositioning of HLXB9 observed was not associated with gene expression thereby suggesting that 
HLXB9 expression was not regulated by a position effect mechanism.  
Finally, the prognostic significance of differential expression of HLXB9 was investigated by datamining 
breast cancer survival databases. Contrary to expectation, HLXB9 overexpression was found to be 
detrimental to patients relapse free and overall survival. HLXB9 overexpression was also a negative 
prognostic indicator in patients diagnosed with lymph node positive, grade 2 or luminal A tumours. 
Additionally, the prognostic significance of HLXB9 expression was compared to genes from well-
established multi gene expression panels Oncotype DX and MammaPrint. Overexpression of HLXB9 
was a better indicator of poor prognosis (relapse and overall survival) than a number of the genes 
currently utilised. Therefore, HLXB9 could be added to the tests to improve their efficacy. 
Overexpression of HLXB9 has been previously been reported to result in an increase in the 
phosphorylation of HLXB9 in insulinomas (Desai et al.2015). In insulinomas, phosphorylation of 
HLXB9 has been found to inhibit apoptosis by downregulating the expression of Cblb, a ubiquitin 
ligase which would normally target C-met, a tyrosine kinase for degradation (Desai et al 2015). 
Further work is required to determine the functional consequence of HLXB9 overexpression in breast 
cancer patients. 
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In conclusion, these studies show the appeal of HLXB9 as a biomarker in cancer. However, further 
investigation is needed to determine the prognostic significance and the clinical characteristics of cancer 
patients who show aberrant expression of HLXB9. Therefore, further studies will be crucial to understand 
the consequence of aberrant HLXB9 expression in cancer. Additionally, studies to identify the function of 
HLXB9 in cancer cells is vital in order to provide further information on the suitability of HLXB9 as a 
biomarker in cancer. 
Future Work 
The following future work is required to fully understand the role of HLXB9 expression in both 
non-cancer states and cancer cells to determine its potential as a cancer biomarker. 
1. Chromatin immunoprecipitation (ChIP) experiments should be carried out to identify HLXB9 
targets genes in non-cancer and cancer samples.  
2. Experiments using RNA silencing (siRNA) could be conducted to investigate the function of 
HLXB9 in breast cancer and leukaemia. By silencing the expression of HLXB9 in normal breast 
or blood cells, the function of this gene in normal cells could be determined. These 
experiments might also help understand how the downregulation of HLXB9 expression might 
contribute to breast cancer development.   
3. Additionally, experiments using phospho-HLXB9 antibodies to determine the composition of 
the HLXB9 aggregates observed in breast cancer cell lines would help determine the function 
of HLXB9 in breast cancer cells. 
4. In this study, overexpression of HLXB9 in breast cancer has also been found to be detrimental 
to patient outcome. Previous studies have also identified HLXB9 overexpression in a subset of 
leukaemia patients with poor prognosis. Therefore overexpressing HLXB9 in breast cancer or 
leukeamia cell lines could also help understand how this overexpression of this gene 
contributes to cancer development and/or progression. In addition, siRNA experiments to 
knock down HLXB9 expression in a cell line overexpressing HLXB9 would be useful to 
determine if a gain of apoptotic function occurs in cell lines. 
5. As the suggested experiments are carried out on cell lines, which are known to be able to 
evolve in vitro introducing artefacts not seen in patients, primary breast cancer patients’ 
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samples could be analysed in order to fully understand the dysregulation of HLXB9 in breast 
cancer. 
6. Comparing breast cancer chromatin (where HLXB9 located at the nuclear periphery is 
transcriptionally active) to leukaemia cells chromatin (where HLXB9 is located at the periphery is 
transcriptionally silent) could help with understanding the mechanism of HLXB9 expression. This 
could be done by staining for open or closed chromatin markers. 
7. Finally, expression analysis of the HLXB9-AS2 gene in breast cancer cells should be carried out to 
determine the function of this non-coding RNA. In order to eliminate the possibility of this gene’s 
detection as an artefact of the reverse transcription cDNA synthesis reaction, strand specific RT-PCR 
or cDNA synthesis in the presence of actinomycin D could be carried out. If the expression of HLXB9-
AS2 is confirmed in breast cancer cell lines, the function of HLXB9-AS2 in non-cancer breast and 
breast cancer can then be further investigated. Furthermore, comparing the impact of HLXB9 and 
HLXB9-AS2 gene expression on patient survival would be used to determine if there is a correlation 
between their expression and patient survival.  
All of the proposed future work will provide valuable insight into how HLXB9 is expressed, the impact of 
this expression in cancer and determine if this gene could be used as a biomarker in cancer. 
  




































BreastMark Km plotter 
HR P N HR P N 
3110 HLXB9 1.42 5.1E-05 2091 1.52 1.0E-04 1402 
Oncotype DX gene panel 
4288 KI67 1.77 5.2E-11 2091 1.46 4.7E-04 1402 
6790 STK15 1.79 3.1E-11 2091 1.81 5.5E-08 1402 
332 Survivin 2.02 7.8E-16 2091 1.67 2.4E-06 1402 
891 CCNB1 1.93 5.6E-12 1796 1.51 9.6E-03 626 
4605 MYBL2 1.79 1.3E-11 2091 1.98 5.5E-10 1402 
4320 MMP11 1.35 5.3E-04 2091 1.14 2.4E-01 1402 
1515 CTSL2 1.58 1.1E-07 2091 1.67 2.9E-06 1402 
2886 GRB7 1.49 3.0E-06 2091 1.27 3.0E-02 1402 
2064 HER2 1.01 9.0E-01 2091 0.97 8.3E-01 626 
2099 ER 0.69 1.9E-05 2091 0.65 8.0E-05 1402 
5241 PGR 0.61 3.4E-08 2091 0.62 2.7E-03 626 
596 BCL2 0.64 3.4E-07 2091 0.56 1.0E-07 1402 
57758 SCUBE2 0.58 5.6E-06 1285 0.58 5.0E-07 1402 
2944 GSTM1 0.62 7.6E-07 1778 0.60 2.9E-06 1402 
968 CD68 1.19 4.7E-02 2091 1.00 1.0E+00 1402 
573 BAG1 0.86 8.2E-02 2091 0.87 3.8E-01 1402 
Table 8.1: Overexpression of HLXB9 is a better indicator of overall survival in breast cancer patients than a 
number of genes used in the Oncotype DX gene panel. Results from analysing overall survival (OS) in KM plotter 




BreastMark KM plotter 
HR P N HR P N 
3110 HLXB9 1.42 5.1E-05 2091 1.52 1.2E-04 1402 
Good Prognosis 
8659 ALDH4 1.13 1.7E-01 1963 0.91 3.9E-01 1402 
8817 FGF18 0.85 5.5E-02 2091 0.98 8.9E-01 626 
27113 BBC3 1.12 2.5E-01 1796 1.04 7.0E-01 1402 
57593 EBF4 0.56 4.8E-01 48 0.96 8.0E-01 626 
57758 SCUBE2 0.58 5.6E-06 1285 0.58 5.0E-07 1402 
146923 RUNDC1 0.80 1.5E-01 584 0.48 5.8E-06 626 
8840 WISP1 0.80 1.1E-02 2082 0.77 9.6E-02 626 
2947 GSTM3 0.60 2.8E-09 2091 0.51 2.2E-05 626 
151126 ZNF385B 0.64 4.3E-03 575 0.48 5.2E-06 626 
146760 RTN4RL1 1.30 1.4E-01 429 0.68 1.8E-02 626 
10455 PECI 0.74 1.7E-03 1778 1.19 1.1E-01 1402 
7043 TGFB3 0.65 4.8E-07 2091 0.69 6.5E-04 1402 
55351 HSA250839 0.59 2.7E-08 1933 0.69 5.7E-04 1402 
58475 MS4A7 0.60 7.2E-05 879 0.62 3.1E-03 626 
163 AP2B1 0.93 3.8E-01 2091 0.82 6.5E-02 1402 
79132 LGP2 1.04 7.2E-01 1638 0.85 1.5E-01 1402 
Poor Prognosis 
55321 C20ORF46 1.43 9.6E-05 1933 1.26 3.5E-02 1402 
11082 ESM1 1.39 1.5E-04 2043 1.41 1.5E-03 1402 
9134 CCNE2 1.81 4.0E-10 1796 1.83 3.0E-08 1402 
54583 EGLN1 1.37 1.6E-03 1629 1.22 2.1E-01 626 
1058 CENPA 1.86 1.4E-12 2091 1.7 1.3E-06 1402 
9055 PRC1 2.12 5.6E-16 1933 1.97 5.9E-10 1402 
445815 AKAP2 1.14 1.5E-01 1924 0.78 2.6E-02 1402 
10874 NMU 1.55 3.6E-07 2091 1.55 5.1E-05 1402 
3488 IGFBP5 1.08 3.8E-01 2091 1.32 8.7E-02 626 
10531 MP1 1.27 3.2E-02 1443 0.7 3.0E-02 626 
57110 HRASLS 1.43 7.3E-05 1933 1.5 1.9E-04 1402 
8577 TMEFF1 1.15 1.3E-01 1936 1.16 1.7E-01 1402 
4175 MCM6 1.81 1.3E-11 2091 1.09 5.7E-01 626 
643008 SMIM5 NA NA NA 1.33 7.5E-02 626 
83879 CDCA7 1.05 7.8E-01 584 1.35 6.3E-02 626 
5984 RFC4 1.90 2.5E-13 2091 1.45 6.2E-04 1402 
23594 ORC6L 1.70 4.3E-09 1933 1.75 3.5E-07 1402 
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6515 SLC2A3 1.02 8.6E-01 2091 0.97 7.9E-01 1402 
57211 GPR126 1.08 4.0E-01 1796 1.44 9.2E-04 1402 
79791 FBXO31 1.14 1.5E-01 1933 1.76 4.0E-04 626 
1633 DCK 1.34 7.2E-04 2091 1.3 1.5E-02 1402 
51514 L2DTL 1.64 5.8E-08 1933 1.21 2.3E-01 626 
1284 COL4A2 1.23 2.7E-02 1796 1.21 8.6E-02 1402 
9833 KIAA0175 2.13 0.0E+00 2091 2.04 9.2E-11 1402 
92140 MTDH 1.55 5.6E-07 2091 1.54 6.8E-03 626 
51377 UCH37 1.36 7.9E-04 1933 1.13 4.4E-01 626 
51560 RAB6B 1.73 7.3E-09 1933 1.21 2.4E-01 626 
160897 GPR180 1.99 3.3E-05 533 1.17 3.3E-01 626 
79888 FLJ12443 1.59 5.8E-07 1796 1.28 2.5E-02 1402 
8293 SERF1A 0.94 8.8E-01 183 0.83 9.5E-02 1402 
8476 PK428 1.10 2.9E-01 2091 1.24 4.9E-02 1402 
10403 HEC 1.61 4.3E-08 2091 1.56 4.8E-05 1402 
8833 GMPS 1.96 7.2E-14 1908 1.63 9.4E-06 1402 
1894 ECT2 1.60 3.0E-07 1933 1.09 6.0E-01 626 
4318 MMP9 1.06 5.1E-01 2091 1.08 5.0E-01 1402 
5019 OXCT 1.17 6.7E-02 2091 1.05 6.8E-01 1402 
2781 GNAZ 1.23 1.8E-02 2091 1.04 7.1E-01 1402 
2321 FLT1 1.29 4.4E-03 1888 1.14 4.1E-01 626 
2131 EXT1 1.36 4.1E-04 2091 0.89 3.0E-01 1402 
56942 DC13 1.92 1.3E-12 1933 1.73 5.0E-07 1402 
81624 DIAPH3 1.70 2.8E-05 1580 1.53 7.8E-03 626 
169714 QSOX2 1.66 1.5E-03 536 1.13 4.5E-01 626 
286052 LOC286052 NA NA NA 1.18 3.1E-01 626 
51203 LOC51203 2.12 5.6E-16 1933 2.14 6.0E-12 1402 
85453 TSPYL5 1.04 6.8E-01 1787 1.12 3.0E-01 1402 
Table 8.2: Overexpression of HLXB9 is a better indicator of overall survival in breast cancer patients than a 







HR P N HR P N 
3110 HLXB9 1.61 1.0E-03 577 1.31 2.9E-02 901 
Oncotype DX gene panel 
4288 KI67 1.40 1.7E-02 616 1.56 2.9E-04 901 
6790 STK15 1.51 3.1E-03 616 1.55 4.0E-04 901 
332 Survivin 1.75 5.7E-05 616 1.75 6.2E-06 901 
891 CCNB1 1.89 4.4E-06 616 1.85 2.0E-02 227 
4605 MYBL2 1.39 2.0E-02 616 1.55 4.0E-04 901 
4320 MMP11 1.28 9.3E-02 577 1.01 9.5E-01 901 
1515 CTSL2 1.46 9.0E-03 577 1.27 4.8E-02 901 
2886 GRB7 1.89 4.6E-06 616 1.21 1.2E-01 901 
2064 HER2 1.07 6.6E-01 577 1.63 6.4E-02 227 
2099 ER 0.83 2.0E-01 577 0.68 1.9E-03 901 
5241 PGR 0.72 1.8E-02 616 0.45 2.4E-03 227 
596 BCL2 0.71 1.7E-02 577 0.68 1.7E-03 901 
57758 SCUBE2 0.58 9.4E-04 433 0.65 5.0E-04 901 
2944 GSTM1 0.78 1.8E-01 322 0.86 2.3E-01 901 
968 CD68 1.16 2.8E-01 616 1.11 4.1E-01 901 
573 BAG1 1.00 9.9E-01 616 0.86 5.5E-01 227 
Table 8.3: Overexpression of HLXB9 is a better indicator of relapse in breast cancer patients in patients 
diagnosed with grade 2 tumours than a number of genes used in the Oncotype DX gene panel. Results from 











HR P n HR P n 
3110 HLXB9 1.61 1.0E-04 577 1.31 2.9E-02 901 
Good Prognosis  
8659 ALDH4 1.12 4.7E-01 522 1.03 8.4E-01 901 
8817 FGF18 1.03 8.6E-01 616 1.16 5.6E-01 227 
27113 BBC3 1.13 4.1E-01 577 1.14 2.9E-01 901 
57593 KIAA1442 NA NA NA 0.99 9.8E-01 227 
57758 CEGP1 0.58 9.4E-04 433 0.65 5.0E-04 901 
146923 RUNDC1 0.71 7.6E-02 338 0.69 1.5E-01 227 
8840 WISP1 0.80 1.1E-01 614 0.57 3.6E-02 227 
2947 GSTM3 0.89 4.0E-01 616 0.79 3.7E-01 227 
151126 ZNF533 0.69 5.6E-02 336 0.64 9.2E-02 227 
146760 RTN4RL1 1.19 5.2E-01 205 0.79 3.6E-01 227 
10455 PECI 0.75 6.9E-02 493 0.86 2.1E-01 901 
7043 TGFB3 0.94 6.5E-01 577 0.78 3.9E-02 901 
55351 HSA250839 0.73 3.5E-02 548 0.74 1.6E-02 901 
58475 CFFM4 0.76 2.0E-01 299 0.89 6.5E-01 227 
163 AP2B1 1.21 1.9E-01 577 0.84 1.4E-01 901 
79132 LGP2 0.98 8.7E-01 587 1.04 7.3E-01 901 
Poor prognosis  
55321 C20ORF46 1.08 6.2E-01 587 1.10 4.5E-01 901 
11082 ESM1 1.35 4.1E-02 564 1.24 7.9E-02 901 
9134 CCNE2 1.99 6.8E-07 616 1.32 2.5E-02 901 
54583 EGLN1 1.43 1.3E-02 585 1.75 3.2E-02 227 
1058 CENPA 1.49 4.7E-03 616 1.59 2.0E-04 901 
9055 PRC1 1.72 1.3E-04 587 1.53 6.0E-04 901 
445815 AKAP2 1.03 8.5E-01 414 1.10 4.4E-01 901 
10874 NMU 1.62 6.0E-04 616 1.42 4.4E-03 901 
3488 IGFBP5 1.16 3.2E-01 577 1.37 2.3E-01 227 
10531 MP1 1.29 9.9E-02 501 1.08 7.6E-01 227 
57110 LOC57110 1.54 3.5E-03 548 1.51 8.0E-04 901 
8577 TMEFF1 1.02 9.1E-01 483 0.84 1.6E-01 901 
4175 MCM6 2.01 3.9E-07 616 1.30 3.1E-01 227 
643008 LOC643008 NA NA NA 1.17 5.4E-01 227 
83879 CDCA7 1.13 5.3E-01 338 1.41 1.9E-01 227 
5984 RFC4 2.02 3.2E-07 616 1.46 2.2E-03 901 
23594 ORC6L 1.46 8.1E-03 587 1.44 3.2E-03 901 
6515 SLC2A3 0.91 5.1E-01 577 0.94 6.1E-01 901 
57211 DKFZP564D0462 1.15 3.5E-01 577 1.22 1.1E-01 901 
79791 FBXO31 1.06 6.8E-01 587 1.44 1.6E-01 227 
1633 DCK 1.22 1.7E-01 577 0.84 1.7E-01 901 
51514 L2DTL 1.93 7.7E-06 548 1.33 2.7E-01 227 
1284 COL4A2 1.55 2.9E-03 577 1.31 2.6E-02 901 
9833 KIAA0175 2.09 1.1E-07 616 1.82 1.2E-06 901 
92140 MTDH 1.41 1.7E-02 577 1.19 5.1E-01 227 
51377 UCH37 1.10 5.1E-01 587 1.39 2.0E-01 227 
51560 RAB6B 1.06 7.2E-01 548 1.23 4.2E-01 227 
160897 GPR180 1.42 1.1E-01 278 0.81 4.1E-01 227 
79888 FLJ12443 1.82 3.5E-05 577 1.09 4.8E-01 901 
8293 SERF1A 0.87 7.9E-01 39 1.00 9.8E-01 901 
8476 PK428 1.20 2.0E-01 616 1.00 9.8E-01 901 
10403 HEC 1.27 9.7E-02 616 1.60 1.4E-04 901 
8833 GMPS 1.69 1.6E-04 616 1.30 3.7E-02 901 
1894 ECT2 1.72 1.2E-04 587 0.85 5.3E-01 227 
4318 MMP9 1.08 5.9E-01 616 1.41 5.3E-03 901 
5019 OXCT 1.41 1.5E-02 616 1.06 6.5E-01 901 
2781 GNAZ 1.03 8.3E-01 577 1.12 3.6E-01 901 
2321 FLT1 1.06 7.8E-01 299 1.58 7.8E-02 227 
2131 EXT1 1.19 2.1E-01 616 0.93 5.3E-01 901 
56942 DC13 1.52 3.2E-03 587 1.36 1.2E-02 901 
81624 DIAPH3 1.23 2.3E-01 472 1.46 1.5E-01 227 
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169714 QSOX2 1.56 3.8E-02 286 1.40 2.0E-01 227 
286052 LOC286052 NA NA NA 0.99 9.6E-01 227 
51203 LOC51203 1.80 3.3E-05 587 1.61 1.1E-04 901 
85453 TSPYL5 1.05 7.4E-01 575 1.04 7.6E-01 901 
Table 8.4: Overexpression of HLXB9 is a better indicator of relapse in breast cancer patients in patients 
diagnosed with grade 2 tumours than a number of genes used in the MammaPrint gene panel. Results from 





HR P N HR P N 
3110 HLXB9 1.36 8.3E-03 719 1.49 8.10E-05 1133 
Oncotype DX gene panel 
4288 KI67 1.47 6.7E-04 744 1.36 2.3E-03 1133 
6790 STK15 1.52 2.1E-04 744 1.71 1.0E-07 1133 
332 Survivin 1.74 1.5E-06 744 1.66 4.1E-07 1133 
891 CCNB1 1.49 1.4E-03 600 1.73 1.8E-05 724 
4605 MYBL2 1.40 2.9E-03 744 1.65 7.0E-07 1133 
4320 MMP11 1.50 4.4E-04 719 1.24 3.4E-02 1133 
1515 CTSL2 1.78 7.4E-07 719 1.64 6.9E-07 1133 
2886 GRB7 1.15 2.3E-01 744 0.99 9.4E-01 1133 
2064 HER2 0.99 9.3E-01 719 0.92 5.1E-01 724 
2099 ER 0.72 4.0E-03 719 0.6 3.6E-07 1133 
5241 PGR 0.65 1.1E-04 744 0.5 6.6E-08 724 
596 BCL2 0.87 2.4E-01 719 0.61 7.1E-07 1133 
57758 SCUBE2 0.54 6.9E-04 370 0.53 1.4E-10 1133 
2944 GSTM1 0.62 1.3E-03 385 0.65 1.4E-05 1133 
968 CD68 1.28 3.1E-02 744 1.38 1.3E-03 1133 
573 BAG1 0.99 9.4E-01 744 0.8 8.5E-02 724 
Table 8.5: Overexpression of HLXB9 is a better indicator of relapse in breast cancer patients diagnosed with 
lymph node positive tumours than a number of genes used in the Oncotype DX gene panel. Results from 






HR P N HR P N 
3110 HLXB9 1.36 8.3E-03 719 1.49 8.1E-05 1133 
MammaPrint gene signature 
Good Prognosis  
8659 ALDH4 1.09 4.9E-01 672 1.06 5.4E-01 1133 
8817 FGF18 0.99 9.3E-01 744 0.94 6.3E-01 724 
27113 BBC3 1.10 4.4E-01 575 1.11 3.2E-01 1133 
57593 KIAA1442 0.72 5.9E-01 32 0.70 5.8E-03 724 
57758 CEGP1 0.54 6.9E-04 370 0.53 1.4E-10 1133 
146923 RUNDC1 0.71 1.2E-02 489 0.59 3.6E-05 724 
8840 WISP1 0.88 2.6E-01 740 0.82 1.2E-01 724 
2947 GSTM3 0.79 3.8E-02 744 0.77 4.4E-02 724 
151126 ZNF533 0.78 6.0E-02 485 0.66 1.4E-03 724 
146760 RTN4RL1 1.13 4.2E-01 392 0.69 3.3E-03 724 
10455 PECI 0.86 2.2E-01 642 1.12 2.7E-01 1133 
7043 TGFB3 1.03 7.8E-01 719 0.80 2.3E-02 1133 
55351 HSA250839 0.71 4.5E-03 689 0.73 1.9E-03 1133 
58475 CFFM4 0.66 7.6E-04 608 0.63 3.4E-04 724 
163 AP2B1 1.30 2.3E-02 719 0.77 1.0E-02 1133 
79132 LGP2 1.05 7.2E-01 570 0.77 7.6E-03 1133 
Poor prognosis  
55321 C20orf46 1.06 6.4E-01 714 1.32 5.4E-03 1133 
11082 ESM1 1.39 5.0E-03 687 1.58 5.3E-06 1133 
9134 CCNE2 1.39 8.4E-03 600 1.82 2.6E-09 1133 
54583 EGLN1 1.41 7.1E-03 566 1.21 1.4E-01 724 
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1058 CENPA 1.51 3.0E-04 744 1.73 5.8E-08 1133 
9055 PRC1 1.80 3.6E-07 714 1.91 1.1E-10 1133 
445815 AKAP2 1.13 3.8E-01 453 0.86 1.3E-01 1133 
10874 NMU 1.57 7.4E-05 744 1.38 1.3E-03 1133 
3488 IGFBP5 1.16 1.9E-01 719 1.55 7.7E-04 724 
10531 MP1 1.19 3.1E-01 425 1.17 2.2E-01 724 
57110 LOC57110 1.27 4.3E-02 689 1.42 4.5E-04 1133 
8577 TMEFF1 1.16 2.3E-01 647 1.09 3.7E-01 1133 
4175 MCM6 1.61 3.2E-05 744 1.40 8.4E-03 724 
643008 LOC643008 N/A N/A N/A 1.01 9.1E-01 724 
83879 CDCA7 1.25 9.8E-02 489 1.96 1.4E-07 724 
5984 RFC4 1.62 2.1E-05 744 1.53 2.3E-05 1133 
23594 ORC6L 1.74 1.9E-06 714 1.60 2.8E-06 1133 




1.14 3.0E-01 575 1.48 8.4E-05 1133 
79791 FBXO31 1.02 8.8E-01 714 1.65 9.7E-05 724 
1633 DCK 1.17 1.8E-01 719 1.06 5.9E-01 1133 
51514 L2DTL 1.82 6.8E-07 689 1.58 3.8E-04 724 
1284 COL4A2 1.25 8.3E-02 575 1.30 8.2E-03 1133 
9833 KIAA0175 1.76 8.5E-07 744 1.74 3.2E-08 1133 
92140 MTDH 1.29 2.7E-02 719 1.41 7.0E-03 724 
51377 UCH37 1.13 3.0E-01 714 1.27 6.5E-02 724 
51560 RAB6B 1.22 8.4E-02 689 1.45 3.8E-03 724 
160897 GPR180 1.51 4.0E-03 436 1.36 1.7E-02 724 
79888 FLJ12443 1.48 2.3E-03 575 1.19 8.8E-02 1133 
8293 SERF1A 1.19 7.8E-01 25 0.73 1.7E-03 1133 
8476 PK428 1.18 1.5E-01 744 1.15 1.6E-01 1133 
10403 HEC 1.28 2.9E-02 744 1.81 3.8E-09 1133 
8833 GMPS 1.74 1.1E-06 744 1.83 2.1E-09 1133 
1894 ECT2 1.46 1.0E-03 714 1.31 3.2E-02 724 
4318 MMP9 1.27 3.4E-02 744 1.21 5.7E-02 1133 
5019 OXCT 1.14 2.4E-01 744 1.09 3.9E-01 1133 
2781 GNAZ 1.17 1.8E-01 719 1.24 3.1E-02 1133 
2321 FLT1 1.18 2.7E-01 358 0.97 8.4E-01 724 
2131 EXT1 1.18 1.5E-01 744 0.87 1.7E-01 1133 
56942 DC13 1.49 5.3E-04 714 1.64 7.8E-07 1133 
81624 DIAPH3 1.52 4.1E-03 539 1.62 1.7E-04 724 
169714 QSOX2 1.33 4.8E-02 432 1.21 1.4E-01 724 
286052 LOC286052 N/A N/A N/A 1.27 6.2E-02 724 
51203 LOC51203 1.76 1.4E-06 714 1.81 3.3E-09 1133 
85453 TSPYL5 0.98 8.5E-01 571 1.14 1.9E-01 1133 
Table 8.6: Overexpression of HLXB9 is a better indicator of relapse in breast cancer patients diagnosed with 
lymph node positive tumours than a number of genes used in the MammaPrint gene panel. Results from 
analysing overall survival in KM plotter and BreastMark. 
Entrez 
Gene ID 
Gene symbol BreastMark KMPlotter 
HR P n HR P n 
3110 HLXB9 1.16 2.5E-01 875 1.27 3.3E-02 1256 
Oncotype DX gene panel  
4288 KI67 1.68 4.4E-05 902 1.77 4.3E-07 1256 
6790 STK15 2.32 4.0E-11 902 2.15 1.3E-11 1256 
332 Survivin 1.96 8.6E-08 902 2.10 7.6E-11 1256 
891 CCNB1 1.89 3.6E-06 793 1.71 5.0E-02 296 
4605 MYBL2 1.76 8.0E-06 902 1.93 6.0E-09 1256 
4320 MMP11 1.55 1.0E-03 875 1.19 1.2E-01 1256 
1515 CTSL2 1.42 7.1E-03 875 1.55 8.3E-05 1256 
2886 GRB7 1.26 7.0E-02 902 0.85 1.5E-01 1256 
2064 HER2 1.03 8.3E-01 875 0.93 7.9E-01 296 
2099 ER 1.32 5.0E-02 875 1.02 8.9E-01 1256 
5241 PGR 0.80 8.0E-02 902 1.06 8.4E-01 296 
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596 BCL2 0.75 3.0E-02 875 0.71 2.1E-03 1256 
57758 SCUBE2 0.71 3.0E-02 628 0.79 3.2E-02 1256 
2944 GSTM1 0.92 5.6E-01 651 0.69 9.4E-04 1256 
968 CD68 0.96 7.4E-01 902 0.95 6.6E-01 1256 
573 BAG1 1.01 9.1E-01 902 1.10 7.2E-01 296 
Table 8.7: Overexpression of HLXB9 is a better indicator of relapse in breast cancer patients diagnosed with 
ER positive, lymph node negative tumours than a number of genes used in the Oncotype DX gene panel. 







HR P N HR P N 
3110 HLXB9 1.27 3.3E-02 1256 1.16 2.5E-01 875 
Good Prognosis  
8659 ALDH4 0.87 2.0E-01 1256 0.93 6.0E-01 827 
8817 FGF18 0.80 4.1E-01 296 0.79 7.0E-02 902 
27113 BBC3 0.82 7.4E-02 1256 0.74 4.0E-02 766 
57593 KIAA1442 0.65 1.2E-01 1256 NA NA NA 
57758 CEGP1 0.79 3.2E-02 1256 0.71 2.5E-02 628 
146923 RUNDC1 0.82 4.4E-01 296 0.60 3.4E-02 288 
8840 WISP1 0.94 8.1E-01 296 0.80 8.0E-02 898 
2947 GSTM3 0.92 7.5E-01 296 0.82 1.1E-01 902 
151126 ZNF533 0.77 3.2E-01 296 1.13 6.1E-01 284 
146760 RTN4RL1 0.88 6.3E-01 1256 0.76 3.4E-01 186 
10455 PECI 0.95 6.5E-01 1256 0.86 2.6E-01 796 
7043 TGFB3  0.73 4.7E-03 1256 0.83 1.5E-01 875 
55351 HSA250839 0.78 2.9E-02 1256 0.82 1.4E-01 844 
58475 CFFM4 0.69 1.6E-01 296 0.65 3.4E-02 370 
163 AP2B1 0.90 3.6E-01 1256 0.83 1.6E-01 875 
79132 LGP2 0.89 2.8E-01 1256 0.75 4.8E-02 762 
Poor Prognosis  
55321 C20orf46 1.16 1.8E-01 1256 1.01 9.5E-01 871 
11082 ESM1 1.08 4.9E-01 1256 1.29 5.0E-02 866 
9134 CCNE2 1.74 8.6E-07 1256 1.74 6.5E-05 793 
54583 EGLN1 1.58 8.2E-02 296 1.39 1.7E-02 758 
1058 CENPA 1.83 9.3E-08 1256 1.97 9.4E-08 902 
9055 PRC1 2.19 5.7E-12 1256 2.04 1.8E-08 871 
445815 AKAP2  0.83 9.4E-02 1256 0.88 3.5E-01 722 
10874 NMU 1.66 6.5E-06 1256 1.52 1.0E-03 902 
3488 IGFBP5 1.33 2.8E-01 296 1.05 7.4E-01 875 
10531 MP1 1.17 5.6E-01 296 1.18 2.5E-01 686 
57110 LOC57110 1.32 1.2E-02 1256 1.49 2.2E-03 844 
8577 TMEFF1 1.09 4.2E-01 1256 1.30 4.9E-02 800 
4175 MCM6 1.61 7.8E-02 296 1.76 6.9E-06 902 
643008 LOC643008 0.88 6.3E-01 1256 NA NA NA 
83879 CDCA7 1.27 3.7E-01 1256 1.33 2.3E-01 288 
5984 RFC4 1.91 9.4E-09 1256 1.71 2.2E-05 902 
23594 ORC6L 1.41 2.2E-03 1256 1.82 2.5E-06 871 




0.92 4.4E-01 1256 0.87 3.3E-01 766 
79791 FBXO31 0.97 9.1E-01 296 0.85 2.3E-01 871 
1633 DCK 1.17 1.7E-01 1256 1.55 8.0E-04 875 
51514 L2DTL 1.69 5.5E-02 296 1.97 2.0E-07 844 
1284 COL4A2 1.10 3.9E-01 1256 1.12 4.4E-01 766 
9833 KIAA0175 2.19 6.1E-12 1256 1.84 1.2E-06 902 
92140 MTDH 1.06 8.3E-01 296 1.22 1.3E-01 875 
51377 UCH37 1.52 1.2E-01 296 1.16 2.5E-01 871 
51560 RAB6B 0.84 5.2E-01 296 0.81 1.5E-01 844 
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160897 GPR180 1.03 9.2E-01 296 1.20 4.9E-01 248 
79888 FLJ12443 1.30 1.9E-02 1256 1.18 2.5E-01 766 
8293 SERF1A 0.94 6.1E-01 1256 1.66 3.9E-01 27 
8476 PK428 1.09 4.4E-01 1256 1.26 7.3E-02 902 
10403 HEC 2.07 1.3E-10 1256 1.40 8.3E-03 902 
8833 GMPS 1.90 2.4E-08 1256 1.40 8.8E-03 902 
1894 ECT2 1.25 3.9E-01 296 1.72 2.1E-05 871 
4318 MMP9 1.38 4.4E-03 1256 1.23 1.1E-01 902 
5019 OXCT 1.07 5.2E-01 1256 1.00 9.8E-01 902 
2781 GNAZ 1.38 4.1E-03 1256 1.09 5.0E-01 875 
2321 FLT1 1.07 7.9E-01 296 0.92 5.8E-01 646 
2131 EXT1 0.98 8.6E-01 1256 1.16 2.6E-01 902 
56942 DC13 1.70 2.6E-06 1256 1.81 2.9E-06 871 
81624 DIAPH3 1.90 1.7E-02 296 1.09 5.3E-01 764 
169714 QSOX2 1.31 3.0E-01 296 1.54 9.6E-02 252 
286052 LOC286052 1.06 8.3E-01 1256 NA NA NA 
51203 LOC51203 1.94 4.1E-09 1256 1.92 2.2E-07 871 
85453 TSPYL5 0.99 9.1E-01 1256 0.93 6.0E-01 762 
Table 8.8: Overexpression of HLXB9 is a better indicator of relapse in breast cancer patients diagnosed with 
ER positive, lymph node negative tumours than a number of genes used in the MammaPrint gene panel. 




Figure A1: Overexpression of HLXB9 reduces luminal A patients’ survival. High expression of HLXB9 reduces the 
probability of relapse free survival (KM plotter and BreastMark), distant metastasis free survival and overall survival 
(BreastMark only) on breast cancer patients with diagnosed with luminal A breast tumours. 
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Figure A2: Overexpression of HLXB9 expression reduces relapse free survival in breast cancer patients 
diagnosed with luminal B tumors (KM plotter only). 
 
 
Figure A3: Overexpression of HLXB9 reduces the probability of disease free, distance metastasis free and 
overall survival in patients diagnosed with basal tumours (KM plotter only). 
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Figure A4: Overexpression of HLXB9 reduces the overall survival of breast cancer patients diagnosed with 







HR P N HR P N 
3110 HLXB9 1.24 4.0E-02 1035 1.23 1.7E-02 1933 
Oncotype DX gene panel 
4288 KI67 1.32 7.9E-03 1063 1.5 3.9E-06 1933 
6790 STK15 1.70 3.4E-07 1063 2.05 5.6E-16 1933 
332 Survivin 1.68 5.9E-07 1063 1.76 1.8E-10 1933 
891 CCNB1 1.49 4.6E-04 904 2.08 1.1E-08 841 
4605 MYBL2 1.63 4.0E-06 1063 1.66 7.4E-09 1933 
4320 MMP11 1.13 2.3E-01 1035 1.13 1.5E-01 1933 
1515 CTSL2 1.59 1.6E-05 1035 1.41 6.9E-05 1933 
2886 GRB7 1.34 4.8E-03 1063 0.71 8.7E-05 1933 
2064 HER2 0.97 7.9E-01 1035 0.84 1.7E-01 841 
2099 ER 1.17 2.3E-01 1035 0.83 3.4E-02 1933 
5241 PGR 0.92 4.1E-01 1063 0.54 9.4E-07 841 
596 BCL2 0.89 2.8E-01 1035 0.7 5.2E-05 1933 
57758 SCUBE2 1.05 7.6E-01 712 0.58 4.8E-10 1933 
2944 GSTM1 0.79 7.1E-02 738 0.62 4.0E-08 1933 
968 CD68 1.15 1.9E-01 1063 0.87 1.0E-01 1933 
573 BAG1 1.05 6.4E-01 1063 0.77 3.7E-02 841 
Table 8.9: Overexpression of HLXB9 is a better indicator of relapse in breast cancer patients in patients 
diagnosed with luminal A tumours than a number of genes used in the Oncotype DX gene panel. Results from 













HR P N HR P N 
3110 HLXB9 1.24 4.0E-02 1035 1.23 1.7E-02 1933 
Good Prognosis  
8659 ALDH4 1.10 3.5E-01 1015 0.94 4.5E-01 1933 
8817 FGF18 0.91 3.5E-01 1063 0.58 2.7E-05 841 
27113 BBC3 1.27 3.3E-02 901 0.89 1.6E-01 1933 
57593 KIAA1442 0.95 8.9E-01 46 0.6 5.8E-05 841 
57758 CEGP1 1.05 7.6E-01 712 0.58 4.8E-10 1933 
146923 RUNDC1 1.16 4.0E-01 451 0.57 8.6E-06 841 
8840 WISP1 0.93 5.0E-01 1061 0.7 4.0E-03 841 
2947 GSTM3 0.87 1.7E-01 1063 0.78 4.4E-02 841 
151126 ZNF533 1.04 8.1E-01 449 0.69 3.2E-03 841 
146760 RTN4RL1 1.02 9.2E-01 375 0.69 3.3E-03 841 
10455 PECI 0.81 5.4E-02 983 0.83 3.1E-02 1933 
7043 TGFB3  0.90 3.3E-01 1035 0.63 1.3E-07 1933 
55351 HSA250839 0.84 1.0E-01 1003 0.68 1.4E-05 1933 
58475 CFFM4 0.76 3.6E-02 557 0.68 2.6E-03 841 
163 AP2B1 1.00 9.9E-01 1035 0.81 1.4E-02 1933 
79132 LGP2 1.17 1.6E-01 897 1.00 9.6E-01 1933 
Poor Prognosis  
55321 C20orf46 1.09 4.5E-01 1031 0.89 2.0E-01 1933 
11082 ESM1 1.04 7.0E-01 1014 1.02 8.4E-01 1933 
9134 CCNE2 1.58 2.9E-05 929 1.94 4.3E-14 1933 
54583 EGLN1 1.08 5.3E-01 895 1.16 2.3E-01 841 
1058 CENPA 1.49 1.7E-04 1063 1.56 3.4E-07 1933 
9055 PRC1 1.81 1.6E-08 1031 2.28 <1E-16 1933 
445815 AKAP2  1.11 4.1E-01 784 0.9 2.0E-01 1933 
10874 NMU 1.45 4.3E-04 1063 1.63 2.2E-08 1933 
3488 IGFBP5 1.30 1.3E-02 1035 1.26 6.3E-02 841 
10531 MP1 1.06 6.5E-01 797 1.42 4.8E-03 841 
57110 LOC57110 1.09 4.3E-01 1003 1.43 3.5E-05 1933 
8577 TMEFF1 0.87 2.2E-01 987 1.08 3.6E-01 1933 
4175 MCM6 1.63 2.3E-06 1063 1.65 7.7E-05 841 
643008 LOC643008 NA NA NA 0.88 3.1E-01 841 
83879 CDCA7 1.05 7.5E-01 451 1.18 1.9E-01 841 
5984 RFC4 1.39 1.8E-03 1063 1.71 6.9E-10 1933 
23594 ORC6L 1.66 1.6E-06 1031 1.53 1.1E-06 1933 




0.84 1.6E-01 901 
1.07 4.5E-01 1933 
79791 FBXO31 1.00 9.7E-01 1031 1.09 5.0E-01 841 
1633 DCK 1.21 7.6E-02 1035 1.48 5.6E-06 1933 
51514 L2DTL 1.89 2.6E-09 1003 1.82 3.2E-06 841 
1284 COL4A2 1.19 1.3E-01 901 1.15 1.0E-01 1933 
9833 KIAA0175 1.83 6.7E-09 1063 2.09 1.1E-16 1933 
92140 MTDH 1.08 4.6E-01 1035 1.13 3.3E-01 841 
51377 UCH37 0.98 8.6E-01 1031 1.17 2.0E-01 841 
51560 RAB6B 1.10 4.4E-01 1003 0.79 5.6E-02 841 
160897 GPR180 0.90 4.9E-01 402 0.89 3.4E-01 841 
79888 FLJ12443 1.43 1.6E-03 901 1.17 6.5E-02 1933 
8293 SERF1A 1.10 7.8E-01 53 0.78 3.6E-03 1933 
8476 PK428 1.15 1.9E-01 1063 1.22 2.2E-02 1933 
10403 HEC 1.12 3.1E-01 1063 2.15 <1E-16 1933 
8833 GMPS 1.29 2.0E-02 1038 1.76 2.4E-10 1933 
1894 ECT2 1.35 5.0E-03 1031 1.31 3.1E-02 841 
4318 MMP9 1.13 2.5E-01 1063 1.25 9.5E-03 1933 
5019 OXCT 1.01 9.4E-01 1063 0.9 2.2E-01 1933 
2781 GNAZ 1.19 1.2E-01 1035 1.03 7.5E-01 1933 
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2321 FLT1 0.92 5.1E-01 721 0.79 6.8E-02 841 
2131 EXT1 0.98 8.7E-01 1063 1.16 9.6E-02 1933 
56942 DC13 1.69 7.3E-07 1031 1.89 6.0E-13 1933 
81624 DIAPH3 1.35 1.8E-02 899 1.89 5.5E-07 841 
169714 QSOX2 1.03 8.6E-01 402 0.77 3.4E-02 841 
286052 LOC286052  NA NA NA 0.91 4.5E-01 841 
51203 LOC51203 1.77 4.7E-08 1031 2.27 <1E-16 1933 
85453 TSPYL5 1.06 5.9E-01 899 1.04 6.8E-01 1933 
Table 8.10: Overexpression of HLXB9 is a better indicator of relapse in breast cancer patients in patients 
diagnosed with luminal A tumours than a number of genes used in the MammaPrint gene panel. Results from 
analysing overall survival in KMplotter and BreastMark.  
 
 
Figure A5: A map showing the approximate localisation of RP5-1121A15 probe on 7q. The probe contains both 
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